<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <title>༄༊࿆咸鱼の家ོྂཾ࿆࿐</title>
  
  
  <link href="https://blog.kamasylvia.com/atom.xml" rel="self"/>
  
  <link href="https://blog.kamasylvia.com/"/>
  <updated>2023-10-30T00:50:05.717Z</updated>
  <id>https://blog.kamasylvia.com/</id>
  
  <author>
    <name>Laniakea Kamasylvia</name>
    
  </author>
  
  <generator uri="https://hexo.io/">Hexo</generator>
  
  <entry>
    <title>How to Convert Pandas GroupBy Output to DataFrame - Statology</title>
    <link href="https://blog.kamasylvia.com/p/88087611/"/>
    <id>https://blog.kamasylvia.com/p/88087611/</id>
    <published>2023-10-13T00:24:43.000Z</published>
    <updated>2023-10-30T00:50:05.717Z</updated>
    
    <content type="html"><![CDATA[<blockquote><p><a href="https://www.statology.org/pandas-groupby-to-dataframe/">Source</a></p></blockquote><hr><p>This tutorial explains how to convert the output of a pandas GroupBy into a pandas DataFrame.</p><h3 id="Example-Convert-Pandas-GroupBy-Output-to-DataFrame"><strong>Example: Convert Pandas GroupBy Output to DataFrame</strong></h3><p>Suppose we have the following pandas DataFrame that shows the points scored by basketball players on various teams:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br><span class="line">5</span><br><span class="line">6</span><br><span class="line">7</span><br><span class="line">8</span><br><span class="line">9</span><br><span class="line">10</span><br><span class="line">11</span><br><span class="line">12</span><br><span class="line">13</span><br><span class="line">14</span><br><span class="line">15</span><br><span class="line">16</span><br><span class="line">17</span><br><span class="line">18</span><br><span class="line">19</span><br></pre></td><td class="code"><pre><span class="line">import pandas as pd</span><br><span class="line"></span><br><span class="line">#create DataFrame</span><br><span class="line">df = pd.DataFrame(&#123;&#x27;team&#x27;: [&#x27;A&#x27;, &#x27;A&#x27;, &#x27;A&#x27;, &#x27;A&#x27;, &#x27;B&#x27;, &#x27;B&#x27;, &#x27;B&#x27;, &#x27;B&#x27;],</span><br><span class="line">                   &#x27;position&#x27;: [&#x27;G&#x27;, &#x27;G&#x27;, &#x27;F&#x27;, &#x27;C&#x27;, &#x27;G&#x27;, &#x27;F&#x27;, &#x27;F&#x27;, &#x27;F&#x27;],</span><br><span class="line">                   &#x27;points&#x27;: [5, 7, 7, 10, 12, 22, 15, 10]&#125;)</span><br><span class="line"></span><br><span class="line">#view DataFrame</span><br><span class="line">print(df)</span><br><span class="line"></span><br><span class="line">  team position  points</span><br><span class="line">0    A        G       5</span><br><span class="line">1    A        G       7</span><br><span class="line">2    A        F       7</span><br><span class="line">3    A        C      10</span><br><span class="line">4    B        G      12</span><br><span class="line">5    B        F      22</span><br><span class="line">6    B        F      15</span><br><span class="line">7    B        F      10</span><br></pre></td></tr></table></figure><p>We can use the following syntax to count the number of players, grouped by <strong>team</strong> and <strong>position</strong>:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br><span class="line">5</span><br><span class="line">6</span><br><span class="line">7</span><br><span class="line">8</span><br><span class="line">9</span><br><span class="line">10</span><br><span class="line">11</span><br><span class="line">12</span><br><span class="line">13</span><br></pre></td><td class="code"><pre><span class="line">#count number of players, grouped by team and position</span><br><span class="line">group = df.groupby([&#x27;team&#x27;, &#x27;position&#x27;]).size()</span><br><span class="line"></span><br><span class="line">#view output</span><br><span class="line">print(group)</span><br><span class="line"></span><br><span class="line">team  position</span><br><span class="line">A     C           1</span><br><span class="line">      F           1</span><br><span class="line">      G           2</span><br><span class="line">B     F           3</span><br><span class="line">      G           1</span><br><span class="line">dtype: int64</span><br></pre></td></tr></table></figure><p>From the output, we can see the total count of players, grouped by <strong>team</strong> and <strong>position</strong>.</p><p>However, suppose we want our output to display the team name in each row like this:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br><span class="line">5</span><br><span class="line">6</span><br></pre></td><td class="code"><pre><span class="line">team position  count</span><br><span class="line">0    A        C      1</span><br><span class="line">1    A        F      1</span><br><span class="line">2    A        G      2</span><br><span class="line">3    B        F      3</span><br><span class="line">4    B        G      1</span><br></pre></td></tr></table></figure><p>To achieve this output, we can simply use `reset_index()`` when performing the GroupBy:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br><span class="line">5</span><br><span class="line">6</span><br><span class="line">7</span><br><span class="line">8</span><br><span class="line">9</span><br><span class="line">10</span><br><span class="line">11</span><br><span class="line">12</span><br></pre></td><td class="code"><pre><span class="line">#count number of players, grouped by team and position</span><br><span class="line">df_out = df.groupby([&#x27;team&#x27;, &#x27;position&#x27;]).size().reset_index(name=&#x27;count&#x27;)</span><br><span class="line"></span><br><span class="line">#view output</span><br><span class="line">print(df_out)</span><br><span class="line"></span><br><span class="line">  team position  count</span><br><span class="line">0    A        C      1</span><br><span class="line">1    A        F      1</span><br><span class="line">2    A        G      2</span><br><span class="line">3    B        F      3</span><br><span class="line">4    B        G      1</span><br></pre></td></tr></table></figure><p>The output now appears in the format that we wanted.</p><p>Note that the <strong>name</strong> argument within <code>reset_index()</code> specifies the name for the new column produced by GroupBy.</p><p>We can also confirm that the result is indeed a pandas DataFrame:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br></pre></td><td class="code"><pre><span class="line">#display object type of df_out</span><br><span class="line">type(df_out)</span><br><span class="line"></span><br><span class="line">pandas.core.frame.DataFrame</span><br></pre></td></tr></table></figure><p><strong>Note</strong>: You can find the complete documentation for the GroupBy operation in pandas <a href="https://pandas.pydata.org/docs/reference/api/pandas.DataFrame.groupby.html">here</a>.</p><h3 id="Additional-Resources"><strong>Additional Resources</strong></h3><p>The following tutorials explain how to perform other common operations in pandas:</p><p><a href="https://www.statology.org/pandas-cumulative-sum-by-group/">Pandas: How to Calculate Cumulative Sum by Group</a><br><a href="https://www.statology.org/pandas-groupby-count-unique/">Pandas: How to Count Unique Values by Group</a><br><a href="https://www.statology.org/pandas-groupby-correlation/">Pandas: How to Calculate Correlation By Group</a></p>]]></content>
    
    
    <summary type="html">Zach</summary>
    
    
    
    
    <category term="Python" scheme="https://blog.kamasylvia.com/tags/Python/"/>
    
    <category term="Data Science" scheme="https://blog.kamasylvia.com/tags/Data-Science/"/>
    
  </entry>
  
  <entry>
    <title>Enabling Twoside Feature in Typst</title>
    <link href="https://blog.kamasylvia.com/p/9b1b2e16/"/>
    <id>https://blog.kamasylvia.com/p/9b1b2e16/</id>
    <published>2023-09-22T02:41:58.000Z</published>
    <updated>2023-10-30T00:50:05.709Z</updated>
    
    <content type="html"><![CDATA[<h1 id="Introduction">Introduction</h1><p>When it comes to creating professional documents, having a twoside layout with customized margins, headers, and footers can greatly enhance the readability and aesthetic appeal. In this guide, we’ll explore how to enable the twoside feature in Typst and set up personalized margins, headers, and footers to create visually appealing and well-structured documents.</p><h1 id="Enabling-the-Twoside-Layout">Enabling the Twoside Layout</h1><p>The twoside layout in Typst allows for different settings on odd and even pages. Follow these steps to enable the twoside feature:</p><h2 id="Creating-Dynamic-Margins">Creating Dynamic Margins</h2><p>Adjusting the margins for twoside printing is important to maintain a consistent visual appearance and prevent content from being too close to the edge on either side.</p><p>Here’s a guide on how to enable the “twoside” feature in Typst using the margin parameters:</p><ol><li>Open your Typst document and navigate to the page where you want to enable twoside layout.</li><li>Access the page function and set the “margin” parameter to define the margins for the page. The “margin” parameter accepts a dictionary that allows you to set individual margins. In this case, we will focus on the “inside” and “outside” margins.</li></ol><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br></pre></td><td class="code"><pre><span class="line">#set page(</span><br><span class="line">  margin: (inside: 2cm, outside: 3cm)</span><br><span class="line">)</span><br></pre></td></tr></table></figure><p>In the above example, we set the “inside” margin to 2 centimeters and the “outside” margin to 3 centimeters. Adjust these values according to your preferences.</p><h2 id="Creating-Dynamic-Headers-and-Footers">Creating Dynamic Headers and Footers</h2><p>Headers and footers provide important contextual information and navigation aids within your document. Follow these steps to create dynamic headers and footers in Typst:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br><span class="line">5</span><br><span class="line">6</span><br><span class="line">7</span><br><span class="line">8</span><br><span class="line">9</span><br><span class="line">10</span><br><span class="line">11</span><br></pre></td><td class="code"><pre><span class="line">#set page(</span><br><span class="line">header: [</span><br><span class="line">    #locate(loc =&gt; &#123;</span><br><span class="line">      if calc.odd(loc.page()) &#123;</span><br><span class="line">// Odd page content</span><br><span class="line">      &#125; else &#123;</span><br><span class="line">// Even page content</span><br><span class="line">      &#125;</span><br><span class="line">    &#125;)</span><br><span class="line">],</span><br><span class="line">)</span><br></pre></td></tr></table></figure><p>Similarly, you can set up the footer using a similar code structure.</p><h1 id="Conclusion">Conclusion</h1><p>Enabling the twoside feature and customizing margins, headers, and footers in Typst allows you to create visually appealing and well-structured documents. By following the steps outlined in this guide, you can master the art of document layout and enhance the overall reading experience for your audience.</p><p>Remember to consult the Typst documentation for more customization options and examples: <a href="https://typst.app/docs/reference/layout/page/">Page Function – Typst Documentation</a>.</p><p>Start leveraging the twoside feature in Typst today and take your document formatting to the next level!</p><p>Note: The provided code snippets are basic examples to illustrate the concepts. Feel free to further customize your margins, headers, and footers based on your specific requirements and design preferences.</p>]]></content>
    
    
    <summary type="html">&lt;h1 id=&quot;Introduction&quot;&gt;Introduction&lt;/h1&gt;
&lt;p&gt;When it comes to creating professional documents, having a twoside layout with customized margins, headers, and footers can greatly enhance the readability and aesthetic appeal. In this guide, we’ll explore how to enable the twoside feature in Typst and set up personalized margins, headers, and footers to create visually appealing and well-structured documents.&lt;/p&gt;
&lt;h1 id=&quot;Enabling-the-Twoside-Layout&quot;&gt;Enabling the Twoside Layout&lt;/h1&gt;
&lt;p&gt;The twoside layout in Typst allows for different settings on odd and even pages. Follow these steps to enable the twoside feature:&lt;/p&gt;
&lt;h2 id=&quot;Creating-Dynamic-Margins&quot;&gt;Creating Dynamic Margins&lt;/h2&gt;
&lt;p&gt;Adjusting the margins for twoside printing is important to maintain a consistent visual appearance and prevent content from being too close to the edge on either side.&lt;/p&gt;
&lt;p&gt;Here’s a guide on how to enable the “twoside” feature in Typst using the margin parameters:&lt;/p&gt;
&lt;ol&gt;
&lt;li&gt;Open your Typst document and navigate to the page where you want to enable twoside layout.&lt;/li&gt;
&lt;li&gt;Access the page function and set the “margin” parameter to define the margins for the page. The “margin” parameter accepts a dictionary that allows you to set individual margins. In this case, we will focus on the “inside” and “outside” margins.&lt;/li&gt;
&lt;/ol&gt;
&lt;figure class=&quot;highlight plaintext&quot;&gt;&lt;table&gt;&lt;tr&gt;&lt;td class=&quot;gutter&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;1&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;2&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;3&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;td class=&quot;code&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;#set page(&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;  margin: (inside: 2cm, outside: 3cm)&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;)&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/figure&gt;
&lt;p&gt;In the above example, we set the “inside” margin to 2 centimeters and the “outside” margin to 3 centimeters. Adjust these values according to your preferences.&lt;/p&gt;</summary>
    
    
    
    
    <category term="Typst" scheme="https://blog.kamasylvia.com/tags/Typst/"/>
    
  </entry>
  
  <entry>
    <title>ISO 7000 — Graphical symbols for use on equipment — Registered symbols</title>
    <link href="https://blog.kamasylvia.com/p/e37d21a1/"/>
    <id>https://blog.kamasylvia.com/p/e37d21a1/</id>
    <published>2023-09-19T08:32:36.000Z</published>
    <updated>2023-10-30T00:50:06.177Z</updated>
    
    <content type="html"><![CDATA[<h1 id="ISO">ISO</h1><p><a href="https://www.iso.org/obp/ui#iso:pub:PUB400001:en">ISO Symbols</a></p><h1 id="Download-symbols">Download symbols</h1><ul><li><a href="https://commons.wikimedia.org/wiki/File:ISO_english_logo_icon.svg">ISO Blue logo 蓝色 ISO 标志</a></li><li><a href="https://commons.wikimedia.org/wiki/File:Bootstrap_exclamation-triangle.svg">Exclamation-triangle 三角形感叹号</a></li><li><a href="https://commons.wikimedia.org/wiki/File:ISO_7000_-_Ref-No_2497.svg">Date of manufacture 制造日期</a></li><li><a href="https://commons.wikimedia.org/wiki/File:ISO_7000_-_Ref-No_2607.svg">Use by date 失效日期</a></li><li><a href="https://commons.wikimedia.org/wiki/File:ISO_7000_-_Ref-No_2492.svg">Batch code 批号</a></li><li><a href="https://commons.wikimedia.org/wiki/File:ISO_7000_-_Ref-No_2493.svg">Catalogue number 序列号</a></li><li><a href="https://commons.wikimedia.org/wiki/File:ISO_7000_-_Ref-No_2501.svg">Sterilized using ethylene oxide 环氧乙烷灭菌标识</a></li></ul>]]></content>
    
    
    <summary type="html">&lt;h1 id=&quot;ISO&quot;&gt;ISO&lt;/h1&gt;
&lt;p&gt;&lt;a href=&quot;https://www.iso.org/obp/ui#iso:pub:PUB400001:en&quot;&gt;ISO Symbols&lt;/a&gt;&lt;/p&gt;
&lt;h1 id=&quot;Download-symbols&quot;&gt;Download symbols&lt;/h1&gt;
&lt;ul&gt;
&lt;li&gt;&lt;a href=&quot;https://commons.wikimedia.org/wiki/File:ISO_english_logo_icon.svg&quot;&gt;ISO Blue logo 蓝色 ISO 标志&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a href=&quot;https://commons.wikimedia.org/wiki/File:Bootstrap_exclamation-triangle.svg&quot;&gt;Exclamation-triangle 三角形感叹号&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a href=&quot;https://commons.wikimedia.org/wiki/File:ISO_7000_-_Ref-No_2497.svg&quot;&gt;Date of manufacture 制造日期&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a href=&quot;https://commons.wikimedia.org/wiki/File:ISO_7000_-_Ref-No_2607.svg&quot;&gt;Use by date 失效日期&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a href=&quot;https://commons.wikimedia.org/wiki/File:ISO_7000_-_Ref-No_2492.svg&quot;&gt;Batch code 批号&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a href=&quot;https://commons.wikimedia.org/wiki/File:ISO_7000_-_Ref-No_2493.svg&quot;&gt;Catalogue number 序列号&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a href=&quot;https://commons.wikimedia.org/wiki/File:ISO_7000_-_Ref-No_2501.svg&quot;&gt;Sterilized using ethylene oxide 环氧乙烷灭菌标识&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
</summary>
    
    
    
    
    <category term="KDL" scheme="https://blog.kamasylvia.com/tags/KDL/"/>
    
    <category term="ISO" scheme="https://blog.kamasylvia.com/tags/ISO/"/>
    
    <category term="QMS" scheme="https://blog.kamasylvia.com/tags/QMS/"/>
    
  </entry>
  
  <entry>
    <title>[ISO 10993-1 (FDA)] V General Biocompatibility Testing Considerations</title>
    <link href="https://blog.kamasylvia.com/p/b8871b27/"/>
    <id>https://blog.kamasylvia.com/p/b8871b27/</id>
    <published>2023-09-07T00:27:25.000Z</published>
    <updated>2023-10-30T00:50:06.281Z</updated>
    
    <content type="html"><![CDATA[<h1 id="General-Biocompatibility-Testing-Considerations-生物相容性测试注意事项总则">General Biocompatibility Testing Considerations 生物相容性测试注意事项总则</h1><p>Test article preparation is a critical variable in the conduct of the biocompatibility tests. Therefore, it is important to understand how the test articles compare to the medical device in its final finished form (e.g., sterile, if applicable). The example test article documentation language included in Attachment F can be used to detail how any differences may or may not affect biocompatibility of the medical device in its final finished form.</p><p>测试样品的准备是进行生物相容性测试的关键变量。因此，了解测试样品与医疗器械最终成品形式（如适用）的比较情况（例如，是否无菌）非常重要。附件 F 中包含的示例测试样品文档语言可用于详细说明任何差异可能如何影响医疗器械最终成品形式的生物相容性。</p><h2 id="Use-of-Medical-Device-in-Final-Finished-Form-or-Representative-Test-Article-在最终成品形式下使用医疗器械或代表性测试样品">Use of Medical Device in Final Finished Form or Representative Test Article 在最终成品形式下使用医疗器械或代表性测试样品</h2><p>When biocompatibility testing is necessary, the Agency recommends testing medical devices in the condition that they will be used, whenever possible. This could include final, packaged devices, or as sterilized by an end user, if appropriate. If the medical device in its final finished form cannot be used for biocompatibility testing, a test article (e.g., coupons or “representative components”) may be considered. The representative test article should undergo the same manufacturing and sterilization processes, have the same chemical, physical, and surface properties, and have the same ratio of component materials as the medical device in its final finished form. In situations where differences exist between the medical device in its final finished form and the test article, additional information describing how these differences could impact study findings should be provided. For example, when testing an individual device component, a low-level tissue response could be observed, but when all of the components are tested within a medical device in its final finished form, a more robust tissue response could occur. If there are differences between the medical device in its final finished form and the representative test article, additional information may aid in determining the appropriateness of the selected test article. For example, extraction and surface characterization techniques may be appropriate to demonstrate that the surfaces are equivalent in geometry and surface properties, and that the chemicals leaching from the test article display the same kinetics, chemical identity and relative quantity as those eluting from the medical device in its final finished form. For example, for permanent or absorbable implants, FDA may request data from exhaustive extraction studies (per ISO 10993-12) and surface characterization information to support use of the representative test articles. See also Attachment F.</p><p>在进行生物相容性测试时，机构建议尽可能以医疗器械将要使用的状态进行测试。这可以包括最终包装好的设备，或者根据最终用户的需要进行灭菌。如果医疗器械在其最终成品形式下无法用于生物相容性测试，可以考虑使用一个测试样品（例如，样片或“代表性组件”）。代表性测试样品应经过相同的制造和灭菌过程，具有相同的化学、物理和表面性质，并且具有与医疗器械最终成品形式相同的组分材料比例。对于医疗器械最终成品形式与测试样品之间存在差异的情况，应提供描述这些差异可能如何影响研究结果的额外信息。例如，当测试单个器械组件时，可能观察到低水平的组织反应，但当所有组件在医疗器械最终成品形式内进行测试时，可能会出现更强的组织反应。如果医疗器械最终成品形式与代表性测试样品之间存在差异，额外的信息可能有助于确定所选测试样品的适用性。例如，提取和表面特性分析技术可能适用于证明表面的几何形状和性质是相等的，并且从测试样品中溶出的化学物质显示出与医疗器械最终成品形式中析出的化学物质相同的动力学、化学特性和相对含量。例如，对于永久性或可吸收性植入物，FDA 可能会要求进行详尽的提取研究（根据 ISO 10993-12）和表面特性信息，以支持使用代表性测试样品。另请参阅附件 F。</p><h2 id="Testing-of-In-Situ-Polymerizing-and-or-Absorbable-Materials-对原位聚合和-或可吸收材料的测试">Testing of In Situ Polymerizing and/or Absorbable Materials 对原位聚合和/或可吸收材料的测试</h2><p>For devices made from in situ polymerizing and/or absorbable materials, we recommend that test article preparation be representative of the device in its final finished form. In addition, we recommend that biocompatibility be evaluated for the medical device in its final finished form as well as at various time points over the course of polymerization and/or degradation to ensure that starting, intermediate, and final degradation products are assessed. Should biocompatibility assessment of the materials during degradation be needed, preparation of test articles using in vitro degradation methods may be considered with appropriate technical justification. Test articles degraded in vitro may be used for biological testing, and/or chemically analyzed to show that the material breaks down into intermediate or final degradation products that are known to be non-toxic at the levels present. However, depending on the materials of manufacture and the degradation testing conditions, accelerated degradation testing may not result in the same intermediate or final degradation products and therefore may not be acceptable.</p><p>对于使用原位聚合和/或可吸收材料制造的器械，我们建议测试样品的准备应代表器械的最终成品形式。此外，我们建议在聚合和/或降解过程中，对医疗器械的最终成品形式以及不同时间点进行生物相容性评估，以确保评估起始、中间和最终降解产物。如果需要在降解过程中进行材料的生物相容性评估，可以考虑使用体外降解方法制备测试样品，并提供适当的技术依据。经过体外降解的测试样品可以用于生物学测试，或进行化学分析，以展示材料降解为已知无毒的中间或最终降解产物。然而，根据制造材料和降解测试条件的不同，加速降解测试可能不会产生相同的中间或最终降解产物，因此可能不被接受。</p><p>For in vivo tests for devices made of in situ polymerizing or absorbable materials, the assessment time points would depend on the polymerization and degradation kinetics. We recommend that assessments be targeted to demonstrate how the device materials degrade over time and continue until the absorbable material and/or its degradation products are no longer present in the tissue (e.g., microscopically), if possible. Alternatively, it may be acceptable to provide a rationale for ending the study earlier, if the rationale includes an estimate of the percentage (%) of absorbable material remaining in the tissue, and confirmation that a steady state biological tissue response is achieved.</p><p>对于使用原位聚合或可吸收材料制造的器械的体内测试，评估时间点取决于聚合和降解动力学。我们建议评估旨在展示器械材料随时间的降解情况，并持续进行，直到可吸收材料和/或其降解产物不再存在于组织中（例如，通过显微镜观察）。如果可能的话，另一种可接受的做法是提供终止研究的理由，如果该理由包括估计组织中剩余可吸收材料的百分比（%），并确认达到了稳态的生物组织反应。</p><p>For in vitro biocompatibility tests conducted with extracts of an in situ polymerizing or absorbable device, chemical analytical testing of the extract may be useful to determine whether the extract is representative of leachables during the polymerization or degradation processes, and if multiple biocompatibility tests with different extracts are needed to represent different stages of the polymerization or degradation processes. If test articles are pre-polymerized prior to extraction, unreacted constituents that may be available during physiologic polymerization may or may not be available for extraction from a pre-polymerized test article. For systems that may not be polymerizable in traditional extraction media, alternative approaches may be necessary.</p><p>对于使用原位聚合或可吸收器械提取物进行的体外生物相容性测试，化学分析测试提取物可能有助于确定提取物是否代表聚合或降解过程中的可溶性物质，并且如果需要用不同提取物进行多个生物相容性测试以代表聚合或降解过程的不同阶段。如果在提取之前对测试样品进行预聚合，可能会有未反应的成分在生理聚合过程中可能可溶出，也可能无法从预聚合的测试样品中进行提取。对于在传统提取介质中可能无法聚合的系统，可能需要采用替代方法。</p><h2 id="Biological-Response-Resulting-from-Device-Mechanical-Failure-由设备机械故障引起的生物反应">Biological Response Resulting from Device Mechanical Failure 由设备机械故障引起的生物反应</h2><p>Although the scope of ISO 10993-1:2009 specifically excludes biological hazards arising from any mechanical failure, FDA believes this potential risk is important to consider when conducting biocompatibility evaluations. For some devices, it may be possible that mechanical failure could alter the biological response to the device. For example, if coating particles or wear debris are released from a device, those particles could lead to a biological response because of their material properties, such as geometric and/or physicochemical properties<sup class="footnote-ref"><a href="#fn1" id="fnref1">[1]</a></sup>.In addition, coating delamination or component release or failure could expose the biological system to leaching of different chemicals, or to an increased level of chemicals from a substrate material. Another consideration is whether the surface topography could change with mechanical loading in such a way that the biological response changes. We recommend that your test article selection for any biocompatibility testing incorporate these considerations. If your biocompatibility evaluation does not include testing to evaluate potential biological hazards due to mechanical failure, your rationale for why such testing is not needed may include the results of other nonclinical tests, such as bench testing or in vivo animal studies. For example, inadequate surface treatment of nitinol devices might result in non-optimized passivation layers that can be further compromised by mechanical loading, such as during device placement. This could result in nickel, a known renal toxin, sensitizer, genotoxin and possible co-carcinogen, being released at levels that could be toxic. If processing includes an adequate passivation method, and corrosion testing confirms that an appropriate passivation layer exists, the risk for nickel toxicity is minimized, and testing to assess biological endpoints and/or nickel leaching may not be necessary.</p><p>虽然 ISO 10993-1:2009 的范围明确排除了由于任何机械故障而产生的生物危害，但 FDA 认为在进行生物相容性评估时应考虑此潜在风险的重要性。对于某些器械而言，机械故障可能会改变对器械的生物反应。例如，如果设备释放出涂层颗粒或磨损颗粒，这些颗粒可能由于其材料特性（如几何和/或物理化学特性）而导致生物反应。此外，涂层剥离、组件松动或故障可能会使生物系统暴露于不同化学物质的淋漓，或使基板材料释放出更高水平的化学物质<sup class="footnote-ref"><a href="#fn1" id="fnref1:1">[1:1]</a></sup>。另一个考虑因素是在机械载荷下表面拓扑结构是否会发生改变，从而使生物反应发生变化。我们建议在进行任何生物相容性测试时，选择测试样品时要考虑这些因素。如果您的生物相容性评估不包括评估由于机械故障而可能导致的生物危害的测试，您为什么认为不需要进行此类测试的理由可以包括其他非临床测试的结果，例如台架测试或体内动物研究。例如，对于氮化钛设备，如果表面处理不充分，可能导致未经优化的钝化层在设备放置期间受到机械加载等因素的进一步损害。这可能导致镍（已知的肾毒素、致敏剂、基因毒性物质和可能的共诱变剂）被释放到可能具有毒性的水平。如果处理过程包括充分的钝化方法，并且腐蚀测试确认存在适当的钝化层，那么镍毒性的风险将被最小化，因此可能不需要进行评估生物终点和/或镍淋漓的测试。</p><h2 id="Submicron-or-Nanotechnology-Components-亚微米或纳米技术组件">Submicron or Nanotechnology Components 亚微米或纳米技术组件</h2><p>It is now generally accepted[<sup>33][</sup>34] that there can be unique properties associated with submicron(&lt;1 micron) or nanotechnology components such as aggregation, agglomeration, immunogenicity, or toxicity. Medical devices with submicron components may require specialized techniques if characterization and biocompatibility testing is needed. [^35]Limitations may apply when using chemical leachates-based ISO 10993-12 test conditions for the analysis of submicron component biocompatibility assessments. The sponsor should consult relevant literature and standards during the development of test protocols for device-specific submicron or nanotechnology component biocompatibility assessments, and contact the respective Center and review division prior to initiation of any tests.</p><p>目前普遍认为[<sup>33][</sup>34]，亚微米（&lt;1 微米）或纳米技术组件可能具有独特的特性，如聚集、凝聚、免疫原性或毒性。如果需要对具有亚微米组件的医疗器械进行表征和生物相容性测试，可能需要使用专门的技术[^35]。</p><p>For biocompatibility assessment of devices with submicron components, you should consider the following:</p><p>对于具有亚微米组件的器械的生物相容性评估，您应考虑以下几点：</p><ul><li>Careful characterization of the test article.对测试样品进行仔细的表征。</li><li>Selection of extract conditions (e.g., solvent type) that avoid testing artifacts.选择提取条件（例如溶剂类型），以避免测试中的人为因素。</li><li>Assurance that the test article used is representative of the device that is intended to be used clinically.确保所使用的测试样品代表了拟临床使用的器械。</li></ul><p>For test selection, the following items are also important:</p><p>对于测试选择，以下几点也很重要：</p><ul><li>Consideration of standard biocompatibility tests in the context of contemporary literature regarding the validity of individual tests for assessment of devices with submicron components.在考虑使用标准生物相容性测试时，要参考当代文献，了解各个测试方法对于评估具有亚微米组件的器械的有效性。</li><li>Assurance that the submicron components will not interfere with the conduct of a chosen test.确保亚微米组件不会干扰所选择测试的进行。</li><li>Consideration of any additional toxicity issues that might be relevant to submicron particles, such as absorption, distribution, and accumulation into organs, potential metabolism, and elimination, since there are greater concerns associated with submicron particles that cannot be readily detoxified and/or eliminated from the body.考虑与亚微米颗粒相关的任何额外毒性问题，例如吸收、分布和积累到器官中的潜在代谢和排泄。因为与亚微米颗粒相关的担忧更大，这些颗粒可能不能很容易地被解毒和/或排出体外。</li></ul><ol start="33"><li>Kunzmann, A., et al., “Toxicology of engineered nanomaterials: Focus on biocompatibility, biodistribution and biodegradation.” Biochim Biophys Acta, 2011, 1810(3): 361-373.</li><li>Rivera, G.P., et al., &quot; Correlating physico-chemical with toxicological properties of nanoparticles: the present and the future.&quot; ACS Nano,2010,4(10):5527-5531.</li><li>For example, ASTM F1903 “Standard Practice for Testing For Biological Responses to Particles In Vitro,” or ASTM F1904 &quot; Standard Practice for Testing the Biological Responses to Particles in vivo . &quot;</li></ol><h2 id="Test-Article-Preparation-for-Extract-Testing-提取测试中的测试样品准备">Test Article Preparation for Extract Testing 提取测试中的测试样品准备</h2><p>For biocompatibility testing conducted using extracts of the test article<sup class="footnote-ref"><a href="#fn2" id="fnref2">[2]</a></sup>,we recommend that you:</p><p>对于使用测试样品的提取物进行生物相容性测试<sup class="footnote-ref"><a href="#fn2" id="fnref2:1">[2:1]</a></sup>，我们建议您：</p><ul><li>Determine the appropriate amount of test article as outlined in ISO 10993-12 or another FDA-recognized standard (e.g., ASTM F619 “Standard Practice for Extraction of Medical Plastics”), using surface area to extract volume ratios. Mass to extract volume ratios should only be used if surface area cannot be calculated, or if use of mass will result in a test article with a larger surface area to extract volume ratio than recommended by ISO 10993-12. If there is a need for an alternate extraction ratio, appropriate justification should be provided. For example, for fluid path devices or components (where fluids contact the channels in the device or component, and then the fluid enters the body), the fluid path can be filled to capacity. If the ISO 10993-12 recommended surface area to extract volume cannot be achieved, the fluid contacting surface area and extraction volume should be noted in the test report. This approach can be used for both static and dynamic extractions. For some test systems, there may be standardized alternatives for test-specific extraction conditions that provide a different level of extraction (e.g., guinea pig maximization testing per ISO 10993-10&quot;Biological evaluation of medical devices-Part 10: Tests for irritation and skin sensitization,&quot; Annex E).<br>根据 ISO 10993-12 或其他 FDA 认可的标准（例如 ASTM F619 “Standard Practice for Extraction of Medical Plastics”）确定适量的测试样品，使用表面积与提取体积的比例。只有在无法计算表面积或使用质量会导致测试样品的表面积与提取体积比例大于 ISO 10993-12 推荐值时，才应使用质量与提取体积的比例。如果需要使用其他提取比例，应提供适当的理由。例如，对于液体通路器械或组件（其中液体接触器械或组件中的通道，然后进入体内），可以将液体通路填满。如果无法达到 ISO 10993-12 推荐的表面积与提取体积比例，应在测试报告中注明接触液体的表面积和提取体积。这种方法可用于静态和动态提取。对于某些测试系统，可能存在针对特定测试的标准替代提取条件，提供不同水平的提取（例如，按照 ISO 10993-10 &quot;Biological evaluation of medical devices-Part 10: Tests for irritation and skin sensitization&quot;的附录 E 进行的豚鼠最大化测试）。</li><li>Use both polar and nonpolar solvents, such as those described in ISO 10993-12. In some cases, other solvents may be used, where appropriate. For example, a mixed polarity solvent (e.g., cell culture medium with 5-10% serum for cytotoxicity testing) is appropriate to extract both hydrophilic and lipophilic chemicals. Also, where devices do not have direct contact with the body but only have indirect contact via a polar solution (e.g., assessment of the inner channel material of a cardiovascular catheter where the inner channel is only used for the infusion of saline), a rationale for waiving testing with a non-polar solution should be provided. For some tests such as material-mediated pyrogenicity, where the extract is injected intravascularly, a polar extract is sufficient.<br>使用极性和非极性溶剂，例如 ISO 10993-12 中所描述的溶剂。在某些情况下，可以使用其他适当的溶剂。例如，混合极性溶剂（例如细胞培养基中含有 5-10%血清用于细胞毒性测试）适用于提取亲水性和亲脂性化学物质。此外，对于与体内直接接触，但只通过极性溶液（例如评估心血管导管的内部通道材料，其中内部通道仅用于注入盐水）间接接触的器械，应提供放弃使用非极性溶液进行测试的理由。对于一些测试，例如材料介导的发热性测试，其中提取物是静脉内注射的，使用极性提取物就足够了。</li><li>Use extraction conditions that are adequate for testing of extractables and leachables from the device given its intended use. Traditional biocompatibility extraction methods, such as those in ISO 10993-12:2012 (e.g., 37 C for 72 hours; 50 C for 72 hours; 70 C for 24 hours; or 121 C for 1 hour ) are acceptable for many biocompatibility tests. For prolonged contact devices and those categorized as permanent implants, extraction at 37 C may not be sufficient to obtain an extract that represents the chemicals extracted over the duration of device use. However, in some cases, temperatures above 37 C result in chemicals that may not occur in clinical use and may result in adverse biological responses not representative of the medical device in its final finished form. For example, for devices that contain heat labile or heat sensitive materials (e.g., drugs, biomolecules, tissue-derived components), which may have the potential to undergo deformation or material configuration/structural change at high temperature, extraction at 37 C per ISO 10993-12 is recommended, but some additional information on how the chemistry of the device will change over time may also be needed. In all cases, a justification for the selected extraction conditions should be provided.<br>使用适合设备预期用途的可提取物和可溶出物测试的提取条件。对于许多生物相容性测试，传统的生物相容性提取方法，例如 ISO 10993-12:2012 中描述的方法（例如 37 摄氏度提取 72 小时；50 摄氏度提取 72 小时；70 摄氏度提取 24 小时；或 121 摄氏度提取 1 小时）是可以接受的。对于长期接触设备和被归类为永久植入物的设备，在 37 摄氏度下的提取可能无法获得代表设备使用期间提取的化学物质的提取物。然而，在某些情况下，高于 37 摄氏度的温度会导致在临床使用中不会出现的化学物质，并可能导致与最终成品形式的医疗器械不符的不良生物反应。例如，对于含有热敏感材料（例如药物、生物分子、组织来源的成分）的器械，这些材料可能在高温下发生变形或物质构型/结构变化的情况下，建议按照 ISO 10993-12 在 37 摄氏度下进行提取，但可能还需要一些关于设备化学性质随时间变化的其他信息。在所有情况下，应提供所选择提取条件的理由。</li><li>Describe the condition of the test extract (e.g., color, presence of any particles), and describe any changes in the extraction solvent (pre-and post-extraction) and explain the source of these changes (e.g., test article degradation).<br>描述测试提取物的状态（例如颜色、是否有颗粒），并描述提取溶剂的任何变化（提取前和提取后），并解释这些变化的来源（例如测试样品的降解）。</li><li>Use the extracts without additional processing (e.g., no filtration, centrifugation, or other methods to remove particulates; no pH adjustment), unless otherwise justified.<br>除非有合理理由，否则在使用提取物时不进行其他处理（例如无过滤、离心或其他去除颗粒的方法；无 pH 调节）。</li><li>If test article extracts are not used immediately, we recommend that you use them within the time frame outlined in ISO 10993-12 or an equivalent method. We recommend that you describe the details of storage conditions for the test extract, and explain why storage will not affect your test results (i.e., as stated in ISO 10993-12:2012,“stability and homogeneity of extract under storage conditions shall be verified”).<br>如果测试样品提取物不立即使用，建议您在 ISO 10993-12 或等效方法中规定的时间范围内使用它们。建议您描述测试提取物的存储条件的详细信息，并解释为什么存储不会影响您的测试结果（如 ISO 10993-12:2012 所述，“在存储条件下提取物的稳定性和均匀性应予以验证”）。</li></ul><h2 id="Inclusion-of-Multiple-Components-or-Materials-in-a-Single-Test-Article-在单个测试样品中包含多个组件或材料的器械">Inclusion of Multiple Components or Materials in a Single Test Article 在单个测试样品中包含多个组件或材料的器械</h2><p>For devices that include components with different lengths of contact (e.g., categorized as limited, prolonged, or permanent), we recommend that any extract-based biocompatibility testing be conducted separately.<sup class="footnote-ref"><a href="#fn3" id="fnref3">[3]</a></sup> If the components are combined into a single test article, this will dilute the amount of component materials being presented to the test system and may not accurately identify potentially toxic agents that would have been found if the components were tested separately. For example, we recommend testing implants separately from delivery systems or other kit components.</p><p>对于包含具有不同接触时间的组件（例如，被归类为有限、长期或永久的组件）的器械，我们建议将基于提取物的生物相容性测试单独进行。如果将这些组件组合成一个单一的测试样品，将会稀释呈现给测试系统的组件材料的数量，并且可能无法准确识别出如果这些组件分别进行测试可能会发现的潜在有毒物质。例如，我们建议将植入物与输送系统或其他套件组件分开进行测试。</p><p>For devices or device components that contain multiple materials with differing surface areas or differing exposure to the body, if one or more materials is new (i.e., not used before in devices with the same type and duration of contact), it may also be necessary to test the new material component(s) separately as well, to further understand the potential toxicity of this component. For example, for a catheter-based delivery system that contains a new balloon material, tests of the delivery system separate from the balloon may be necessary to ensure adequate assessment of each of the materials.</p><p>对于包含具有不同表面积或在体内接触程度不同的多种材料的器械或器械组件，如果其中一个或多个材料是新材料（即，在具有相同类型和持续时间接触的设备中尚未使用过的材料），可能还需要单独测试新材料组件，以进一步了解该组件的潜在毒性。例如，对于含有新的气囊材料的导管式输送系统，可能需要对输送系统和气囊分别进行测试，以确保对每种材料进行充分评估。</p><hr class="footnotes-sep"><section class="footnotes"><ol class="footnotes-list"><li id="fn1" class="footnote-item"><p>FDA’s &quot; Guidance for Industry and FDA Staff : Preparation and Review of Investigational Device Exemption Applications (IDEs) for Total Artificial Discs&quot; available at <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preparation-and-review-investigational-device-exemption-applications-ides-total-artificial-discs">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preparation-and-review-investigational-device-exemption-applications-ides-total-artificial-discs</a> requests that wear particles, which result from dynamic device loading during use, be assessed “to evaluate the local and systemic responses (e.g., biocompatibility, neurologic response, tissue response, and toxicity) to the wear debris.”<br>FDA 的“针对行业和 FDA 人员的指南：全人工椎间盘置换 IDE 申请的准备和审查”要求评估由使用过程中动态设备加载引起的磨损颗粒，以评估对磨损颗粒的局部和全身反应（如生物相容性、神经反应、组织反应和毒性）。 <a href="#fnref1" class="footnote-backref">↩︎</a> <a href="#fnref1:1" class="footnote-backref">↩︎</a></p></li><li id="fn2" class="footnote-item"><p>For biocompatibility testing, extracts could include leachable residuals at the surface of test articles or extractables migrating from the bulk of test articles. <a href="#fnref2" class="footnote-backref">↩︎</a> <a href="#fnref2:1" class="footnote-backref">↩︎</a></p></li><li id="fn3" class="footnote-item"><p>In many cases , it is acceptable to combine components with limited ( &lt; 24 hour ) use , with an appropriate supporting rationale. However, separate assessments of devices with prolonged (24 hour to 30 day) or permanent 30 day) duration of contact are recommended.<br>在许多情况下，结合具有有限（&lt;24 小时）使用时间的组件是可以接受的，并且需要提供合理的支持理由。然而，我们建议对与长期（24 小时至 30 天）或永久（30 天以上）接触持续时间相关的器械进行单独评估。 <a href="#fnref3" class="footnote-backref">↩︎</a></p></li></ol></section>]]></content>
    
    
    <summary type="html">&lt;h1 id=&quot;General-Biocompatibility-Testing-Considerations-生物相容性测试注意事项总则&quot;&gt;General Biocompatibility Testing Considerations 生物相容性测试注意事项总则&lt;/h1&gt;
&lt;p&gt;Test article preparation is a critical variable in the conduct of the biocompatibility tests. Therefore, it is important to understand how the test articles compare to the medical device in its final finished form (e.g., sterile, if applicable). The example test article documentation language included in Attachment F can be used to detail how any differences may or may not affect biocompatibility of the medical device in its final finished form.&lt;/p&gt;
&lt;p&gt;测试样品的准备是进行生物相容性测试的关键变量。因此，了解测试样品与医疗器械最终成品形式（如适用）的比较情况（例如，是否无菌）非常重要。附件 F 中包含的示例测试样品文档语言可用于详细说明任何差异可能如何影响医疗器械最终成品形式的生物相容性。&lt;/p&gt;
&lt;h2 id=&quot;Use-of-Medical-Device-in-Final-Finished-Form-or-Representative-Test-Article-在最终成品形式下使用医疗器械或代表性测试样品&quot;&gt;Use of Medical Device in Final Finished Form or Representative Test Article 在最终成品形式下使用医疗器械或代表性测试样品&lt;/h2&gt;
&lt;p&gt;When biocompatibility testing is necessary, the Agency recommends testing medical devices in the condition that they will be used, whenever possible. This could include final, packaged devices, or as sterilized by an end user, if appropriate. If the medical device in its final finished form cannot be used for biocompatibility testing, a test article (e.g., coupons or “representative components”) may be considered. The representative test article should undergo the same manufacturing and sterilization processes, have the same chemical, physical, and surface properties, and have the same ratio of component materials as the medical device in its final finished form. In situations where differences exist between the medical device in its final finished form and the test article, additional information describing how these differences could impact study findings should be provided. For example, when testing an individual device component, a low-level tissue response could be observed, but when all of the components are tested within a medical device in its final finished form, a more robust tissue response could occur. If there are differences between the medical device in its final finished form and the representative test article, additional information may aid in determining the appropriateness of the selected test article. For example, extraction and surface characterization techniques may be appropriate to demonstrate that the surfaces are equivalent in geometry and surface properties, and that the chemicals leaching from the test article display the same kinetics, chemical identity and relative quantity as those eluting from the medical device in its final finished form. For example, for permanent or absorbable implants, FDA may request data from exhaustive extraction studies (per ISO 10993-12) and surface characterization information to support use of the representative test articles. See also Attachment F.&lt;/p&gt;
&lt;p&gt;在进行生物相容性测试时，机构建议尽可能以医疗器械将要使用的状态进行测试。这可以包括最终包装好的设备，或者根据最终用户的需要进行灭菌。如果医疗器械在其最终成品形式下无法用于生物相容性测试，可以考虑使用一个测试样品（例如，样片或“代表性组件”）。代表性测试样品应经过相同的制造和灭菌过程，具有相同的化学、物理和表面性质，并且具有与医疗器械最终成品形式相同的组分材料比例。对于医疗器械最终成品形式与测试样品之间存在差异的情况，应提供描述这些差异可能如何影响研究结果的额外信息。例如，当测试单个器械组件时，可能观察到低水平的组织反应，但当所有组件在医疗器械最终成品形式内进行测试时，可能会出现更强的组织反应。如果医疗器械最终成品形式与代表性测试样品之间存在差异，额外的信息可能有助于确定所选测试样品的适用性。例如，提取和表面特性分析技术可能适用于证明表面的几何形状和性质是相等的，并且从测试样品中溶出的化学物质显示出与医疗器械最终成品形式中析出的化学物质相同的动力学、化学特性和相对含量。例如，对于永久性或可吸收性植入物，FDA 可能会要求进行详尽的提取研究（根据 ISO 10993-12）和表面特性信息，以支持使用代表性测试样品。另请参阅附件 F。&lt;/p&gt;
&lt;h2 id=&quot;Testing-of-In-Situ-Polymerizing-and-or-Absorbable-Materials-对原位聚合和-或可吸收材料的测试&quot;&gt;Testing of In Situ Polymerizing and/or Absorbable Materials 对原位聚合和/或可吸收材料的测试&lt;/h2&gt;
&lt;p&gt;For devices made from in situ polymerizing and/or absorbable materials, we recommend that test article preparation be representative of the device in its final finished form. In addition, we recommend that biocompatibility be evaluated for the medical device in its final finished form as well as at various time points over the course of polymerization and/or degradation to ensure that starting, intermediate, and final degradation products are assessed. Should biocompatibility assessment of the materials during degradation be needed, preparation of test articles using in vitro degradation methods may be considered with appropriate technical justification. Test articles degraded in vitro may be used for biological testing, and/or chemically analyzed to show that the material breaks down into intermediate or final degradation products that are known to be non-toxic at the levels present. However, depending on the materials of manufacture and the degradation testing conditions, accelerated degradation testing may not result in the same intermediate or final degradation products and therefore may not be acceptable.&lt;/p&gt;
&lt;p&gt;对于使用原位聚合和/或可吸收材料制造的器械，我们建议测试样品的准备应代表器械的最终成品形式。此外，我们建议在聚合和/或降解过程中，对医疗器械的最终成品形式以及不同时间点进行生物相容性评估，以确保评估起始、中间和最终降解产物。如果需要在降解过程中进行材料的生物相容性评估，可以考虑使用体外降解方法制备测试样品，并提供适当的技术依据。经过体外降解的测试样品可以用于生物学测试，或进行化学分析，以展示材料降解为已知无毒的中间或最终降解产物。然而，根据制造材料和降解测试条件的不同，加速降解测试可能不会产生相同的中间或最终降解产物，因此可能不被接受。&lt;/p&gt;
&lt;p&gt;For in vivo tests for devices made of in situ polymerizing or absorbable materials, the assessment time points would depend on the polymerization and degradation kinetics. We recommend that assessments be targeted to demonstrate how the device materials degrade over time and continue until the absorbable material and/or its degradation products are no longer present in the tissue (e.g., microscopically), if possible. Alternatively, it may be acceptable to provide a rationale for ending the study earlier, if the rationale includes an estimate of the percentage (%) of absorbable material remaining in the tissue, and confirmation that a steady state biological tissue response is achieved.&lt;/p&gt;</summary>
    
    
    
    
  </entry>
  
  <entry>
    <title>[ISO 10993-1 (FDA)] IV ISO 10993 --- Part 1 and the FDA-Modified Matrix</title>
    <link href="https://blog.kamasylvia.com/p/1000abb9/"/>
    <id>https://blog.kamasylvia.com/p/1000abb9/</id>
    <published>2023-09-06T06:55:51.000Z</published>
    <updated>2023-10-30T00:50:06.281Z</updated>
    
    <content type="html"><![CDATA[<h1 id="ISO-10993-—-Part-1-and-the-FDA-Modified-Matrix-第-1-部分和-FDA-修改的矩阵">ISO 10993 — Part 1 and the FDA-Modified Matrix 第 1 部分和 FDA 修改的矩阵</h1><p>This guidance considers the assessment of biocompatibility to be an evaluation of the medical device in its final finished form, including sterilization, if applicable. However, sponsors should understand the biocompatibility of each device component and any interactions between components that could occur. This is particularly important when the combination of device components could mask or complicate interpretation of a biocompatibility evaluation. For example, if a metal stent has a polymer coating that may separate over time, then the results of a final device biocompatibility assessment may not fully reflect the longer-term clinical performance of the device, and biocompatibility evaluation of the stent with and without the coating may be needed. Similarly, for an in situ polymerizing and absorbable sealant, where the materials present will change over time, separate evaluations of the pre-polymerized, polymerized, and degrading sealant may be needed.</p><p>该指南认为生物相容性评估是对医疗器械在其最终成品形态下（如适用）进行评估，包括灭菌过程。然而，赞助商应了解每个器械组成部分的生物相容性以及可能发生的组分之间的相互作用。当器械组分的组合可能掩盖或使生物相容性评估的解释复杂化时，这一点尤其重要。例如，如果金属支架具有可能随时间分离的聚合物涂层，那么最终器械生物相容性评估的结果可能无法完全反映器械的长期临床表现，因此可能需要对带涂层和不带涂层的支架进行生物相容性评估。同样地，对于在体内聚合和可吸收的止血剂而言，其中材料会随时间变化，可能需要对预聚合、聚合和降解止血剂进行单独评估。</p><h2 id="Evaluation-of-Local-and-Systemic-Risks-局部和系统风险评估">Evaluation of Local and Systemic Risks 局部和系统风险评估</h2><p>Biological evaluation of medical devices is performed to determine the acceptability of any potential adverse biological response resulting from contact of the component materials of the device with the body. The device materials should not, either directly (e.g., via surface-bound chemicals or physical properties) or through the release of their material constituents: (i) produce adverse local or systemic effects; (ii) be carcinogenic; or (iii) produce adverse reproductive and/or developmental effects, unless it can be determined that the benefits of the use of that material outweigh the risks associated with an adverse biological response. Therefore, evaluation of any new device intended for human use requires information from a systematic analysis to ensure that the benefits provided by the device in its final finished form will outweigh any potential risks produced by device materials over the intended duration and use of the device in or on the exposed tissues.</p><p>医疗器械的生物学评估是为了确定器械组分材料与人体接触可能引起的任何潜在不良生物反应的可接受性。无论是直接（例如通过表面化学物质或物理特性）还是通过其材料成分的释放，器械材料都不应：(i) 产生不良的局部或全身效应；(ii) 具有致癌性；或 (iii) 产生不良的生殖和/或发育效应，除非可以确定使用该材料的益处超过与不良生物反应相关的风险。因此，对于任何新的用于人体的器械，都需要通过系统分析获得信息，以确保器械在其最终成品形态下所提供的益处将超过器械材料在预期使用期限和使用部位对暴露组织所产生的潜在风险。</p><p>When selecting the appropriate endpoints for biological evaluation of a medical device, one should consider the chemical characteristics of the device materials and the nature, degree, frequency, and duration of exposure to the body (i.e., intended use), as outlined inAttachment A. In general, the biocompatibility endpoints to be considered include: in vitro cytotoxicity; acute, subchronic and chronic toxicity; irritation; sensitization; hemocompatibility; implantation; genotoxicity; carcinogenicity; and effects on reproduction, including developmental effects. However, depending on device physical properties (e.g., surface topography, device geometry),<sup class="footnote-ref"><a href="#fn1" id="fnref1">[1]</a></sup> the intended use of the device, target population, and/or the nature of contact with the body, not every biocompatibility endpoint will require testing. In contrast, the biocompatibility endpoints identified inAttachment A may not be sufficient to demonstrate the safety of certain devices (e.g., devices that include submicron or nanotechnology components, see Section V.D). In addition, biocompatibility endpoints such as neurotoxicity and immunotoxicity should be considered for devices where local or end organ toxicity assessments relevant to the implant location or toxicity issues of concern would not be assessed in a traditional biocompatibility study. For example, a neurological device having direct contact with brain parenchyma and cerebrospinal fluid (CSF) may necessitate an animal implant test to evaluate its pathological and physiological effects (e.g., effects on the brain parenchyma, neurobehavioral effects and/or neurological deficits, and effects on the functional mechanisms of the choroid plexus and arachnoid villi to secrete and absorb CSF). The specific clinical application and the materials used in the manufacture of the new device will guide selection of the appropriate biocompatibility evaluations. Where available, device-specific guidance documents may include additional safety assessments to be considered within the context of a biocompatibility evaluation.</p><p>在选择医疗器械的生物学评估合适终点时，应考虑器械材料的化学特性以及与人体的接触性质、程度、频率和持续时间（即预期使用），如附件 A 所述。一般而言，应考虑的生物相容性终点包括：体外细胞毒性；急性、亚慢性和慢性毒性；刺激性；致敏性；血液相容性；植入性；基因毒性；致癌性；以及对生殖的影响，包括发育效应。然而，根据器械的物理特性（例如表面形貌、器械几何形状）、器械的预期使用、目标人群和/或与人体接触的性质，不是每个生物相容性终点都需要进行测试。相反，附件 A 中确定的生物相容性终点可能不足以证明某些器械的安全性（例如包含亚微米或纳米技术组分的器械，请参见第 V.D 节）。此外，对于需要评估与植入位置相关的局部或终末器官毒性以及相关的毒性问题的器械，还应考虑神经毒性和免疫毒性等生物相容性终点，这些无法在传统的生物相容性研究中进行评估。例如，与脑实质和脑脊液（CSF）直接接触的神经器械可能需要进行动物植入测试，以评估其对脑实质、神经行为以及脉络丛和蜘蛛膜对分泌和吸收 CSF 的功能机制的病理和生理影响。具体的临床应用和新器械制造中使用的材料将指导选择适当的生物相容性评估。如有相关的器械特定指南文件，可能包括在生物相容性评估范围内考虑的其他安全评估。</p><p>Some devices are made of materials that have been well characterized both chemically and physically in the published literature and/or have a long history of safe use in legally US-marketed medical devices. It may not be necessary to conduct testing for all or a portion of the biocompatibility endpoints suggested in the FDA matrix of this guidance. For example, if the sponsor is able to document the use of a particular material (e.g., 316L stainless steel) in a legally-marketed predicate device or a legally-marketed device with comparable tissue exposure, and is able to explain why manufacturing is not expected to adversely impact biocompatibility, additional testing may not be necessary to address some or all of the biocompatibility endpoints recommended for consideration in Attachment A. Sponsors may also leverage information from existing marketing applications to support a rationale that the biocompatibility of the device has been established.<sup class="footnote-ref"><a href="#fn2" id="fnref2">[2]</a></sup> Refer to Section III, Risk Management for Biocompatibility Evaluations, for additional information on how to use prior information in lieu of new testing. Also, refer to Attachment F, Component and Device Documentation Examples, for additional information on comparisons to a legally-marketed device.</p><p>某些器械采用的材料在已发表的文献中在化学和物理上都得到了充分的表征，并且在美国市场上合法销售的医疗器械中已经有了长期安全使用的历史。可能不需要针对 FDA 指南中建议的所有或部分生物相容性终点进行测试。例如，如果赞助商能够记录在合法销售的前体器械或具有可比组织暴露的合法销售器械中使用某种特定材料（例如 316L 不锈钢），并且能够解释为什么制造不会对生物相容性产生不利影响，那么可能不需要进行额外的测试来处理在附件 A 中建议考虑的一些或全部生物相容性终点。赞助商还可以利用现有的市场申请信息来支持设备生物相容性已经得到验证的合理性。有关如何使用先前信息以代替新测试的更多信息，请参考第 III 节的风险管理部分。此外，请参考附件 F 中的组件和设备文档示例，了解与合法销售器械的比较的更多信息。</p><h2 id="B-FDA-Use-of-ISO-10993-1-FDA-使用-ISO-10993-1-标准">B.FDA Use of ISO 10993-1 <em>FDA 使用 ISO 10993-1 标准</em></h2><p>The International Organization for Standardization (ISO), in an effort to harmonize biocompatibility testing, developed a standard for biological evaluation of medical devices (ISO 10993). The scope of this multi-part standard is to evaluate the effects of medical device materials on the body. The first part of this standard,&quot;Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process,&quot;provides a framework in which to plan biological evaluation of medical devices, and if needed, guidance for selecting tests to evaluate the biological response to medical devices. Most of the other parts of the ISO 10993 standard series discuss appropriate methods to conduct biological tests that may be identified when following Part 1 of the standard. With the 2009 revision of the ISO 10993-1 standard, the focus of the document changed from how to determine which biocompatibility tests to conduct, to an approach that considers existing information prior to determining if biocompatibility testing is needed.</p><p>国际标准化组织（ISO）为了协调生物相容性测试，制定了医疗器械生物评价的标准（ISO 10993）。这个多部分标准的范围是评估医疗器械材料对人体的影响。该标准的第一部分，《医疗器械的生物评价-第 1 部分：在风险管理流程中的评估和测试》，提供了一个框架来规划医疗器械的生物评价，以及在需要时选择评估医疗器械生物反应的测试的指导。ISO 10993 标准系列的其他大部分部分讨论了在遵循该标准的第一部分时可能确定的进行生物测试的适当方法。</p><p>With the advancement of scientific knowledge regarding the basic mechanisms of tissue responses, FDA agrees with the ISO 10993-1:2009 revision focus on minimizing the “number and exposure of test animals by giving preference to chemical constituent testing and in vitro models, in situations where these methods yield equally relevant information to that obtained from in vivo models.”<sup class="footnote-ref"><a href="#fn3" id="fnref3">[3]</a></sup> For FDA submissions, biocompatibility information for the device in its final finished form, either developed through the risk management process or from biocompatibility testing (using both in vitro and in vivo models), and/or adequate chemical characterization in conjunction with supplementary biocompatibility information that adequately address the biocompatibility risks of the device should be provided.</p><p>随着对组织反应基本机制的科学知识的进一步了解，FDA 同意 ISO 10993-1：2009 修订版本的重点是通过优先考虑化学成分测试和体外模型来减少“测试动物的数量和接触次数，在这些方法产生与体内模型获得的信息同等相关的情况下”。对于 FDA 的提交，应提供设备在其最终成品形式中的生物相容性信息，无论是通过风险管理流程开发的还是通过生物相容性测试（使用体外和体内模型），以及充分的化学表征信息，以及足够解决设备生物相容性风险的补充生物相容性信息。</p><p>ISO 10993-1 uses an approach to biocompatibility evaluation that is very similar to the original Tripartite Biocompatibility Guidance (G87-1)<sup class="footnote-ref"><a href="#fn4" id="fnref4">[4]</a></sup>, including the same seven general principles.</p><p>ISO 10993-1 采用了与原始的三方生物相容性指南（G87-1）<sup class="footnote-ref"><a href="#fn4" id="fnref4:1">[4:1]</a></sup>非常相似的生物相容性评估方法，包括相同的七个基本原则。</p><ol><li><p>The selection of material(s) to be used in device manufacture and its biocompatibility evaluation should initially take into account the likelihood of direct or indirect tissue contact and any available information for the materials of manufacture, for example, chemical formulation for each component material, including adhesives, known and suspected impurities, and constituents associated with processing.</p><p>在设备制造过程中，选择要使用的材料及其生物相容性评估应首先考虑与组织直接或间接接触的可能性，以及有关制造材料的任何可用信息，例如每个组件材料的化学配方，包括粘合剂、已知和疑似杂质以及与加工相关的成分。</p><p>For the purposes of submission to the FDA, in situations where details pertaining to the materials of manufacture may be proprietary information held by the material supplier, a master file for the material component(s) may assist in determining the formulation of some components of the final device (see Attachment B). However, this information alone may not be sufficient to establish the biocompatibility of the device. Currently there is no standard established for the content or completeness of a device master file. Because the information in a master file may be specific to the material and may not address device fabrication, the information contained in master files may be insufficient to address all of the characterization or biocompatibility questions that pertain to the medical device in its final finished form.</p><p>对于提交给 FDA 的目的，在制造材料的详细信息可能是材料供应商持有的专有信息的情况下，有关材料组分的主文件可能有助于确定最终设备的某些组件的配方（见附件 B）。然而，仅凭这些信息可能不足以确定设备的生物相容性。目前还没有为设备主文件的内容或完整性建立标准。由于主文件中的信息可能特定于材料，并且可能不涉及设备制造，主文件中包含的信息可能不足以解决与医疗器械最终成品相关的所有特性或生物相容性问题。</p></li><li><p>The material(s) of manufacture, the device in its final finished form, and possible leachable chemicals or degradation products should be considered for their relevance to the overall biocompatibility evaluation of the device.</p><p>在设备的整体生物相容性评估中，应考虑到制造材料、最终成品设备以及可能溶出的化学物质或降解产物的相关性。</p></li><li><p>Endpoints relevant to the biocompatibility evaluation should take into account the nature, degree, frequency, duration, and conditions of exposure of the device materials to the body. This principle may lead to the categorization of devices that would facilitate the selection of appropriate endpoints for inclusion in the overall biocompatibility evaluation.</p><p>与生物相容性评估相关的终点应考虑到设备材料与人体接触的性质、程度、频率、持续时间和条件。该原则可能导致对设备进行分类，以便在整体生物相容性评估中选择适当的终点。</p></li></ol><ol start="4"><li><p>Any in vitro or in vivo biological safety experiments or tests should be conducted in accordance with recognized Good Laboratory Practice (GLP) regulations <sup class="footnote-ref"><a href="#fn5" id="fnref5">[5]</a></sup> including, but not limited to, the assignment of competent trained staff in the conduct of biocompatibility testing.</p><p>一切体外或体内的生物安全实验或测试应按照公认的良好实验室规范（GLP）法规进行<sup class="footnote-ref"><a href="#fn5" id="fnref5:1">[5:1]</a></sup>，包括但不限于指定经过专业培训的员工进行生物相容性测试。</p><p>For the purposes of submission to the FDA, if information on these types of nonclinical laboratory studies <sup class="footnote-ref"><a href="#fn6" id="fnref6">[6]</a></sup> is provided, a statement that all such studies have been conducted in compliance with applicable requirements in the Good Laboratory Practice regulation in 21 CFR 58 should also be provided. If any such study was not conducted in compliance with such regulation (e.g., for supporting historical data included with a regulatory submission), a statement detailing how the study complies with each part of the GLP regulations must be provided, with an explanation of how, without an independent audit, the Agency can be assured that all of the data reported in the results represent all data obtained (e.g., the results are reported unbiased and the data not selected for inclusion).</p><p>对于提交给 FDA 的目的，如果提供了关于这些非临床实验室研究<sup class="footnote-ref"><a href="#fn6" id="fnref6:1">[6:1]</a></sup>的信息，还应提供一个声明，说明所有这些研究都符合 21 CFR 58 良好实验室规范法规的适用要求。如果任何这样的研究未按照该法规进行（例如用于支持监管提交的历史数据），必须提供一份详细说明，说明该研究如何符合 GLP 法规的每个部分，并解释在没有独立审计的情况下，机构如何确保所报告的所有数据都代表所获得的所有数据（例如，结果报告无偏差，数据未选取以进行包含）。</p></li><li><p>When test data are provided , complete experimental data , complete to the extent that an independent conclusion could be made, should be submitted to the reviewing authority.</p><p>在提供测试数据时，应提交完整的实验数据，完整到足以得出独立结论的程度，以供审查机构使用。</p><p>For the purposes of submission to the FDA, if testing is conducted according to a recognized standard that does not require data reporting, submission of the test data is not required.</p><p>对于提交给 FDA 的目的，如果测试是根据不需要数据报告的公认标准进行的，则不需要提交测试数据。</p></li><li><p>Any change in chemical composition, manufacturing process, physical configuration (e.g., size, geometry, surface properties) or intended use of the device should be evaluated with respect to possible changes in biocompatibility and the need for additional biocompatibility testing.</p><p>设备的化学成分、制造工艺、物理结构（例如尺寸、几何形状、表面特性）或预期用途的任何变化都应评估其对生物相容性可能造成的影响，并评估是否需要进行额外的生物相容性测试。</p></li><li><p>The biocompatibility evaluation performed in accordance with this guidance should be considered in conjunction with information obtained from other nonclinical tests, clinical studies, and postmarket experiences for a safety assessment that incorporates all available relevant information.</p><p>根据本指南进行的生物相容性评估应与从其他非临床测试、临床研究和市场后经验中获得的信息结合考虑，以进行安全评估，并纳入所有可用的相关信息。</p></li></ol><h2 id="The-FDA-Modified-Matrix-FDA-修改后的矩阵">The FDA-Modified Matrix FDA 修改后的矩阵</h2><p>Like ISO 10993-1:2009, this guidance also uses a tabular format (matrix) to outline the recommendations for biological effects evaluation based on the various factors discussed above for biocompatibility information to be submitted in support of an IDE or marketing application.</p><p>与 ISO 10993-1:2009 一样，本指南也使用表格格式（矩阵）来概述基于上述各种因素的生物效应评估建议，以支持 IDE 或营销申请提交的生物相容性信息。</p><p>Unlike G95-1, the matrix in this guidance consists of a single table. Attachment A, Evaluation Endpoints for Consideration, includes biocompatibility endpoints for consideration recommended by ISO 10993-1:2009, and additional endpoints FDA recommends for consideration as previously identified in G95-1. Some of the endpoints in this table (chronic toxicity, carcinogenicity, reproductive/developmental toxicity and degradation) are not included as separate columns in Annex A of ISO 10993-1:2009, but were included in previous revisions of ISO 10993-1, as well as G95-1. In addition, we have added a column for material-mediated pyrogenicity, which is included as a subset of acute systemic toxicity in ISO 10993-1:2009. Attachment D is a biocompatibility evaluation flow chart explaining when additional biocompatibility evaluations may be needed, and is slightly revised from the prior version in G95-1. Additional evaluations beyond those recommended in ISO 10993-1 may be requested to fully characterize the biocompatibility profile, if novel materials or manufacturing processes are used (i.e., materials or processes that have not previously been used in a legally US-marketed medical device with the same type and duration of contact).</p><p>与 G95-1 不同，本指南中的矩阵由一个单独的表格组成。附件 A“考虑的评估终点”包括 ISO 10993-1:2009 推荐的考虑生物相容性终点，以及 FDA 推荐的其他终点，这些终点在 G95-1 中已经提及。本表格中的一些终点（慢性毒性、致癌性、生殖/发育毒性和降解）在 ISO 10993-1:2009 的附录 A 中并未列为单独的列，但在之前的版本中以及 G95-1 中被包含进去。此外，我们还添加了一个用于材料介导的致热原性的列，该列作为 ISO 10993-1:2009 中急性全身毒性的一个子集。附件 D 是一张生物相容性评估流程图，解释了何时可能需要额外的生物相容性评估，并与 G95-1 中的先前版本略有修改。如果使用了新材料或制造工艺（即以前未在合法销售的同类型和接触持续时间的美国医疗器械中使用的材料或工艺），可能会要求进行超出 ISO 10993-1 推荐的额外评估，以充分描述生物相容性特征。</p><p>If the device has multiple types of exposure, you should include information to address each exposure category identified for the device, <sup class="footnote-ref"><a href="#fn7" id="fnref7">[7]</a></sup>even though testing may not be necessary for every exposure category, in your overall biocompatibility assessment. For example, a pacemaker may include both a pulse generator that is implanted subcutaneously and leads that are implanted within the cardiovasculature. Therefore, we have considered these devices to be classified as both tissue contact and blood contact devices for the evaluation of biocompatibility.</p><p>如果设备存在多种类型的接触，您应包含有关设备所识别的每个接触类别的信息<sup class="footnote-ref"><a href="#fn7" id="fnref7:1">[7:1]</a></sup>，即使并非每个接触类别都需要进行测试，在您的整体生物相容性评估中也要考虑到。例如，起搏器可能包括植入皮下的脉冲发生器和植入心血管内的引导线。因此，我们认为这些设备在生物相容性评估中既属于组织接触设备，也属于血液接触设备。</p><p>In general, FDA agrees with the framework established in ISO 10993-1 for identification of the nature and duration of contact (e.g., cumulative effects with repeat use).<sup class="footnote-ref"><a href="#fn8" id="fnref8">[8]</a></sup>However, FDA has made several modifications to the evaluations identified in that standard for the reasons outlined in Section IV.D and Attachment A.</p><p>总体而言，FDA 认同 ISO 10993-1 中建立的用于识别接触性质和持续时间（例如，重复使用的累积效应）的框架<sup class="footnote-ref"><a href="#fn8" id="fnref8:1">[8:1]</a></sup>。然而，出于第 IV.D 节和附件 A 所列原因，FDA 对该标准中确定的评估进行了若干修改。</p><h2 id="Endpoint-Assessment-终点评估">Endpoint Assessment 终点评估</h2><p>As described in Attachments A and C, sponsors should evaluate each biocompatibility endpoint and whether there is a need for additional testing. All biological effects included in the matrix may not be relevant for all devices. Thus, the modified matrix is only a framework for the selection of endpoints for consideration and not a checklist of required biocompatibility testing. A scientific rationale to support the use of previously collected information in lieu of additional biocompatibility testing should be included with the submission for each endpoint identified in Attachment A. Chemical formulation and processing information may not always be needed for all medical device submissions; however, this information may assist the sponsor to support justifications for waiving testing for any recommended endpoints.</p><p>如附件 A 和 C 所述，赞助商应评估每个生物相容性终点，并确定是否需要进行额外的测试。矩阵中包含的所有生物效应可能并不适用于所有设备。因此，修改后的矩阵仅是用于选择需要考虑的终点的框架，而不是必需的生物相容性测试清单。对于附件 A 中确定的每个终点，在提交时应包含支持使用先前收集的信息代替额外生物相容性测试的科学理据。化学配方和加工信息可能并非对所有医疗器械提交都是必需的；然而，这些信息可能有助于赞助商为豁免任何推荐终点的测试提供理由。</p><p>ISO 10993-1:2009, Clause 4.1 states that “Evaluation may include both a study of relevant preclinical and clinical experience and actual testing. Such an evaluation might result in the conclusion that no testing is needed if the material has a demonstrable safe history of use in a specified role and physical form that is equivalent to that of the device under design.”<sup class="footnote-ref"><a href="#fn9" id="fnref9">[9]</a></sup>To conclude that no additional biocompatibility testing is needed, the sponsor should provide evidence that for each material, the type and duration of tissue contact, physical form, formulation, processing, component interactions, and storage conditions are the same as for the comparator device(s), or the comparator device is demonstrated to be “worst case” compared to the proposed device. In cases where there are differences, such differences should be explained and justified as to how prior data are applicable to support a biocompatibility assessment of the medical device in its final finished form. In vivo animal data and/or clinical data may be of limited utility (as discussed previously in Section III) if specific biocompatibility endpoints are not included as part of the data collected for these studies.</p><p>ISO 10993-1:2009 第 4.1 条规定：“评估可以包括相关的临床前和临床经验研究以及实际测试。如果材料在指定角色和物理形式下具有可证明的安全使用历史，与设计中的设备相等，那么这样的评估可能会得出不需要进行测试的结论。”<sup class="footnote-ref"><a href="#fn9" id="fnref9:1">[9:1]</a></sup>为了得出不需要额外生物相容性测试的结论，赞助商应提供证据，证明每种材料的组织接触类型和持续时间、物理形式、配方、加工、组件相互作用和存储条件与比较设备相同，或证明比较设备相对于拟议设备来说是“最坏情况”。在存在差异的情况下，应解释和证明这些差异如何适用于支持最终成品形式的医疗器械的生物相容性评估。如果特定生物相容性终点不作为这些研究所收集数据的一部分，那么在体动物数据和/或临床数据可能具有有限的用途（如前面第 III 节所讨论）。</p><hr class="footnotes-sep"><section class="footnotes"><ol class="footnotes-list"><li id="fn1" class="footnote-item"><p>For example, a material may be selected to provide a certain stiffness required for the device to perform appropriately (i.e., device characteristic), but may also have other material characteristics that could impact the biological response to the device (e.g., hydrophilic or hydrophobic surface).<br>例如，可能会选择一种材料以提供器械所需的特定刚度（即器械特性），但该材料还可能具有其他特性，可能会影响对器械的生物反应（例如亲水或疏水表面）。 <a href="#fnref1" class="footnote-backref">↩︎</a></p></li><li id="fn2" class="footnote-item"><p>For the purposes of a biocompatibility evaluation, leveraging information from other marketing applications could be appropriate in support of 510(k)s, PMAs, De Novos, HDEs, and initiation of IDEs.<br>为了进行生物相容性评估，利用其他市场申请的信息可能适用于支持 510(k)、PMA、De Novo、HDE 和 IDE 的启动。 <a href="#fnref2" class="footnote-backref">↩︎</a></p></li><li id="fn3" class="footnote-item"><p>ISO 10993-1:2009 “Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process.” <a href="#fnref3" class="footnote-backref">↩︎</a></p></li><li id="fn4" class="footnote-item"><p>In 1986, FDA, Health and Welfare Canada, and Health and Social Services UK issued the Tripartite Biocompatibility Guidance for Medical Devices. FDA subsequently issued General Program Memorandum G87-1 “Tripartite Biocompatibility Guidance” (April 24, 1987). This Guidance was used by FDA reviewers, as well as by manufacturers of medical devices until 1995, to select appropriate tests to evaluate the adverse biological responses to medical devices. FDA then issued Blue Book Memorandum G95-1 &quot;Use of International Standard ISO-10993, “Biological Evaluation of Medical Devices Part-1: Evaluation and Testing,” (May 1, 1995). The final version of this guidance supersedes both G87-1 and G95-1.<br>1986 年，FDA、加拿大卫生福利部和英国卫生及社会服务部发布了三方医疗器械生物相容性指南。FDA 随后发布了《G87-1 三方生物相容性指南》（1987 年 4 月 24 日）。这个指南被 FDA 的审核人员以及医疗器械制造商用于选择适当的测试方法来评估医疗器械的不良生物反应，直到 1995 年。FDA 随后发布了《G95-1 国际标准 ISO-10993 的使用，《医疗器械生物评价第 1 部分：评估和测试》（1995 年 5 月 1 日）。本指南的最终版本取代了 G87-1 和 G95-1。 <a href="#fnref4" class="footnote-backref">↩︎</a> <a href="#fnref4:1" class="footnote-backref">↩︎</a></p></li><li id="fn5" class="footnote-item"><p>FDA does not recognize ISO/IEC 17025 “General requirements for the competence of testing and calibration laboratories.”<br>FDA 不承认 ISO/IEC 17025《测试和校准实验室的能力的一般要求》。 <a href="#fnref5" class="footnote-backref">↩︎</a> <a href="#fnref5:1" class="footnote-backref">↩︎</a></p></li><li id="fn6" class="footnote-item"><p>See definition of nonclinical laboratory study at 21 CFR 58.3(d).<br>参见 21 CFR 58.3(d)对非临床实验室研究的定义。 <a href="#fnref6" class="footnote-backref">↩︎</a> <a href="#fnref6:1" class="footnote-backref">↩︎</a></p></li><li id="fn7" class="footnote-item"><p>We encourage sponsors to contact the appropriate Center and review division if there is a question about the appropriate evaluations for a particular device type.<br>如果对特定设备类型的适当评估存在疑问，我们鼓励赞助商与适当的中心和审查部门联系。 <a href="#fnref7" class="footnote-backref">↩︎</a> <a href="#fnref7:1" class="footnote-backref">↩︎</a></p></li><li id="fn8" class="footnote-item"><p>See ISO 10993-1:2009, Clause 5.2 “Categorization by nature of body contact” and Clause 5.3&quot;Categorization by duration of contact.&quot;<br>参见 ISO 10993-1:2009，第 5.2 节“按接触性质分类”和第 5.3 节“按接触持续时间分类”。 <a href="#fnref8" class="footnote-backref">↩︎</a> <a href="#fnref8:1" class="footnote-backref">↩︎</a></p></li><li id="fn9" class="footnote-item"><p>See ISO 10993-1:2009, Section 4 “General principles applying to biological evaluation of medical devices,” Clause 4.1.<br>参见 ISO 10993-1:2009，第 4 节“适用于医疗器械生物评价的一般原则”，第 4.1 条。 <a href="#fnref9" class="footnote-backref">↩︎</a> <a href="#fnref9:1" class="footnote-backref">↩︎</a></p></li></ol></section>]]></content>
    
    
    <summary type="html">&lt;h1 id=&quot;ISO-10993-—-Part-1-and-the-FDA-Modified-Matrix-第-1-部分和-FDA-修改的矩阵&quot;&gt;ISO 10993 — Part 1 and the FDA-Modified Matrix 第 1 部分和 FDA 修改的矩阵&lt;/h1&gt;
&lt;p&gt;This guidance considers the assessment of biocompatibility to be an evaluation of the medical device in its final finished form, including sterilization, if applicable. However, sponsors should understand the biocompatibility of each device component and any interactions between components that could occur. This is particularly important when the combination of device components could mask or complicate interpretation of a biocompatibility evaluation. For example, if a metal stent has a polymer coating that may separate over time, then the results of a final device biocompatibility assessment may not fully reflect the longer-term clinical performance of the device, and biocompatibility evaluation of the stent with and without the coating may be needed. Similarly, for an in situ polymerizing and absorbable sealant, where the materials present will change over time, separate evaluations of the pre-polymerized, polymerized, and degrading sealant may be needed.&lt;/p&gt;
&lt;p&gt;该指南认为生物相容性评估是对医疗器械在其最终成品形态下（如适用）进行评估，包括灭菌过程。然而，赞助商应了解每个器械组成部分的生物相容性以及可能发生的组分之间的相互作用。当器械组分的组合可能掩盖或使生物相容性评估的解释复杂化时，这一点尤其重要。例如，如果金属支架具有可能随时间分离的聚合物涂层，那么最终器械生物相容性评估的结果可能无法完全反映器械的长期临床表现，因此可能需要对带涂层和不带涂层的支架进行生物相容性评估。同样地，对于在体内聚合和可吸收的止血剂而言，其中材料会随时间变化，可能需要对预聚合、聚合和降解止血剂进行单独评估。&lt;/p&gt;
&lt;h2 id=&quot;Evaluation-of-Local-and-Systemic-Risks-局部和系统风险评估&quot;&gt;Evaluation of Local and Systemic Risks 局部和系统风险评估&lt;/h2&gt;
&lt;p&gt;Biological evaluation of medical devices is performed to determine the acceptability of any potential adverse biological response resulting from contact of the component materials of the device with the body. The device materials should not, either directly (e.g., via surface-bound chemicals or physical properties) or through the release of their material constituents: (i) produce adverse local or systemic effects; (ii) be carcinogenic; or (iii) produce adverse reproductive and/or developmental effects, unless it can be determined that the benefits of the use of that material outweigh the risks associated with an adverse biological response. Therefore, evaluation of any new device intended for human use requires information from a systematic analysis to ensure that the benefits provided by the device in its final finished form will outweigh any potential risks produced by device materials over the intended duration and use of the device in or on the exposed tissues.&lt;/p&gt;
&lt;p&gt;医疗器械的生物学评估是为了确定器械组分材料与人体接触可能引起的任何潜在不良生物反应的可接受性。无论是直接（例如通过表面化学物质或物理特性）还是通过其材料成分的释放，器械材料都不应：(i) 产生不良的局部或全身效应；(ii) 具有致癌性；或 (iii) 产生不良的生殖和/或发育效应，除非可以确定使用该材料的益处超过与不良生物反应相关的风险。因此，对于任何新的用于人体的器械，都需要通过系统分析获得信息，以确保器械在其最终成品形态下所提供的益处将超过器械材料在预期使用期限和使用部位对暴露组织所产生的潜在风险。&lt;/p&gt;
&lt;p&gt;When selecting the appropriate endpoints for biological evaluation of a medical device, one should consider the chemical characteristics of the device materials and the nature, degree, frequency, and duration of exposure to the body (i.e., intended use), as outlined in
Attachment A. In general, the biocompatibility endpoints to be considered include: in vitro cytotoxicity; acute, subchronic and chronic toxicity; irritation; sensitization; hemocompatibility; implantation; genotoxicity; carcinogenicity; and effects on reproduction, including developmental effects. However, depending on device physical properties (e.g., surface topography, device geometry),&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn1&quot; id=&quot;fnref1&quot;&gt;[1]&lt;/a&gt;&lt;/sup&gt; the intended use of the device, target population, and/or the nature of contact with the body, not every biocompatibility endpoint will require testing. In contrast, the biocompatibility endpoints identified in
Attachment A may not be sufficient to demonstrate the safety of certain devices (e.g., devices that include submicron or nanotechnology components, see Section V.D). In addition, biocompatibility endpoints such as neurotoxicity and immunotoxicity should be considered for devices where local or end organ toxicity assessments relevant to the implant location or toxicity issues of concern would not be assessed in a traditional biocompatibility study. For example, a neurological device having direct contact with brain parenchyma and cerebrospinal fluid (CSF) may necessitate an animal implant test to evaluate its pathological and physiological effects (e.g., effects on the brain parenchyma, neurobehavioral effects and/or neurological deficits, and effects on the functional mechanisms of the choroid plexus and arachnoid villi to secrete and absorb CSF). The specific clinical application and the materials used in the manufacture of the new device will guide selection of the appropriate biocompatibility evaluations. Where available, device-specific guidance documents may include additional safety assessments to be considered within the context of a biocompatibility evaluation.&lt;/p&gt;
&lt;p&gt;在选择医疗器械的生物学评估合适终点时，应考虑器械材料的化学特性以及与人体的接触性质、程度、频率和持续时间（即预期使用），如附件 A 所述。一般而言，应考虑的生物相容性终点包括：体外细胞毒性；急性、亚慢性和慢性毒性；刺激性；致敏性；血液相容性；植入性；基因毒性；致癌性；以及对生殖的影响，包括发育效应。然而，根据器械的物理特性（例如表面形貌、器械几何形状）、器械的预期使用、目标人群和/或与人体接触的性质，不是每个生物相容性终点都需要进行测试。相反，附件 A 中确定的生物相容性终点可能不足以证明某些器械的安全性（例如包含亚微米或纳米技术组分的器械，请参见第 V.D 节）。此外，对于需要评估与植入位置相关的局部或终末器官毒性以及相关的毒性问题的器械，还应考虑神经毒性和免疫毒性等生物相容性终点，这些无法在传统的生物相容性研究中进行评估。例如，与脑实质和脑脊液（CSF）直接接触的神经器械可能需要进行动物植入测试，以评估其对脑实质、神经行为以及脉络丛和蜘蛛膜对分泌和吸收 CSF 的功能机制的病理和生理影响。具体的临床应用和新器械制造中使用的材料将指导选择适当的生物相容性评估。如有相关的器械特定指南文件，可能包括在生物相容性评估范围内考虑的其他安全评估。&lt;/p&gt;
&lt;p&gt;Some devices are made of materials that have been well characterized both chemically and physically in the published literature and/or have a long history of safe use in legally US-marketed medical devices. It may not be necessary to conduct testing for all or a portion of the biocompatibility endpoints suggested in the FDA matrix of this guidance. For example, if the sponsor is able to document the use of a particular material (e.g., 316L stainless steel) in a legally-marketed predicate device or a legally-marketed device with comparable tissue exposure, and is able to explain why manufacturing is not expected to adversely impact biocompatibility, additional testing may not be necessary to address some or all of the biocompatibility endpoints recommended for consideration in Attachment A. Sponsors may also leverage information from existing marketing applications to support a rationale that the biocompatibility of the device has been established.&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn2&quot; id=&quot;fnref2&quot;&gt;[2]&lt;/a&gt;&lt;/sup&gt; Refer to Section III, Risk Management for Biocompatibility Evaluations, for additional information on how to use prior information in lieu of new testing. Also, refer to Attachment F, Component and Device Documentation Examples, for additional information on comparisons to a legally-marketed device.&lt;/p&gt;
&lt;p&gt;某些器械采用的材料在已发表的文献中在化学和物理上都得到了充分的表征，并且在美国市场上合法销售的医疗器械中已经有了长期安全使用的历史。可能不需要针对 FDA 指南中建议的所有或部分生物相容性终点进行测试。例如，如果赞助商能够记录在合法销售的前体器械或具有可比组织暴露的合法销售器械中使用某种特定材料（例如 316L 不锈钢），并且能够解释为什么制造不会对生物相容性产生不利影响，那么可能不需要进行额外的测试来处理在附件 A 中建议考虑的一些或全部生物相容性终点。赞助商还可以利用现有的市场申请信息来支持设备生物相容性已经得到验证的合理性。有关如何使用先前信息以代替新测试的更多信息，请参考第 III 节的风险管理部分。此外，请参考附件 F 中的组件和设备文档示例，了解与合法销售器械的比较的更多信息。&lt;/p&gt;</summary>
    
    
    
    
    <category term="KDL" scheme="https://blog.kamasylvia.com/tags/KDL/"/>
    
    <category term="QMS" scheme="https://blog.kamasylvia.com/tags/QMS/"/>
    
    <category term="FDA" scheme="https://blog.kamasylvia.com/tags/FDA/"/>
    
  </entry>
  
  <entry>
    <title>[ISO 10993-1 (FDA)] III Risk Management for Biocompatibility Evaluations</title>
    <link href="https://blog.kamasylvia.com/p/1c062eb7/"/>
    <id>https://blog.kamasylvia.com/p/1c062eb7/</id>
    <published>2023-09-06T01:23:22.000Z</published>
    <updated>2023-10-30T00:50:06.281Z</updated>
    
    <content type="html"><![CDATA[<h1 id="Risk-Management-for-Biocompatibility-Evaluations-生物相容性的风险管理">Risk Management for Biocompatibility Evaluations 生物相容性的风险管理</h1><p>As stated in ISO 10993-1, the biological evaluation of a medical device (or a material component of such) should be conducted within the framework of a risk management process. Such a process should generally begin with assessment of the device, including the material components, the manufacturing processes, the clinical use of the device including the intended anatomical location, and the frequency and duration of exposure. Considering this information, the potential risks from a biocompatibility perspective should be identified. Such risks might include chemical toxicity, unacceptable biological response to physical characteristics of the device, and aspects of manufacturing and processing that could alter the physicochemical characteristics of the device, which could lead to changes in the biocompatibility response. Once the risks have been identified, the sponsor should assess what information is already available regarding those risks and identify the knowledge gaps that remain. Considering the potential biological impact, a plan should be developed to address the knowledge gaps either by biocompatibility testing or other evaluations that appropriately address the risks. The interpretation of the overall biocompatibility evaluation should be considered in the appropriate benefit-risk context.</p><p>根据 ISO 10993-1 的规定，医疗器械（或其材料组成部分）的生物评价应在风险管理过程的框架内进行。这样的过程通常应从对设备的评估开始，包括材料组成部分、制造工艺、设备的临床使用情况（包括预期的解剖位置）以及暴露的频率和持续时间。根据这些信息，应该确定生物相容性风险。这些风险可能包括化学毒性、对设备的物理特性产生不可接受的生物反应，以及可能改变设备物理化学特性的制造和加工方面，导致生物相容性反应发生变化。一旦确定了风险，主办方应评估已有的有关这些风险的信息，并确定尚存的知识空白。考虑到潜在的生物影响，应制定一个计划，通过生物相容性测试或其他适当的评估来解决这些知识空白，以适当地应对风险。应将整体生物相容性评价的解释考虑在适当的利益和风险背景下。</p><h2 id="Risk-Assessment-of-the-Medical-Device-医疗器械的风险评估">Risk Assessment of the Medical Device 医疗器械的风险评估</h2><p>The risk assessment should evaluate the final finished device. The Agency makes a clearance or approval decision for a medical device as it is supplied in its final finished form. The Agency does not clear or approve individual materials that are used in the fabrication of medical devices. Therefore, the risk assessment should evaluate not only the materials used in the device, but also the processing of the materials, the manufacturing methods (including the sterilization process), and any residuals from manufacturing aids used during the process.</p><p>风险评估应评估最终的成品设备。当医疗器械以其最终成品形式提供时，机构会对其进行审批或批准决定。机构不会对用于制造医疗器械的个别材料进行审批或批准。因此，风险评估应该评估不仅设备中使用的材料，还应考虑材料的处理、制造方法（包括灭菌过程）以及制造过程中使用的任何辅助材料残留物。</p><p>The risk assessment should also consider the proposed clinical use of the device, including the anatomical location, duration of exposure, and intended use population. For example, for pediatric patients with a limited life expectancy, the tolerance for risk associated with a permanently implanted medical device may be higher than the tolerance for risk from the same device in an otherwise healthy pediatric population. The potential exposure duration should also consider which material components of the device have direct or indirect contact with tissue, and whether exposure would be a one-time exposure, a constant exposure over time, or an intermittent exposure over time that could have a cumulative effect. For example, pacemaker pulse generators commonly contain internal electronic components made from chemicals that could be toxic to the body, but appropriate bench testing can demonstrate that the pulse generator is hermetically sealed and will limit exposure of those chemicals to the surrounding tissues.</p><p>风险评估还应考虑设备的拟议临床使用情况，包括解剖位置、暴露持续时间和拟定使用人群。例如，对于寿命有限的儿科患者来说，与永久植入的医疗器械相关的风险容忍度可能高于对同一设备在其他健康儿童人群中的风险容忍度。潜在的暴露持续时间还应考虑设备的哪些材料组成部分与组织直接或间接接触，并且暴露是一次性的、持续不断的，还是随时间间歇性的暴露，可能具有累积效应。例如，起搏器脉冲发生器通常包含由对人体有毒的化学物质制成的内部电子元件，但适当的台架测试可以证明脉冲发生器是密封的，会限制这些化学物质对周围组织的暴露。</p><h2 id="Identification-of-Potential-Risks-潜在风险的识别">Identification of Potential Risks 潜在风险的识别</h2><p>An assessment of potential biocompatibility risk should include not only chemical toxicity, but also physical characteristics that might contribute to an unwanted tissue response. These characteristics can include surface properties, forces on surrounding tissue (e.g., mechanical, thermal, electromagnetic), geometry, and presence of particulates, among others. In addition, changes in manufacturing and processing parameters can also have an impact on biocompatibility. For example, the original processing for an implanted device might include placing the device in an acid bath to facilitate passivation of the implant surface. If this passivation process is changed to eliminate the acid bath in favor of a different method of passivating the surface, removal of the acid bath might unintentionally lead to a smaller reduction in pyrogenic material, which could result in pyrogenic reactions (fever) following implantation of the device. Another common change that might impact biocompatibility is a change in resin supplier. For example, if the new resin supplier does not remove all processing solvents (some of which may be known toxic compounds, such as formaldehyde), the final manufactured device could cause unexpected toxicities (e.g., cytotoxicity, irritation, sensitization, genotoxicity) that were not seen with devices manufactured from the original resin.</p><p>对潜在的生物相容性风险的评估不仅应包括化学毒性，还应考虑可能导致不良组织反应的物理特性。这些特性可以包括表面特性、对周围组织的作用力（如机械、热、电磁力）、几何形状和颗粒的存在，等等。此外，制造和加工参数的变化也可能对生物相容性产生影响。例如，原始的植入装置的处理过程可能包括将装置放入酸浴中以促进表面钝化。如果将这种钝化过程改变为使用其他方法进行表面钝化而不使用酸浴，去除酸浴可能无意中导致对致热原材料的减少较小，从而可能导致装置植入后引起致热反应（发热）。另一个可能影响生物相容性的常见变化是树脂供应商的更换。例如，如果新的树脂供应商未能去除所有加工溶剂（其中一些可能是已知的有毒化合物，如甲醛），则最终制造的装置可能引起意外的毒性反应（如细胞毒性、刺激性、致敏性、遗传毒性），而这些反应在使用原始树脂制造的装置中未曾出现。</p><p>Sources of information on potential biocompatibility risks can include, but are not limited to, a manufacturer’s previous experience with the same material(s), preferably in the same or similar anatomical location; reported experience from other manufacturers using the same material in the same or similar anatomical location; information provided by the material supplier (e.g., in a master file<sup class="footnote-ref"><a href="#fn1" id="fnref1">[1]</a></sup>, see Attachment B); chemical or surface analysis of the device in its final finished form; and the published literature. In certain situations, clinical experience, such as postmarket surveillance information, may be informative. For example, for a limited duration, skin-contacting device, patient experience that includes information on potential for irritation or sensitization can be useful to the risk assessment.</p><p>关于潜在生物相容性风险的信息来源包括但不限于制造商对相同材料的先前经验（最好是在相同或类似的解剖位置），其他制造商在相同或类似解剖位置使用相同材料的经验报告，材料供应商提供的信息（如主文件中的信息，请参见附件 B），对最终成品设备的化学或表面分析，以及已发表的文献。在某些情况下，临床经验，如事后市场监测信息，可能是有启发性的。例如，对于有限时期的与皮肤接触的装置，包括有关刺激或致敏潜力的信息对风险评估是有用的。</p><p>When leveraging data from experience with a particular device for a new device submission to FDA, it is important to understand how the tested device compares to the device under consideration. In general, the more similar the tested device and device under consideration are, including their intended use, the more applicable the risk information is likely to be. For example, for a vascular catheter comprised of a certain polymer, citing experience with the same polymer in a blood-contacting device will be more applicable than experience with a similar polymer in a device that only contacts mucosal membranes. Similarly, experience with device components made using the same formulation and processing (e.g., for devices within a product family) will be more applicable than experience with device components made by a different manufacturer where the formulation and processing are unknown.</p><p>当利用与新设备提交给 FDA 的特定设备的经验数据时，了解受测设备与待考虑设备的比较是很重要的。一般而言，受测设备与待考虑设备越相似，包括其预期使用方式，相关的风险信息就越适用。例如，对于由特定聚合物组成的血管导管，引用相同聚合物在与血液接触的设备中的经验将比引用相似聚合物在仅与粘膜接触的设备中的经验更为适用。同样地，对于使用相同配方和加工的设备成分（例如产品系列中的设备），与使用不同制造商制造的成分，配方和加工方式不详的设备成分的经验将更为适用。</p><p>A master file for a material, device component, and/or device may be useful if it includes information on recommended processing of the material or component and any biological testing already performed (see Attachment B). A master file should also contain a risk assessment provided by the supplier that includes a discussion of the chemical formulation and structure of the material or component and information on how to evaluate a device made from that material.</p><p>材料、设备成分和/或设备的主文件如果包括有关材料或成分的推荐加工信息以及已执行的生物测试的信息，将会非常有用（请参见附件 B）。主文件还应包含供应商提供的风险评估，其中包括对材料或成分的化学配方和结构进行讨论的信息，以及如何评估由该材料制成的设备。</p><p>In certain situations, a sponsor may propose to use a material that has known toxicities but where the material could be acceptable for the end use. In this case, the risk assessment should include consideration of the intended use population that will use (e.g., protective mask for clinician) or be treated with the device and a discussion of potential benefits of using the chosen material as well as potential mitigations that have been considered (e.g., hermetically sealing).</p><p>在某些情况下，赞助商可能会提议使用已知有毒性的材料，但该材料在最终使用中可能是可接受的。在这种情况下，风险评估应包括考虑将使用该设备的预期使用人群（例如，临床医生的防护口罩）或接受该设备治疗的人群，并讨论使用所选择材料的潜在益处以及已考虑的潜在缓解措施（例如，密封）。</p><p>A chemical analysis of the materials used in a device in its final finished form can be informative. Chemical analysis can be particularly helpful to demonstrate that chemical toxicity testing from a previously cleared or approved medical device is relevant to a device under review by the Agency. For example, in some circumstances, a chemical analysis can demonstrate that the extractables and leachables in a biocompatibility extract have not changed, eliminating the need for additional biocompatibility testing using that type of solvent. In addition, chemical analyses can be used to assess the toxicological risk of the chemicals that elute from devices. For example, chemical analysis using exhaustive extraction techniques (per ISO 10993-12) can also be helpful to evaluate long-term toxicity endpoints such as potential carcinogens. Extraction techniques could also be used to identify intermediate and final breakdown products in a material that is either synthesized in vivo (e.g., in situ polymerizing materials) or intended to be absorbable (e.g., degradable materials). However, chemical analysis is usually insufficient to identify all of the risks of the device in its final finished form, because it will not consider aspects of the finished device such as surface properties (e.g., rough versus polished surface) or device geometry that could affect the biological response in certain scenarios (e.g., thrombogenicity, implantation). In addition, the outcomes of chemical analyses are often sensitive to the parameters of the test. Extraction solvents should be selected to optimize compatibility with the device materials and provide information on the types of chemicals that are likely to be extracted in clinical use. Solvents that swell the polymer, cause the polymer to degrade or dissolve, or interfere with detection of chemicals should be used with caution.</p><p>对设备最终成品中使用的材料进行化学分析可以提供有益信息。化学分析对于证明先前获得清除或批准的医疗器械的化学毒性测试与正在审查的设备相关性特别有帮助。例如，在某些情况下，化学分析可以证明生物相容性提取物中的可萃取物和可溶出物没有发生变化，从而不需要使用该类型溶剂进行额外的生物相容性测试。此外，化学分析可用于评估从设备中溶出的化学物质的毒理风险。例如，使用详尽的提取技术（符合 ISO 10993-12）进行化学分析，还可以帮助评估潜在致癌物等长期毒性终点。提取技术还可用于识别在体内合成（例如，原位聚合材料）或预期可吸收（例如，可降解材料）的材料中的中间和最终分解产物。然而，化学分析通常无法识别设备在最终成品形式中的所有风险，因为它不会考虑最终设备的表面特性（例如，粗糙与抛光表面）或可能影响某些情况下生物反应的设备几何形状（例如，血栓形成，植入）。此外，化学分析的结果通常对测试参数敏感。应选择溶剂以优化与设备材料的兼容性，并提供有关在临床使用中可能被提取的化学物质类型的信息。使用会使聚合物膨胀、降解或溶解，或干扰化学物质检测的溶剂应谨慎使用。</p><p>Finally, there may be potential hazards that are not addressed by available information. In certain cases, such as the addition of a new chemical to a standard formulation, individual toxicity information for the added chemical and starting material may be insufficient due to the potential for chemical interactions between the material and added chemical. Thus, the risk assessment should consider what is known about the additional material, the base material, and potential chemical interactions between the two.</p><p>最后，可能存在无法通过现有信息解决的潜在危害。在某些情况下，例如将新化学物质添加到标准配方中，由于材料与添加化学物质之间的化学相互作用的潜在可能性，添加化学物质和起始材料的个体毒性信息可能是不足的。因此，风险评估应考虑关于附加材料、基础材料以及两者之间的潜在化学相互作用的已知信息。</p><h2 id="Considering-Available-Information-to-Identify-and-Mitigate-Risks-根据现有信息识别和缓解风险">Considering Available Information to Identify and Mitigate Risks 根据现有信息识别和缓解风险</h2><p>In order to reduce unnecessary testing, including animal testing<sup class="footnote-ref"><a href="#fn2" id="fnref2">[2]</a></sup>, FDA recommends that sponsors consider all available relevant information when conducting their risk assessment. FDA believes that the following information should be included in your risk assessment, if applicable:</p><p>为了减少不必要的测试，包括动物测试<sup class="footnote-ref"><a href="#fn2" id="fnref2:1">[2:1]</a></sup>，FDA 建议赞助商在进行风险评估时考虑所有可用的相关信息。如果适用，FDA 认为以下信息应包括在您的风险评估中：</p><ol><li><p>Literature and other publicly available information: Sponsors should review all available toxicity literature and other publicly available information to determine the toxicity risks for the materials used to manufacture their medical device. If data are not available to evaluate the safety of a compound, then the concept of Threshold of Toxicological Concern (TTC)<sup class="footnote-ref"><a href="#fn3" id="fnref3">[3]</a></sup> can be used to assess some biocompatibility endpoints.</p><p>文献和其他公开可获得的信息：赞助商应查阅所有可用的毒性文献和其他公开可获得的信息，以确定用于制造其医疗器械的材料的毒性风险。如果没有数据来评估化合物的安全性，则可以使用毒理学关注阈（Threshold of Toxicological Concern，TTC）<sup class="footnote-ref"><a href="#fn3" id="fnref3:1">[3:1]</a></sup>的概念来评估一些生物相容性终点。</p><p>Sponsors should also review available literature and other publicly available information to identify specific risks associated with the use of their device and possible mitigation measures. For example, literature could inform manufacturers that nitinol passivation of a peripheral stent should be conducted appropriately to ensure that nickel, a chemical with known toxicities, does not leach from the device when implanted. Literature could also be useful in identifying the potential breakdown products of an absorbable device, allowing the sponsor to conduct more focused testing to characterize and analyze these chemicals as a device degrades. Sponsors should be selective in how literature and other publicly available information are used to inform their risk assessment; all available information should be considered in the context of how relevant the information might be to a specific medical device. For example, status of a device material or component as “generally recognized as safe” (GRAS) by FDA as a food additive may or may not be informative for a medical device risk assessment because it may not be appropriate to extrapolate use in food to device-specific tissue contact, such as muscle or circulating blood. In addition, when considering available literature with respect to specific device materials, sponsors should also evaluate whether such information is relevant in light of the manufacturing and processing for the medical device. Similarly, literature or other publicly available information such as clinical data may become less relevant when changes in materials or suppliers occur. Such changes may affect the safety or effectiveness of a medical device and should be considered appropriately in any risk assessment provided to FDA.</p><p>赞助商还应审阅可获得的文献和其他公开信息，以识别与其设备使用相关的具体风险，并提出可能的缓解措施。例如，文献可以告知制造商，为确保植入时设备中已知具有毒性的镍等化学物质不会溶出，外周支架的氮化钛钝化处理应进行适当的操作。文献还可以帮助确定可吸收设备的潜在降解产物，使赞助商能够进行更有针对性的测试，以对这些化学物质进行表征和分析。赞助商在使用文献和其他公开可获得的信息指导风险评估时应选择性地运用，并将所有可用信息与特定医疗器械的相关性相结合考虑。例如，FDA 将某种设备材料或组件视为“FDA 普遍承认为安全”（GRAS）的食品添加剂，并不能直接适用于与肌肉或循环血液等特定组织接触的医疗器械的风险评估，因此不宜将其推广应用。此外，在考虑与特定设备材料相关的文献时，赞助商还应评估这些信息在医疗器械的制造和加工过程中是否具有相关性。同样，在发生材料或供应商变更时，文献或其他公开可获得的信息，如临床数据，可能变得不那么相关。此类变更可能会影响医疗器械的安全性或有效性，因此应在向 FDA 提供的任何风险评估中适当地加以考虑。</p></li></ol><p>If literature is used to waive testing for certain biocompatibility endpoints, thesubmission should include information on the applicability of the dose, route, andfrequency of exposure from the literature report(s) as compared to the proposeddevice use. In addition, while literature may be appropriate to evaluate certainbiocompatibility endpoints, it may not be appropriate to waive allbiocompatibility testing. For example, No Observed Adverse Effect Level(NOAEL) and Lowest Observed Adverse Effect Level (LOAEL) data should bederived from studies relevant to the endpoint under consideration. For example,NOAELs and LOAELs from a systemic toxicity study can often be used to waiveacute, subchronic, or chronic system toxicity testing, but might not be relevant forgenotoxicity, local and systemic carcinogenicity, sensitization, irritation orreproductive toxicity assessments, if these endpoints are not assessed in thestudies selected to develop NOAELs or LOAELs. However, NOAEL/LOAELvalues developed to consider reproductive toxicity may be used to assess thepotential reproductive toxicity of compounds released from devices that are not indirect contact with reproductive tissues.</p><p>如果文献用于豁免某些生物相容性终点测试，提交应包括关于文献报告中剂量、途径和频率的适用性信息，与拟议的器械使用进行比较。此外，虽然文献可能适用于评估某些生物相容性终点，但不一定适用于豁免所有生物相容性测试。例如，无观察到的不良影响水平（NOAEL）和最低观察到的不良影响水平（LOAEL）数据应来源于与所考虑终点相关的研究。例如，系统毒性研究中的 NOAEL 和 LOAEL 通常可用于豁免急性、亚慢性或慢性系统毒性测试，但对于基因毒性、局部和全身致癌性、致敏、刺激或生殖毒性评估可能不相关，如果这些终点在用于发展 NOAEL 或 LOAEL 的研究中未进行评估。然而，用于考虑生殖毒性的 NOAEL/LOAEL 值可用于评估与生殖组织直接接触的器械释放的化合物的潜在生殖毒性。</p><ol><li><p>Clinical experience: Clinical experience should be considered in the overallbenefit-risk profile for the device where the totality of the data available for thedevice may inform whether more testing is needed, or if any testing is needed atall. For example, clinical experience may be useful to mitigate problematicfindings in an in vitro biocompatibility or in vivo animal study. In other cases,testing to address long-term biocompatibility endpoints (e.g., genotoxicity,chronic toxicity, or carcinogenicity) may not be necessary if the patient’s lifeexpectancy in the intended use population is limited.</p><p>临床经验：临床经验应考虑到设备的整体效益风险概况，以确定是否需要进行更多的测试，或者是否需要进行任何测试。例如，临床经验可能有助于缓解体外生物相容性或体内动物研究中的问题发现。在其他情况下，如果预期使用人群的患者预期寿命有限，可能无需进行长期生物相容性终点（例如基因毒性、慢性毒性或致癌性）的测试。</p><p>Generally, clinical studies are not sufficiently sensitive to identify biocompatibility concerns. Clinical or sub-clinical symptoms that result from the presence of a non-biocompatible material may not be identifiable, or may result in symptoms that are indistinguishable from the disease state such that the clinical data may not be informative to the biocompatibility evaluation. For example, blood vessel occlusion at the site of an implanted stent could be indicative of a toxic response to the stent materials or be related to damage to the stent during implantation (e.g., due to operator error or a delivery device malfunction).However, in limited circumstances, clinical experience may mitigate certain identified risks. For example, if there is previous clinical experience with a particular medical device (either from a clinical study or via marketing outside of the US), and there have been no issues with anaphylaxis, then biocompatibility testing for complement activation may not be necessary. Similarly, in an Investigational Device Exemption (IDE) study, first in human study data may be useful to initiate a study on a revised device design, while biocompatibility evaluations are being completed in parallel, and it may be acceptable to provide complete biocompatibility information once the device design is finalized for commercialization, depending on the risks posed to patients.<sup class="footnote-ref"><a href="#fn4" id="fnref4">[4]</a></sup></p><p>一般来说，临床研究对于识别生物相容性问题的敏感性不足。由于非生物相容材料的存在导致的临床或亚临床症状可能无法识别，或者可能导致与疾病状态无法区分的症状，因此临床数据可能对生物相容性评估无效。例如，植入支架的血管阻塞可能表明对支架材料的毒性反应，也可能与植入过程中支架损坏有关（例如，由于操作者错误或传递装置故障）。然而，在一些有限的情况下，临床经验可能有助于缓解特定的风险。例如，如果已经有关于特定医疗器械的临床经验（无论是来自临床研究还是在美国以外市场上销售），并且没有出现过过敏反应的问题，则可能无需进行补体激活的生物相容性测试。同样，在调查性设备豁免（IDE）研究中，首次人体研究数据可能有助于启动对修订设备设计的研究，同时与生物相容性评估同时进行，根据对患者造成的风险，一旦设备设计最终确定用于商业化，提供完整的生物相容性信息可能是可接受的。</p></li></ol><ol start="2"><li>Clinical experience may also inform biocompatibility evaluation of next generation devices. For example, some clinical studies of specific absorbable medical devices demonstrated that the absorption kinetics were not accurately predicted by the nonclinical performance (bench or animal) studies. This information has been helpful when evaluating a next generation device using an improved bench model for the absorption of the device, and for assessing how the type and amount of chemicals released with absorption over time might affect biocompatibility.</li></ol><p>临床经验也可以为下一代设备的生物相容性评估提供信息。例如，某些特定可吸收医疗器械的临床研究表明，吸收动力学并不能准确预测非临床性能（台架或动物）研究的结果。这些信息在使用改进的台架模型评估下一代设备的吸收过程，并评估随时间释放的化学物质类型和数量对生物相容性的影响时非常有帮助。</p><p>However, there are also situations where FDA has not found clinical experience to provide relevant biocompatibility information. For example, providing clinical information that a particular implant material has a long history of use would not typically be sufficient to support the biocompatibility of an implant made from the same material because manufacturing and processing could affect the final chemistry presented to the body. In addition, such information is often too broad and general to be useful.</p><p>然而，也存在 FDA 未发现临床经验提供相关生物相容性信息的情况。例如，提供特定植入材料具有长期使用历史的临床信息通常不足以支持由相同材料制成的植入物的生物相容性，因为制造和加工可能会影响最终呈现给人体的化学成分。此外，这类信息通常过于广泛和概括，不具备实用性。</p><ol start="3"><li><p>Animal study experience: Data from an in vivo animal study of the medical device in its final finished form may be used in lieu of some biocompatibility tests. Testing performed in a relevant animal model can be used if the study was designed to include assessments for biocompatibility endpoints. These studies should evaluate the biological response to the test article implanted in a clinically relevant implantation site. For example, separate biocompatibility assessments for implantation, in vivo thrombogenicity, and acute, subchronic, and chronic toxicity may not be needed if these endpoints were included in the in vivo animal study design with an appropriate study endpoint, and the scientific principles and recommendations in the appropriate ISO 10993 test method were considered and applied.</p><p>动物研究经验：在某些生物相容性测试之外，可以使用最终成品形式的医疗器械在活体动物研究中获得的数据。如果研究设计中包括了对生物相容性终点的评估，那么在相关动物模型中进行的测试是可以使用的。这些研究应该评估临床相关植入部位中测试物体的生物反应。例如，如果这些终点在活体动物研究设计中包含了适当的研究终点，并且考虑和应用了适当的 ISO 10993 测试方法的科学原理和建议，那么就不需要单独进行有关植入、体内血栓形成、急性、亚慢性和慢性毒性的生物相容性评估。</p><p>If animal study data (e.g., histology, necropsy) identifies adverse biological responses, some additional biocompatibility testing may be warranted. For example, glutaraldehyde-fixed tissue heart valves may show toxic effects in animal studies as well as some standard biocompatibility assays, such as cytotoxicity and genotoxicity. These findings would usually trigger the need for additional studies, such as chemical characterization and dose ranging cytotoxicity and genotoxicity studies of suspected chemical toxins released from the device to confirm the cause of the adverse findings and to determine if additional mitigations are needed.</p><p>如果动物研究数据（例如组织学、尸检）发现了不良的生物反应，可能需要进行一些额外的生物相容性测试。例如，动物研究中可能显示出戊二醛固定的组织心瓣具有毒性效应，以及一些标准的生物相容性测定，如细胞毒性和遗传毒性。这些发现通常会触发进一步的研究需求，例如对疑似从器械释放的化学毒素进行化学特性和剂量范围内的细胞毒性和遗传毒性研究，以确认不良结果的原因，并确定是否需要额外的改进措施。</p><p>Animal experience may also inform biocompatibility evaluation of next generation devices. For example, animal study data from the literature regarding absorbable adhesion barriers made of a certain material could provide information related to the timeframe of absorption and potential adverse effects for a new or modified device.</p><p>动物经验也可以为下一代设备的生物相容性评估提供信息。例如，关于某种特定材料制成的可吸收粘连阻隔物的动物研究文献可能提供与吸收时间和潜在不良效应有关的信息，这对于新的或修改后的设备是有帮助的。</p><p>However, there are also situations where FDA has not found animal data to provide relevant biocompatibility information. For example, data from the literature indicating that a particular implant material is biocompatible may not be sufficient to support the biocompatibility of a device made from the same material because manufacturing and processing likely will affect the final device chemistry presented to the body. Similarly, animal studies designed to assess human factors and studies conducted in animal cadavers would not typically include assessment of biological response, and therefore may not be useful to support a biocompatibility evaluation.</p><p>然而，也存在 FDA 未发现动物数据提供相关生物相容性信息的情况。例如，文献中表明某种特定植入材料具有生物相容性的数据可能不足以支持由相同材料制成的设备的生物相容性，因为制造和加工很可能会影响最终呈现给人体的设备化学成分。同样，旨在评估人体因素的动物研究和在动物尸体上进行的研究通常不包括生物反应的评估，因此可能无法支持生物相容性评估。</p></li><li><p>Medical device standards: Standards specific to a particular device type or material may be helpful to inform a risk assessment; however, the extent to which the standard could be utilized may be dependent on the specificity of the standard and/or the specific material. Ideally, a standard would have sufficient specificity to provide useful information regarding material risks. For example, standards that outline both mechanical and chemical properties of a device type with pass/fail criteria may be particularly informative to FDA’s review because of the specificity of such a standard. Standards that address bulk material composition can also be informative as a starting point for incorporating material characterization into a risk assessment. For example, it may be appropriate to use material standards to support the biocompatibility evaluation of 316L stainless steel surgical vascular clamps, as long as any risks associated with manufacturing are appropriately considered and mitigated (see Section IV.A). Given the effects that manufacturing and processing may have on a polymer as incorporated into the final finished medical device, use of material standards may not be sufficient to identify biocompatibility risks for devices made from polymers.</p><p>医疗器械标准：针对特定设备类型或材料的标准可能有助于风险评估；然而，标准的适用程度可能取决于标准的特异性和/或特定材料。理想情况下，一个标准应具有足够的特异性，以提供有关材料风险的有用信息。例如，对于同时概述设备类型的机械和化学性能，并具备合格/不合格标准的标准，可能会对 FDA 的审查提供特别有益的信息，因为此类标准的特异性较高。解决原料物质组成的标准也可以作为将物质特性纳入风险评估的起点参考。例如，对于 316L 不锈钢外科血管夹这类设备，使用物质标准来支持生物相容性评估可能是合适的，只要制造过程中的任何风险得到适当的考虑和缓解（参见第 IV.A 节）。鉴于制造和加工对聚合物在最终医疗器械中的影响，使用物质标准可能不足以识别由聚合物制成的设备的生物相容性风险。</p></li><li><p>Devices previously reviewed by FDA: Experience with medical device materials previously reviewed by FDA (e.g., in previous generation devices, PMA-approved devices, predicate devices) are also relevant for consideration as part of a risk assessment. Such information may be more informative when a sponsor is able to leverage their own experience, rather than that from another manufacturer or supplier as the manufacturing and processing of the device material may be unknown. Sponsors should be specific in their risk assessment regarding how devices previously reviewed by FDA are being utilized to identify potential risks and/or mitigate identified risks. Sponsors should be as specific as possible when referencing devices previously reviewed by FDA, including submission numbers or master file numbers, and references to specific test reports or data in a submission (if applicable). Sponsors should also provide a specific comparison of the subject device materials to device materials previously reviewed by FDA. It may be helpful to use the documentation examples provided in Attachment F to provide such a comparison.</p><p>FDA 先前审查的设备：与 FDA 先前审查的医疗器械材料的经验（例如，在先前的设备、PMA 批准的设备或基准设备中）也是风险评估的相关考虑因素。当赞助商能够利用自己的经验而不是来自其他制造商或供应商的经验时，此类信息可能更具信息价值，因为设备材料的制造和加工可能是未知的。在风险评估中，赞助商应具体说明如何利用 FDA 先前审查的设备来识别潜在风险和/或减轻已确定的风险。赞助商在引用 FDA 先前审查的设备时应尽可能具体，包括提交编号或主文件编号，并引用提交中的特定测试报告或数据（如果适用）。赞助商还应提供对比受评设备材料与 FDA 先前审查的设备材料的具体比较。使用附件 F 中提供的文档示例来进行此类比较可能是有帮助的。</p></li></ol><h2 id="Submission-and-Interpretation-提交与解释">Submission and Interpretation 提交与解释</h2><p>FDA recommends that sponsors provide their risk assessment at the beginning of the biocompatibility section in a submission to CDRH or CBER. Based on the considerations outlined above, the sponsor should clearly summarize their conclusions regarding their risk assessment and explain the relationship between the identified biocompatibility risks and the information available to mitigate the identified risks, and identify any knowledge gaps that remain. The sponsor should then identify any biocompatibility testing or other evaluations that were conducted to mitigate any remaining risks.</p><p>FDA 建议赞助商在向 CDRH 或 CBER 提交时，在生物相容性部分的开始提供风险评估。根据上述考虑，赞助商应清楚总结他们对风险评估的结论，并解释已确定的生物相容性风险与可降低这些风险的信息之间的关系，并确定任何仍存在的知识缺口。然后，赞助商应说明已进行的任何生物相容性测试或其他评估，以降低任何剩余风险。</p><p>The sponsor should also explain any toxicities and adverse effects identified in their biocompatibility testing or other evaluations. As a part of the risk assessment, the sponsor should discuss any other available information (such as the results of in vivo animal studies) that might provide additional context for interpretation. For example, if a device made from polypropylene shows a grade 2 cytotoxicity with L929 cells, which might be acceptable per ISO 10993-5 “Biological evaluation of medical devices — Part 5: Tests for in vitro cytotoxicity,” the sponsor should provide additional information regarding the potential source of the toxicity, since polypropylene is generally not expected to elicit a cytotoxicity response of this level. Conversely, skin-contacting electrodes with adhesives containing detergents might be expected to have higher than grade 2 cytotoxicity with L929 cells, which could be acceptable if the sponsor is able to confirm that there are no other chemical constituents causing the adverse cytotoxic response. In general, potential toxicities identified through biocompatibility testing should be evaluated considering the intended use of the device and as part of the overall benefit-risk assessment.</p><p>赞助商还应解释他们在生物相容性测试或其他评估中发现的任何毒性和不良反应。作为风险评估的一部分，赞助商应讨论任何其他可用信息（例如体内动物研究的结果），以提供额外的解释背景。例如，如果聚丙烯制成的器械在 L929 细胞中表现出 2 级细胞毒性，可能符合 ISO 10993-5《医疗器械生物学评价-第 5 部分：体外细胞毒性试验》的要求，赞助商应提供有关毒性的潜在来源的额外信息，因为通常不会预期聚丙烯会引起这个水平的细胞毒性反应。相反，含有清洁剂的与皮肤接触的电极可能会在 L929 细胞中表现出高于 2 级的细胞毒性，如果赞助商能够确认没有其他化学成分引起不良的细胞毒性反应，这可能是可以接受的。总的来说，通过生物相容性测试确定的潜在毒性应在考虑设备的预期用途和整体利益风险评估的一部分进行评估。</p><p>During the biocompatibility evaluation, if chemical characterization testing is conducted per ISO 10993-18 &quot; Biological evaluation of medical devices — Part 18 : Chemical characterization of materials&quot; or ISO/TS 10993-19&quot;Biological evaluation of medical devices — Part 19: Physico-chemical , morphological and topographical characterization of materials,&quot; it is important to understand that these standards include only general information regarding multiple analytical techniques and no acceptance criteria. Therefore, to support a declaration of conformity, as a part of the supplemental information used to support the use of these standards, we recommend that a rationale for the selected method(s) and protocols be presented with your results so that FDA can assess whether the information obtained will support the biocompatibility of your device.</p><p>在生物相容性评估期间，如果按照 ISO 10993-18《医疗器械生物学评价-第 18 部分：材料的化学特性评价》或 ISO/TS 10993-19《医疗器械生物学评价-第 19 部分：材料的物理化学、形态学和拓扑学特性评价》进行化学表征测试，重要的是要了解这些标准仅包含关于多种分析技术的一般信息，没有接受标准。因此，为了支持一份符合性声明，作为用于支持使用这些标准的补充信息的一部分，建议您在结果中提供选择方法和协议的理由，以便 FDA 评估所获得的信息是否支持您器械的生物相容性。</p><p>Attachment C provides an example biocompatibility risk assessment summary table, which FDA has generally found useful from a review perspective. Sponsors may find that utilizing this approach and format is helpful when developing their own biocompatibility risk assessment. FDA will review the risk assessment as part of the overall biocompatibility evaluation and determine whether the risks, mitigations, and biocompatibility testing or other information is appropriate to support the biocompatibility of the medical device. Sponsors may wish to discuss their plan for conducting an appropriate risk assessment with FDA early in their device development process. FDA recommends that sponsors use the Q-Submission process to facilitate these discussions.<sup class="footnote-ref"><a href="#fn5" id="fnref5">[5]</a></sup> While FDA generally cannot review a detailed risk assessment under the Q-Submission process, it is often helpful to discuss the planned approach for such a risk assessment. Pre-Submissions may be particularly helpful to obtain feedback regarding a risk assessment in the following and other instances:</p><p>附件 C 提供了一个生物相容性风险评估摘要表的示例，从评审角度来看，FDA 通常认为这是有用的。赞助商在开发自己的生物相容性风险评估时，可能会发现采用这种方法和格式是有帮助的。FDA 将作为整体生物相容性评估的一部分，审查风险评估，并确定风险、缓解措施和生物相容性测试或其他信息是否适合支持医疗器械的生物相容性。赞助商可能希望在设备开发过程的早期与 FDA 讨论进行适当的风险评估计划。FDA 建议赞助商使用 Q-提交流程促进这些讨论。<sup class="footnote-ref"><a href="#fn5" id="fnref5:1">[5:1]</a></sup>虽然 FDA 通常无法在 Q-提交流程中审查详细的风险评估，但讨论计划中的风险评估方法通常是有帮助的。在以下情况和其他情况下，预提交可能特别有助于获得有关风险评估的反馈：</p><ul><li>When developing an in vitro test battery for hemocompatibility to determine whether the validation information being developed might be appropriate for a particular clinical indication;<br>在开发用于血液相容性的体外测试组合以确定正在开发的验证信息是否适用于特定的临床适应症时；</li><li>When determining whether additional biocompatibility evaluations may be needed if questionable or inconclusive findings have occurred in any previously conducted biocompatibility evaluations, or in the event that novel materials are used;<sup class="footnote-ref"><a href="#fn6" id="fnref6">[6]</a></sup><br>在确定是否需要进行额外的生物相容性评估，如果先前进行的任何生物相容性评估中存在可疑或不确定的结果，或者使用了新型材料时；<sup class="footnote-ref"><a href="#fn6" id="fnref6:1">[6:1]</a></sup></li><li>When designing in vivo or ex vivo studies intended to address biocompatibility endpoints;<br>在设计旨在解决生物相容性终点的体内或体外研究时；</li><li>When designing chemical analysis protocols that use accelerating factors (e.g., heat) to simulate patient exposure to medical device materials over time;<br>在设计化学分析方案时使用加速因素（例如热）来模拟患者长期接触医疗器械材料的情况；</li><li>When determining how to prepare absorbable devices for biocompatibility testing (e.g., unpolymerized, pre-polymerized, partially degraded, or fully degraded test articles).<br>在确定如何准备可吸收器械进行生物相容性测试时（例如未聚合、预聚合、部分降解或完全降解的试验品）。</li></ul><hr class="footnotes-sep"><section class="footnotes"><ol class="footnotes-list"><li id="fn1" class="footnote-item"><p>Additional Information regarding master files for devices is available online at: <a href="https://www.fda.gov/medical-devices/premarket-approval-pma/master-files">https://www.fda.gov/medical-devices/premarket-approval-pma/master-files</a>. <br>关于设备的主文件的其他信息可在以下网址找到: <a href="https://www.fda.gov/medical-devices/premarket-approval-pma/master-files%E3%80%82">https://www.fda.gov/medical-devices/premarket-approval-pma/master-files。</a> <a href="#fnref1" class="footnote-backref">↩︎</a></p></li><li id="fn2" class="footnote-item"><p>FDA supports the principles of the “3Rs,” to reduce, refine, and replace animal use in testing when feasible. We encourage sponsors to consult with us if it they wish to use a non-animal testing method they believe is suitable, adequate, qualified for use with medical devices, and feasible. We will consider if such an alternative method could be assessed for equivalency to an animal test method.<br>FDA 支持“3R”原则，即在可行的情况下减少、改进和替代动物使用进行测试。如果赞助商希望使用一种非动物测试方法，并认为该方法适用、充分、适合用于医疗器械并可行，我们鼓励他们与我们咨询。我们将考虑是否可以对这种替代方法进行等效性评估，以替代动物试验方法。 <a href="#fnref2" class="footnote-backref">↩︎</a> <a href="#fnref2:1" class="footnote-backref">↩︎</a></p></li><li id="fn3" class="footnote-item"><p>Refer to ICH M7 &quot;Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk&quot;available at<a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m7r1-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m7r1-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential</a>information on use of the TTC and structure activity relationship (SAR) modeling to address genotoxicity and carcinogenicity issues within a risk management process.<br>请参阅 ICH M7《评估和控制药品中 DNA 活性（致突变）杂质以限制潜在致癌风险》（可在<a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m7r1-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m7r1-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential</a>以了解有关使用 TTC 和结构活性关系（SAR）模型来处理遗传毒性和致癌性问题的信息，这是在风为了减少不必要的测试，包括动物测试 1，FDA 建议赞助商在进行风险评估时充分考虑所有可用的相关信息。 <a href="#fnref3" class="footnote-backref">↩︎</a> <a href="#fnref3:1" class="footnote-backref">↩︎</a></p></li><li id="fn4" class="footnote-item"><p>FDA considers biocompatibility information, collectively with other nonclinical and preclinical information, inthe review of Early Feasibility Study (EFS) IDE applications and through the review of devices grantedBreakthrough designation and determines, through our benefit-risk analysis, what biocompatibility endpoints arenecessary for evaluation prior to initiation of clinical studies as well as what evaluations may be appropriatelyconducted in parallel with clinical data collection. For more information, see “Investigational Device Exemptions(IDEs) for Early Feasibility Medical Device Clinical Studies, Including Certain First in Human (FIH) Studies:Guidance for Industry and Food and Drug Administration Staff” available at <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-device-exemptions-ides-early-feasibility-medical-device-clinical-studies-including">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-device-exemptions-ides-early-feasibility-medical-device-clinical-studies-including</a> and “Breakthrough Devices Program: Guidance for Industry and Food and DrugAdministration Staff” available at <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/breakthrough-devices-program">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/breakthrough-devices-program</a>. <br>FDA 将生物相容性信息与其他非临床和临床前信息综合考虑，在审查早期可行性研究（EFS）的 IDE 申请以及审查获得突破性认定的设备时，通过我们的利益与风险分析确定在临床研究开始之前需要评估的生物相容性终点，以及可以与临床数据收集同时进行适当评估的内容。更多信息，请参阅“用于早期可行性医疗器械临床研究的调查性装置豁免（IDEs），包括某些首次人体（FIH）研究：行业和食品药品管理局人员指南”，网址为 <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-device-exemptions-ides-early-feasibility-medical-device-clinical-studies-including">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-device-exemptions-ides-early-feasibility-medical-device-clinical-studies-including</a> 和“突破性设备计划：行业和食品药品管理局人员指南”，网址为 <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/breakthrough-devices-program">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/breakthrough-devices-program</a> 。 <a href="#fnref4" class="footnote-backref">↩︎</a></p></li><li id="fn5" class="footnote-item"><p>Refer to FDA’s guidance document &quot;Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program: Guidance for Industry and Food and Drug Administration Staffapos; available at<a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program</a> <a href="#fnref5" class="footnote-backref">↩︎</a> <a href="#fnref5:1" class="footnote-backref">↩︎</a></p></li><li id="fn6" class="footnote-item"><p>Novel materials are not commonly used to manufacture medical devices. Novel materials are mentioned throughout this document to provide transparency regarding FDA’s current thinking and recommendations regarding biocompatibility evaluation of devices made from these materials. However, we recognize that these recommendations will not apply to the majority of device submissions.<br>新型材料并不常用于制造医疗器械。本文件中提到新型材料，是为了透明地介绍 FDA 关于使用这些材料制造器械的生物相容性评估的当前思路和建议。然而，我们认识到这些建议不适用于大多数器械提交。 <a href="#fnref6" class="footnote-backref">↩︎</a> <a href="#fnref6:1" class="footnote-backref">↩︎</a></p></li></ol></section>]]></content>
    
    
    <summary type="html">&lt;h1 id=&quot;Risk-Management-for-Biocompatibility-Evaluations-生物相容性的风险管理&quot;&gt;Risk Management for Biocompatibility Evaluations 生物相容性的风险管理&lt;/h1&gt;
&lt;p&gt;As stated in ISO 10993-1, the biological evaluation of a medical device (or a material component of such) should be conducted within the framework of a risk management process. Such a process should generally begin with assessment of the device, including the material components, the manufacturing processes, the clinical use of the device including the intended anatomical location, and the frequency and duration of exposure. Considering this information, the potential risks from a biocompatibility perspective should be identified. Such risks might include chemical toxicity, unacceptable biological response to physical characteristics of the device, and aspects of manufacturing and processing that could alter the physicochemical characteristics of the device, which could lead to changes in the biocompatibility response. Once the risks have been identified, the sponsor should assess what information is already available regarding those risks and identify the knowledge gaps that remain. Considering the potential biological impact, a plan should be developed to address the knowledge gaps either by biocompatibility testing or other evaluations that appropriately address the risks. The interpretation of the overall biocompatibility evaluation should be considered in the appropriate benefit-risk context.&lt;/p&gt;
&lt;p&gt;根据 ISO 10993-1 的规定，医疗器械（或其材料组成部分）的生物评价应在风险管理过程的框架内进行。这样的过程通常应从对设备的评估开始，包括材料组成部分、制造工艺、设备的临床使用情况（包括预期的解剖位置）以及暴露的频率和持续时间。根据这些信息，应该确定生物相容性风险。这些风险可能包括化学毒性、对设备的物理特性产生不可接受的生物反应，以及可能改变设备物理化学特性的制造和加工方面，导致生物相容性反应发生变化。一旦确定了风险，主办方应评估已有的有关这些风险的信息，并确定尚存的知识空白。考虑到潜在的生物影响，应制定一个计划，通过生物相容性测试或其他适当的评估来解决这些知识空白，以适当地应对风险。应将整体生物相容性评价的解释考虑在适当的利益和风险背景下。&lt;/p&gt;
&lt;h2 id=&quot;Risk-Assessment-of-the-Medical-Device-医疗器械的风险评估&quot;&gt;Risk Assessment of the Medical Device 医疗器械的风险评估&lt;/h2&gt;
&lt;p&gt;The risk assessment should evaluate the final finished device. The Agency makes a clearance or approval decision for a medical device as it is supplied in its final finished form. The Agency does not clear or approve individual materials that are used in the fabrication of medical devices. Therefore, the risk assessment should evaluate not only the materials used in the device, but also the processing of the materials, the manufacturing methods (including the sterilization process), and any residuals from manufacturing aids used during the process.&lt;/p&gt;
&lt;p&gt;风险评估应评估最终的成品设备。当医疗器械以其最终成品形式提供时，机构会对其进行审批或批准决定。机构不会对用于制造医疗器械的个别材料进行审批或批准。因此，风险评估应该评估不仅设备中使用的材料，还应考虑材料的处理、制造方法（包括灭菌过程）以及制造过程中使用的任何辅助材料残留物。&lt;/p&gt;
&lt;p&gt;The risk assessment should also consider the proposed clinical use of the device, including the anatomical location, duration of exposure, and intended use population. For example, for pediatric patients with a limited life expectancy, the tolerance for risk associated with a permanently implanted medical device may be higher than the tolerance for risk from the same device in an otherwise healthy pediatric population. The potential exposure duration should also consider which material components of the device have direct or indirect contact with tissue, and whether exposure would be a one-time exposure, a constant exposure over time, or an intermittent exposure over time that could have a cumulative effect. For example, pacemaker pulse generators commonly contain internal electronic components made from chemicals that could be toxic to the body, but appropriate bench testing can demonstrate that the pulse generator is hermetically sealed and will limit exposure of those chemicals to the surrounding tissues.&lt;/p&gt;
&lt;p&gt;风险评估还应考虑设备的拟议临床使用情况，包括解剖位置、暴露持续时间和拟定使用人群。例如，对于寿命有限的儿科患者来说，与永久植入的医疗器械相关的风险容忍度可能高于对同一设备在其他健康儿童人群中的风险容忍度。潜在的暴露持续时间还应考虑设备的哪些材料组成部分与组织直接或间接接触，并且暴露是一次性的、持续不断的，还是随时间间歇性的暴露，可能具有累积效应。例如，起搏器脉冲发生器通常包含由对人体有毒的化学物质制成的内部电子元件，但适当的台架测试可以证明脉冲发生器是密封的，会限制这些化学物质对周围组织的暴露。&lt;/p&gt;
&lt;h2 id=&quot;Identification-of-Potential-Risks-潜在风险的识别&quot;&gt;Identification of Potential Risks 潜在风险的识别&lt;/h2&gt;
&lt;p&gt;An assessment of potential biocompatibility risk should include not only chemical toxicity, but also physical characteristics that might contribute to an unwanted tissue response. These characteristics can include surface properties, forces on surrounding tissue (e.g., mechanical, thermal, electromagnetic), geometry, and presence of particulates, among others. In addition, changes in manufacturing and processing parameters can also have an impact on biocompatibility. For example, the original processing for an implanted device might include placing the device in an acid bath to facilitate passivation of the implant surface. If this passivation process is changed to eliminate the acid bath in favor of a different method of passivating the surface, removal of the acid bath might unintentionally lead to a smaller reduction in pyrogenic material, which could result in pyrogenic reactions (fever) following implantation of the device. Another common change that might impact biocompatibility is a change in resin supplier. For example, if the new resin supplier does not remove all processing solvents (some of which may be known toxic compounds, such as formaldehyde), the final manufactured device could cause unexpected toxicities (e.g., cytotoxicity, irritation, sensitization, genotoxicity) that were not seen with devices manufactured from the original resin.&lt;/p&gt;</summary>
    
    
    
    
    <category term="KDL" scheme="https://blog.kamasylvia.com/tags/KDL/"/>
    
    <category term="QMS" scheme="https://blog.kamasylvia.com/tags/QMS/"/>
    
    <category term="FDA" scheme="https://blog.kamasylvia.com/tags/FDA/"/>
    
  </entry>
  
  <entry>
    <title>[ISO 10993-1 (FDA)] II Scope</title>
    <link href="https://blog.kamasylvia.com/p/7c451663/"/>
    <id>https://blog.kamasylvia.com/p/7c451663/</id>
    <published>2023-09-06T00:56:30.000Z</published>
    <updated>2023-10-30T00:50:06.281Z</updated>
    
    <content type="html"><![CDATA[<h1 id="Scope-范围">Scope 范围</h1><p>The scope of this document and accompanying attachments is limited to the biologicalevaluation of sterile and non-sterile medical devices that come into direct or indirect contactwith the human body. This document specifically covers the use of ISO 10993-1 but also isrelevant to other biocompatibility standards (e.g., other parts of the ISO#footnote<sup class="footnote-ref"><a href="#fn1" id="fnref1">[1]</a></sup> 10993 series ofstandards, ASTM<sup class="footnote-ref"><a href="#fn2" id="fnref2">[2]</a></sup>, ICH<sup class="footnote-ref"><a href="#fn3" id="fnref3">[3]</a></sup>, OECD<sup class="footnote-ref"><a href="#fn4" id="fnref4">[4]</a></sup>, USP<sup class="footnote-ref"><a href="#fn5" id="fnref5">[5]</a></sup>).</p><p>本文件及附件的范围仅限于直接或间接与人体接触的无菌和非无菌医疗器械的生物评价。本文件特别涵盖了 ISO 10993-1 的使用，但也适用于其他生物相容性标准（例如，ISO<sup class="footnote-ref"><a href="#fn1" id="fnref1:1">[1:1]</a></sup> 10993 系列标准的其他部分，ASTM<sup class="footnote-ref"><a href="#fn2" id="fnref2:1">[2:1]</a></sup>，ICH<sup class="footnote-ref"><a href="#fn3" id="fnref3:1">[3:1]</a></sup>，OECD<sup class="footnote-ref"><a href="#fn4" id="fnref4:1">[4:1]</a></sup>，USP<sup class="footnote-ref"><a href="#fn5" id="fnref5:1">[5:1]</a></sup>）。</p><p>This document discusses the following topics:</p><p>本文件讨论以下主题：</p><ul><li>use of risk assessments for biocompatibility evaluations for a proposed medical device;<br>对拟议医疗器械进行生物相容性评价的风险评估使用；</li><li>use of ISO 10993-1 and the FDA-modified matrix (Attachment A) to determine the relevant biocompatibility endpoints for an evaluation;<br>使用 ISO 10993-1 和 FDA 修改后的矩阵（附件 A）确定评价的相关生物相容性终点；</li><li>general biocompatibility testing considerations, including test article preparation;<br>一般生物相容性测试考虑事项，包括试验品的制备；</li><li>specific considerations for the following testing: cytotoxicity, sensitization, hemocompatibility, pyrogenicity, implantation, genotoxicity, carcinogenicity, reproductive and developmental toxicity, and degradation assessments;<br>以下测试的特定考虑事项：细胞毒性，致敏性，血液相容性，致热原性，植入，遗传毒性，致癌性，生殖和发育毒性以及降解评估；</li><li>chemical assessment recommendations#footnote<sup class="footnote-ref"><a href="#fn6" id="fnref6">[6]</a></sup>; and <br>化学评估建议<sup class="footnote-ref"><a href="#fn6" id="fnref6:1">[6:1]</a></sup>；以及</li><li>considerations for labeling devices as “-free.”<br>标记设备为“无某物”的考虑事项。</li></ul><p>In addition, this guidance includes the following attachments that are intended to serve asresources:</p><p>此外，本指南还包括以下附件，旨在作为资源使用：</p><ul><li>Attachment B: Device Master Files (MAFs) for Biocompatibility Evaluations, which includes information that we recommend including in an MAF;<br>附件 B：用于生物相容性评价的设备主文件（MAFs），其中包含我们建议在 MAF 中包含的信息。</li><li>Attachment C: Summary Biocompatibility Documentation, which includes an exampletable that we recommend using to summarize the biocompatibility information used tosupport a submission;<br>附件 C：汇总生物相容性文件，其中包括一个示例表格，我们建议使用该表格汇总用于支持提交的生物相容性信息；</li><li>Attachment D: Biocompatibility Evaluation Flow Chart, which illustrates how toproceed with a biocompatibility evaluation;<br>附件 D：生物相容性评估流程图，说明如何进行生物相容性评估；</li><li>Attachment E: Content of a Biocompatibility Test Report, which includes therecommended contents of a test report;<br>附件 E：生物相容性测试报告内容，包括测试报告的推荐内容；</li><li>Attachment F: Component and Device Documentation Examples, which outlinesexample documentation language that we recommend using when comparing thecomposition of a test article to the composition of a finished medical device or incomparing the composition of a previously legally US-marketed device to thecomposition of a current device; and<br>附件 F：组件和器械文件示例，概述了在比较测试样品的组成与成品医疗器械的组成或在比较先前在美国合法上市的器械与当前器械的组成时，我们推荐使用的文件语言示例；</li><li>Attachment G: Glossary, which includes terms and definitions used in this guidance.<br>附件 G：术语表，包括本指南中使用的术语和定义。</li></ul><p>If there are other FDA-recognized consensus standards#footnote<sup class="footnote-ref"><a href="#fn7" id="fnref7">[7]</a></sup> that address biocompatibility issues forparticular types of devices (e.g., ISO 7405 “Dentistry - Evaluation of biocompatibility ofmedical devices used in dentistry”), the recommendations in the more device-specific standardshould be followed. In some cases, such as for dental devices, the biocompatibilityrecommendations in the device-specific standard should be used instead of the recommendationsoutlined in ISO 10993-1. In contrast, some device-specific guidances include recommendationsregarding biocompatibility evaluations, that should be considered in conjunction with ISO10993-1. For example, the FDA guidance “Content of Premarket Notifications for Conventionaland High Permeability Hemodialyzers”#footnote<sup class="footnote-ref"><a href="#fn8" id="fnref8">[8]</a></sup> specifies that subcomponent testing is recommendeddue to the high surface area of the membrane component of a hemodialyzer, and testing of thecomplete device is only recommended if “the extraction conditions (i.e., volume of solvent usedper surface area of test article) are more rigorous than those recommended in ISO 10993.” Inthis case, if biocompatibility testing of a hemodialyzer is conducted on the final device, FDArecommends that the hemodialyzer be filled to capacity with the solvent, resulting in a muchhigher surface area to extract volume ratio, as compared to recommendations from ISO 10993-12“Biological evaluation of medical devices-Part 12: Sample preparation and referencematerials.” However, if non-membrane components are tested separately, then use of ISO10993-12 recommendations for test article preparation would apply.</p><p>如果有其他 FDA 认可的共识标准@fn:10 针对特定类型的器械地址生物相容性问题（例如，ISO 7405 “牙科 - 评估牙科医疗器械的生物相容性”），应遵循更具体器械标准中的建议。在某些情况下，例如牙科器械，应使用器械特定标准中的生物相容性建议，而不是 ISO 10993-1 中概述的建议。相反，一些器械特定的指南包括关于生物相容性评估的建议，应与 ISO 10993-1 一起考虑。例如，FDA 指南 “常规和高渗透性血透器的市前通知内容”@fn:11 指定了推荐进行亚组件测试，这是由于血透器膜组件的大表面积所决定的，仅当 “提取条件（即，溶剂用量与测试样品表面积之比）比 ISO 10993 中推荐的更严格时” 才推荐进行整个器械的测试。在这种情况下，如果对血透器进行了最终器械的生物相容性测试，FDA 建议将血透器填满溶剂，从而产生比 ISO 10993-12 中的建议更高的表面积与提取体积比率。然而，如果对非膜组分进行单独测试，那么应使用 ISO 10993-12 中有关测试样品准备的建议。</p><p>Note that if your product is a combination product with a device constituent part<sup class="footnote-ref"><a href="#fn9" id="fnref9">[9]</a></sup>, the generalprinciples of this guidance would apply, although additional or modified testing may be<sup class="footnote-ref"><a href="#fn10" id="fnref10">[10]</a></sup> needed. For example, sample preparation of biologic-device combination products may bedependent on the type of product and the endpoint being assessed, and such detailed guidancespecific to biocompatibility evaluation of combination products are not within the scope of thisdocument. As such, we encourage you to discuss combination products with the appropriateCenter and review division who will initiate proper consultation on combination product-specificbiocompatibility concerns as appropriate.</p><p>请注意，如果您的产品是含有器械成分<sup class="footnote-ref"><a href="#fn9" id="fnref9:1">[9:1]</a></sup>的组合产品，本指南的一般原则仍然适用，尽管可能<sup class="footnote-ref"><a href="#fn10" id="fnref10:1">[10:1]</a></sup>需要额外或修改后的测试。例如，生物-器械组合产品的样品制备可能取决于产品类型和评估的终点，而有关生物相容性评估的组合产品的详细指导不在本文件的范围内。因此，我们鼓励您与适当的中心和审评部门讨论组合产品，并根据需要进行有关组合产品特定生物相容性问题的咨询。</p><p>We also recognize that an ISO standard is a document that undergoes periodic review and issubject to revision. Through the FDA standards recognition process, we provide informationregarding the extent of recognition of the ISO 10993 series of standards and otherbiocompatibility standards through Supplemental Information Sheets published on the FDAwebsite<sup class="footnote-ref"><a href="#fn11" id="fnref11">[11]</a></sup>. FDA recommends that complete test reports be provided for all tests performedbecause the ISO 10993 series of standards include general methods with multiple options, and insome cases do not include acceptance criteria or address assessment of results<sup class="footnote-ref"><a href="#fn12" id="fnref12">[12]</a></sup>. Therefore,when a declaration of conformity is submitted for an FDA-recognized standard in the ISO 10993series, a copy of the supplemental information used to support the declaration (e.g., a copy of thestudy test report as described in Attachment E) should also be provided<sup class="footnote-ref"><a href="#fn13" id="fnref13">[13]</a></sup>. FDA will makeupdates to this guidance document as appropriate, should future revisions to ISO 10993-1 orother FDA recognized biocompatibility standards result in significant changes to therecommendations in this document.</p><p>我们也认识到 ISO 标准是一份经过定期审查并可能进行修订的文件。通过 FDA 标准认可流程，我们通过在 FDA 网站<sup class="footnote-ref"><a href="#fn11" id="fnref11:1">[11:1]</a></sup>上发布的补充信息表格提供有关 ISO 10993 系列标准和其他生物相容性标准的认可程度的信息。FDA 建议提供所有测试的完整测试报告，因为 ISO 10993 系列标准包括多种选项的通用方法，并且在某些情况下不包括验收标准或结果<sup class="footnote-ref"><a href="#fn12" id="fnref12:1">[12:1]</a></sup>评估。因此，当向 FDA 承认的 ISO 10993 系列标准提交符合性声明时，还应提供用于支持声明的补充信息的副本（例如，如附件 E 所述的研究测试报告的副本）<sup class="footnote-ref"><a href="#fn13" id="fnref13:1">[13:1]</a></sup>。如果 ISO 10993-1 或其他 FDA 认可的生物相容性标准的未来修订对本文件中的建议产生重大变化，FDA 将适时更新本指南文件。</p><p>Sponsors are advised to initiate discussions with the appropriate Center and review division priorto the initiation of long-term testing of any new device to ensure that, if testing is needed, theproper testing will be conducted.</p><p>在开始对任何新设备进行长期测试之前，建议主办方与相应的中心和审评部门进行讨论，以确保必要时能够进行适当的测试。</p><hr class="footnotes-sep"><section class="footnotes"><ol class="footnotes-list"><li id="fn1" class="footnote-item"><p>ISO stands for International Organization for Standardization, an international standards developmentorganization. See <a href="http://www.iso.org/iso/home.html">http://www.iso.org/iso/home.html</a> for more information.<br>ISO 代表国际标准化组织，是一个国际标准制定组织。有关更多信息，请参阅 <a href="http://www.iso.org/iso/home.html%E3%80%82">http://www.iso.org/iso/home.html。</a> <a href="#fnref1" class="footnote-backref">↩︎</a> <a href="#fnref1:1" class="footnote-backref">↩︎</a></p></li><li id="fn2" class="footnote-item"><p>ASTM stands for American Society for Testing and Materials, an international standards developmentorganization. See <a href="http://www.astm.org/ABOUT/overview.html">http://www.astm.org/ABOUT/overview.html</a> for more information.<br>ASTM 代表美国材料试验协会，是一个国际标准制定组织。有关更多信息，请参阅 <a href="http://www.astm.org/ABOUT/overview.html%E3%80%82">http://www.astm.org/ABOUT/overview.html。</a> <a href="#fnref2" class="footnote-backref">↩︎</a> <a href="#fnref2:1" class="footnote-backref">↩︎</a></p></li><li id="fn3" class="footnote-item"><p>ICH stands for International Conference on Harmonisation, an international standards development organization.See <a href="http://www.ich.org/about/vision.html">http://www.ich.org/about/vision.html</a> for more information.<br>ICH 代表国际协调会议，是一个国际标准制定组织。有关更多信息，请参阅 <a href="http://www.ich.org/about/vision.html%E3%80%82">http://www.ich.org/about/vision.html。</a> <a href="#fnref3" class="footnote-backref">↩︎</a> <a href="#fnref3:1" class="footnote-backref">↩︎</a></p></li><li id="fn4" class="footnote-item"><p>OECD stands for Organisation for Economic Co-operation and Development, an international standardsdevelopment organization. See <a href="http://www.oecd.org/for">http://www.oecd.org/for</a> more information.<br>OECD 代表经济合作与发展组织，是一个国际标准制定组织。有关更多信息，请参阅 <a href="http://www.oecd.org/%E3%80%82">http://www.oecd.org/。</a> <a href="#fnref4" class="footnote-backref">↩︎</a> <a href="#fnref4:1" class="footnote-backref">↩︎</a></p></li><li id="fn5" class="footnote-item"><p>USP stands for U.S. Pharmacopeial Convention, a United States standards development organization. See<a href="http://www.usp.org/about-usp">http://www.usp.org/about-usp</a> for more information.<br>USP 代表美国药典委员会，是一个美国标准制定组织。有关更多信息，请参阅 <a href="http://www.usp.org/about-usp%E3%80%82">http://www.usp.org/about-usp。</a> <a href="#fnref5" class="footnote-backref">↩︎</a> <a href="#fnref5:1" class="footnote-backref">↩︎</a></p></li><li id="fn6" class="footnote-item"><p>All issues specific to the evaluation of color additives in medical devices included in the draft version of thisguidance were removed, and the intent is for these items to be addressed in a separate guidance document.<br>关于在本指南草案中包含的医疗器械中颜料添加剂评价的所有问题已被移除，意图是将这些问题在单独的指南文件中解决。 <a href="#fnref6" class="footnote-backref">↩︎</a> <a href="#fnref6:1" class="footnote-backref">↩︎</a></p></li><li id="fn7" class="footnote-item"><p>Refer to FDA’s “Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for MedicalDevices: Guidance for Industry and Food and Drug Administration Staff,” available at<a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/appropriate-use-voluntary-consensus-standards-premarket-submissions-medical-devices">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/appropriate-use-voluntary-consensus-standards-premarket-submissions-medical-devices</a> for information regarding the recognition and use of national andinternational consensus standards during the evaluation of premarket submissions for medical devices.<br>请参考 FDA 的《医疗器械前市场提交中志愿共识标准的适当使用：行业和食品药品管理局人员指南》，获取有关在评估医疗器械前市场提交时识别和使用国家和国际共识标准的信息。网址: <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/appropriate-use-voluntary-consensus-standards-premarket-submissions-medical-devices">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/appropriate-use-voluntary-consensus-standards-premarket-submissions-medical-devices</a> <a href="#fnref7" class="footnote-backref">↩︎</a></p></li><li id="fn8" class="footnote-item"><p>Available at <a href="https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/content-premarket-notifications-conventional-and-high-permeability-hemodialyzers-guidance-industry">https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/content-premarket-notifications-conventional-and-high-permeability-hemodialyzers-guidance-industry</a> <br>请参考: <a href="https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/content-premarket-notifications-conventional-and-high-permeability-hemodialyzers-guidance-industry">https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/content-premarket-notifications-conventional-and-high-permeability-hemodialyzers-guidance-industry</a> <a href="#fnref8" class="footnote-backref">↩︎</a></p></li><li id="fn9" class="footnote-item"><p>Please refer to 21 CFR 3.2(e) for the definition of a combination product.<br>请参考 21 CFR 3.2(e) 中关于组合产品的定义。 <a href="#fnref9" class="footnote-backref">↩︎</a> <a href="#fnref9:1" class="footnote-backref">↩︎</a></p></li><li id="fn10" class="footnote-item"><p>The term “may” is used here and throughout the document to indicate that the final determination on whetheradditional information should be provided will depend on the specifics of the final device under consideration.<br>此处及本文件中的术语“可能”表示最终是否需要提供额外信息将取决于最终考虑的设备的具体情况。 <a href="#fnref10" class="footnote-backref">↩︎</a> <a href="#fnref10:1" class="footnote-backref">↩︎</a></p></li><li id="fn11" class="footnote-item"><p>See FDA’s Database on Recognized Consensus Standards and input “10993-1” for the Supplemental InformationSheet.<br>请参考 FDA 公认共识标准数据库，并输入“10993-1”获取补充信息表格。 <a href="#fnref11" class="footnote-backref">↩︎</a> <a href="#fnref11:1" class="footnote-backref">↩︎</a></p></li><li id="fn12" class="footnote-item"><p>In the case of Abbreviated 510(k)s, a summary of the methods often is needed to ensure that the test wasconducted in the same way as for a predicate device, and that the same evaluation criteria were used. If it is easierfor the sponsor to submit a copy of the test report, which is not required by FDA, this would be acceptable. ForSpecial 510(k)s, refer to the guidance “The Special 510(k) Program,” available at <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/special-510k-program">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/special-510k-program</a>, for more information about FDA’srecommended biocompatibility information that should be included.<br>对于简化 510(k) 的情况，通常需要提供方法摘要，以确保测试与参比器械相同，并使用相同的评估标准。如果主办方更容易提交测试报告的副本（FDA 不要求），这也是可以接受的。对于特殊 510(k)，请参考“特殊 510(k) 计划”的指南，了解 FDA 建议包括的生物相容性信息。网址: <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/special-510k-program">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/special-510k-program</a> <a href="#fnref12" class="footnote-backref">↩︎</a> <a href="#fnref12:1" class="footnote-backref">↩︎</a></p></li><li id="fn13" class="footnote-item"><p>Refer to FDA’s “Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for MedicalDevices: Guidance for Industry and Food and Drug Administration Staff” for information regarding the recognitionand use of national and international consensus standards, including declarations of conformity to these standards,during the evaluation of premarket submissions for medical devices.<br>请参考 FDA 的《医疗器械前市场提交中志愿共识标准的适当使用：行业和食品药品管理局人员指南》，了解在评估医疗器械前市场提交时识别和使用国家和国际共识标准，包括对这些标准的符合性声明的信息。 <a href="#fnref13" class="footnote-backref">↩︎</a> <a href="#fnref13:1" class="footnote-backref">↩︎</a></p></li></ol></section>]]></content>
    
    
    <summary type="html">&lt;h1 id=&quot;Scope-范围&quot;&gt;Scope 范围&lt;/h1&gt;
&lt;p&gt;The scope of this document and accompanying attachments is limited to the biological
evaluation of sterile and non-sterile medical devices that come into direct or indirect contact
with the human body. This document specifically covers the use of ISO 10993-1 but also is
relevant to other biocompatibility standards (e.g., other parts of the ISO#footnote&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn1&quot; id=&quot;fnref1&quot;&gt;[1]&lt;/a&gt;&lt;/sup&gt; 10993 series of
standards, ASTM&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn2&quot; id=&quot;fnref2&quot;&gt;[2]&lt;/a&gt;&lt;/sup&gt;, ICH&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn3&quot; id=&quot;fnref3&quot;&gt;[3]&lt;/a&gt;&lt;/sup&gt;, OECD&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn4&quot; id=&quot;fnref4&quot;&gt;[4]&lt;/a&gt;&lt;/sup&gt;, USP&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn5&quot; id=&quot;fnref5&quot;&gt;[5]&lt;/a&gt;&lt;/sup&gt;).&lt;/p&gt;
&lt;p&gt;本文件及附件的范围仅限于直接或间接与人体接触的无菌和非无菌医疗器械的生物评价。本文件特别涵盖了 ISO 10993-1 的使用，但也适用于其他生物相容性标准（例如，ISO&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn1&quot; id=&quot;fnref1:1&quot;&gt;[1:1]&lt;/a&gt;&lt;/sup&gt; 10993 系列标准的其他部分，ASTM&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn2&quot; id=&quot;fnref2:1&quot;&gt;[2:1]&lt;/a&gt;&lt;/sup&gt;，ICH&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn3&quot; id=&quot;fnref3:1&quot;&gt;[3:1]&lt;/a&gt;&lt;/sup&gt;，OECD&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn4&quot; id=&quot;fnref4:1&quot;&gt;[4:1]&lt;/a&gt;&lt;/sup&gt;，USP&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn5&quot; id=&quot;fnref5:1&quot;&gt;[5:1]&lt;/a&gt;&lt;/sup&gt;）。&lt;/p&gt;
&lt;p&gt;This document discusses the following topics:&lt;/p&gt;
&lt;p&gt;本文件讨论以下主题：&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;use of risk assessments for biocompatibility evaluations for a proposed medical device;&lt;br&gt;
对拟议医疗器械进行生物相容性评价的风险评估使用；&lt;/li&gt;
&lt;li&gt;use of ISO 10993-1 and the FDA-modified matrix (Attachment A) to determine the relevant biocompatibility endpoints for an evaluation;&lt;br&gt;
使用 ISO 10993-1 和 FDA 修改后的矩阵（附件 A）确定评价的相关生物相容性终点；&lt;/li&gt;
&lt;li&gt;general biocompatibility testing considerations, including test article preparation;&lt;br&gt;
一般生物相容性测试考虑事项，包括试验品的制备；&lt;/li&gt;
&lt;li&gt;specific considerations for the following testing: cytotoxicity, sensitization, hemocompatibility, pyrogenicity, implantation, genotoxicity, carcinogenicity, reproductive and developmental toxicity, and degradation assessments;&lt;br&gt;
以下测试的特定考虑事项：细胞毒性，致敏性，血液相容性，致热原性，植入，遗传毒性，致癌性，生殖和发育毒性以及降解评估；&lt;/li&gt;
&lt;li&gt;chemical assessment recommendations#footnote&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn6&quot; id=&quot;fnref6&quot;&gt;[6]&lt;/a&gt;&lt;/sup&gt;; and &lt;br&gt;
化学评估建议&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn6&quot; id=&quot;fnref6:1&quot;&gt;[6:1]&lt;/a&gt;&lt;/sup&gt;；以及&lt;/li&gt;
&lt;li&gt;considerations for labeling devices as “-free.”&lt;br&gt;
标记设备为“无某物”的考虑事项。&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;In addition, this guidance includes the following attachments that are intended to serve as
resources:&lt;/p&gt;
&lt;p&gt;此外，本指南还包括以下附件，旨在作为资源使用：&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Attachment B: Device Master Files (MAFs) for Biocompatibility Evaluations, which includes information that we recommend including in an MAF;&lt;br&gt;
附件 B：用于生物相容性评价的设备主文件（MAFs），其中包含我们建议在 MAF 中包含的信息。&lt;/li&gt;
&lt;li&gt;Attachment C: Summary Biocompatibility Documentation, which includes an example
table that we recommend using to summarize the biocompatibility information used to
support a submission;&lt;br&gt;
附件 C：汇总生物相容性文件，其中包括一个示例表格，我们建议使用该表格汇总用于支持提交的生物相容性信息；&lt;/li&gt;
&lt;li&gt;Attachment D: Biocompatibility Evaluation Flow Chart, which illustrates how to
proceed with a biocompatibility evaluation;&lt;br&gt;
附件 D：生物相容性评估流程图，说明如何进行生物相容性评估；&lt;/li&gt;
&lt;li&gt;Attachment E: Content of a Biocompatibility Test Report, which includes the
recommended contents of a test report;&lt;br&gt;
附件 E：生物相容性测试报告内容，包括测试报告的推荐内容；&lt;/li&gt;
&lt;li&gt;Attachment F: Component and Device Documentation Examples, which outlines
example documentation language that we recommend using when comparing the
composition of a test article to the composition of a finished medical device or in
comparing the composition of a previously legally US-marketed device to the
composition of a current device; and&lt;br&gt;
附件 F：组件和器械文件示例，概述了在比较测试样品的组成与成品医疗器械的组成或在比较先前在美国合法上市的器械与当前器械的组成时，我们推荐使用的文件语言示例；&lt;/li&gt;
&lt;li&gt;Attachment G: Glossary, which includes terms and definitions used in this guidance.&lt;br&gt;
附件 G：术语表，包括本指南中使用的术语和定义。&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;If there are other FDA-recognized consensus standards#footnote&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn7&quot; id=&quot;fnref7&quot;&gt;[7]&lt;/a&gt;&lt;/sup&gt; that address biocompatibility issues for
particular types of devices (e.g., ISO 7405 “Dentistry - Evaluation of biocompatibility of
medical devices used in dentistry”), the recommendations in the more device-specific standard
should be followed. In some cases, such as for dental devices, the biocompatibility
recommendations in the device-specific standard should be used instead of the recommendations
outlined in ISO 10993-1. In contrast, some device-specific guidances include recommendations
regarding biocompatibility evaluations, that should be considered in conjunction with ISO
10993-1. For example, the FDA guidance “Content of Premarket Notifications for Conventional
and High Permeability Hemodialyzers”#footnote&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn8&quot; id=&quot;fnref8&quot;&gt;[8]&lt;/a&gt;&lt;/sup&gt; specifies that subcomponent testing is recommended
due to the high surface area of the membrane component of a hemodialyzer, and testing of the
complete device is only recommended if “the extraction conditions (i.e., volume of solvent used
per surface area of test article) are more rigorous than those recommended in ISO 10993.” In
this case, if biocompatibility testing of a hemodialyzer is conducted on the final device, FDA
recommends that the hemodialyzer be filled to capacity with the solvent, resulting in a much
higher surface area to extract volume ratio, as compared to recommendations from ISO 10993-12
“Biological evaluation of medical devices-Part 12: Sample preparation and reference
materials.” However, if non-membrane components are tested separately, then use of ISO
10993-12 recommendations for test article preparation would apply.&lt;/p&gt;</summary>
    
    
    
    
    <category term="KDL" scheme="https://blog.kamasylvia.com/tags/KDL/"/>
    
    <category term="QMS" scheme="https://blog.kamasylvia.com/tags/QMS/"/>
    
    <category term="FDA" scheme="https://blog.kamasylvia.com/tags/FDA/"/>
    
  </entry>
  
  <entry>
    <title>[ISO 10993-1 (FDA)] I Introduction</title>
    <link href="https://blog.kamasylvia.com/p/b187d42/"/>
    <id>https://blog.kamasylvia.com/p/b187d42/</id>
    <published>2023-09-06T00:34:13.000Z</published>
    <updated>2023-10-30T00:50:06.281Z</updated>
    
    <content type="html"><![CDATA[<p>This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff or Office responsible for this guidance as listed on the title page.</p><p>该指南代表美国食品和药物管理局（FDA）对此主题的当前思考。它不为任何人设立权利，并且对 FDA 或公众没有约束力。如果符合适用法规的要求，您可以采用替代方法。要讨论替代方法，请联系负责此指南的 FDA 工作人员或办公室，其联系信息列在标题页上。</p><h1 id="Introduction">Introduction</h1><p>FDA has developed this guidance document to assist industry in preparing PremarketApplications (PMAs), Humanitarian Device Exceptions (HDEs), Investigational DeviceExemption (IDE) Applications , Premarket Notifications (510(k)s) , and De Novo requests formedical devices that come into direct contact or indirect contact with the human body<sup class="footnote-ref"><a href="#fn1" id="fnref1">[1]</a></sup> in orderto determine the potential for an unacceptable adverse biological response resulting from contactof the component materials of the device with the body. The purpose of this guidance is toprovide further clarification and updated information on the use of International Standard ISO10993-1, “Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process” to support applications to FDA. This guidance replaces Office of DeviceEvaluation (ODE) Blue Book Memorandum #G95-1 (1995), entitled “Use of InternationalStandard ISO-10993, 'Biological Evaluation of Medical Devices — Part 1: Evaluation and Testing.” This guidance document also incorporates several new considerations, including theuse of risk-based approaches to determine if biocompatibility testing is needed, chemicalassessment recommendations, and recommendations for biocompatibility test article preparationfor devices with submicron or nanotechnology components and for devices made from in situ polymerizing and/or absorbable materials, which were not previously discussed in G95-1.</p><p>FDA 制定了本指南文件，以协助行业准备前市场申请（PMA）、人道设备例外（HDE）、调查性设备豁免（IDE）申请、预市通知（510(k)）和 De Novo 请求，这些申请涉及直接或间接与人体<sup class="footnote-ref"><a href="#fn1" id="fnref1:1">[1:1]</a></sup>接触的医疗器械，以确定器械的组分材料与人体接触可能导致不可接受的不良生物反应的潜在风险。本指南的目的是进一步明确和更新有关使用国际标准 ISO 10993-1《医疗器械的生物学评价 — 第 1 部分：在风险管理过程中的评估和测试》以支持向 FDA 提交申请的信息。本指南取代了 1995 年 FDA 器械评估办公室（ODE）的蓝皮书备忘录 #G95-1，题为《国际标准 ISO-10993 的使用，'医疗器械的生物学评价 — 第 1 部分：评估和测试》。本指南文件还融入了几个新的考虑因素，包括使用基于风险的方法确定是否需要生物相容性测试、化学评估建议以及对具有亚微米或纳米技术组分以及由原位聚合和/或可吸收材料制成的器械的生物相容性试验物品准备的建议，这些在 G95-1 中以前没有讨论过。在评估新设备时，赞助商应明确说明设备是否没有直接或间接组织接触，并且不需要进一步的生物相容性信息。</p><p>When assessing new devices, the sponsor should specifically state if the device does not haveany direct or indirect tissue contact<sup class="footnote-ref"><a href="#fn2" id="fnref2">[2]</a></sup>, and no further biocompatibility information would beneeded.</p><p>在评估新设备时，赞助商应明确说明设备是否没有直接或间接组织接触<sup class="footnote-ref"><a href="#fn2" id="fnref2:1">[2:1]</a></sup>，并且不需要进一步的生物相容性信息。</p><p>When assessing device modifications, the sponsor should specifically state if the modificationdoes not result in a change to any direct or indirect tissue-contacting components, and no furtherbiocompatibility information would typically be needed. However, if the change could affectother parts of the device with direct or indirect contact that were not changed, a biocompatibilityevaluation should be conducted to assess the potential impact of the change. For example, if anew non-contact internal component is added, but it requires the application of heat in order tojoin to another component that has patient contact, the patient-contacting component may beimpacted by the application of heat such that biocompatibility could be impacted, and should beassessed.</p><p>在评估设备修改时，赞助商应明确说明修改是否不会导致任何直接或间接与组织接触的组分发生变化，并且通常不需要进一步的生物相容性信息。然而，如果变更可能影响未更改的设备的其他部分，这些部分与直接或间接接触有关，则应进行生物相容性评估以评估变更的潜在影响。例如，如果添加了一个新的非接触式内部组件，但它需要应用热量与另一个与患者接触的组件连接，那么受热应用可能影响与患者接触的组件，从而需要进行生物相容性评估。</p><p>For the current edition of the FDA-recognized consensus standard(s) referenced in thisdocument, see the FDA Recognized Consensus Standards Database#footnote<sup class="footnote-ref"><a href="#fn3" id="fnref3">[3]</a></sup>.</p><p>有关本文档中引用的 FDA 认可的共识标准的最新版本，请参阅 FDA 认可的共识标准数据库<sup class="footnote-ref"><a href="#fn3" id="fnref3:1">[3:1]</a></sup>。</p><p>Throughout this guidance document, the terms “we”, “us”, and “our” refer to FDA staff . “You”and “your” refers to the sponsor.</p><p>在本指南文件中，“我们”、&quot;我们的&quot;指的是 FDA 工作人员。&quot;您&quot;和&quot;您的&quot;指的是赞助商。</p><p>FDA’s guidance documents, including this guidance, do not establish legally enforceableresponsibilities. Instead, guidances describe the Agency’s current thinking on a topic and shouldbe viewed only as recommendations, unless specific regulatory or statutory requirements arecited. The use of the word should in Agency guidances means that something is suggested orrecommended, but not required.</p><p>FDA 的指南文件，包括本指南，不确定法律上可执行的责任。相反，指南描述了机构对某一主题的当前思考，只应视为建议，除非引用了具体的法规或法定要求。指南中使用的&quot;应该&quot;一词表示建议或推荐，但不是必需的。</p><hr class="footnotes-sep"><section class="footnotes"><ol class="footnotes-list"><li id="fn1" class="footnote-item"><p>For the purposes of this document, the term “human body” refers to either patient tissues or the clinical practitioner. For example, masks or gloves intended for protective purposes by clinical practitioners should be assessed for biocompatibility. Similarly, medical devices such as implants or skin electrodes also should be assessed for biocompatibility.<br>根据本文件的目的，“人体”一词指的是患者组织或临床医生。例如，临床医生用于保护目的的口罩或手套应进行生物相容性评估。同样，植入物或皮肤电极等医疗器械也应进行生物相容性评估。 <a href="#fnref1" class="footnote-backref">↩︎</a> <a href="#fnref1:1" class="footnote-backref">↩︎</a></p></li><li id="fn2" class="footnote-item"><p>For non-contact devices, there is no direct or indirect contact with the body (e.g., stand alone software), so it wouldbe sufficient for the biocompatibility evaluation to confirm that there are no direct or indirect tissue contactingcomponents, and no further biocompatibility information is needed. However, for devices with transient contact,assessment of biocompatibility risk should be conducted to determine if testing is needed.<br>对于非接触式设备，其与人体没有直接或间接接触（例如，独立软件），因此，生物相容性评估只需确认不存在直接或间接与组织接触的组件即可，无需进一步的生物相容性信息。然而，对于有瞬时接触的设备，应进行生物相容性风险评估以确定是否需要进行测试。 <a href="#fnref2" class="footnote-backref">↩︎</a> <a href="#fnref2:1" class="footnote-backref">↩︎</a></p></li><li id="fn3" class="footnote-item"><p>Available at <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm</a>. <br>请参考 <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm%E3%80%82">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm。</a> <a href="#fnref3" class="footnote-backref">↩︎</a> <a href="#fnref3:1" class="footnote-backref">↩︎</a></p></li></ol></section>]]></content>
    
    
    <summary type="html">&lt;p&gt;This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff or Office responsible for this guidance as listed on the title page.&lt;/p&gt;
&lt;p&gt;该指南代表美国食品和药物管理局（FDA）对此主题的当前思考。它不为任何人设立权利，并且对 FDA 或公众没有约束力。如果符合适用法规的要求，您可以采用替代方法。要讨论替代方法，请联系负责此指南的 FDA 工作人员或办公室，其联系信息列在标题页上。&lt;/p&gt;
&lt;h1 id=&quot;Introduction&quot;&gt;Introduction&lt;/h1&gt;
&lt;p&gt;FDA has developed this guidance document to assist industry in preparing Premarket
Applications (PMAs), Humanitarian Device Exceptions (HDEs), Investigational Device
Exemption (IDE) Applications , Premarket Notifications (510(k)s) , and De Novo requests for
medical devices that come into direct contact or indirect contact with the human body&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn1&quot; id=&quot;fnref1&quot;&gt;[1]&lt;/a&gt;&lt;/sup&gt; in order
to determine the potential for an unacceptable adverse biological response resulting from contact
of the component materials of the device with the body. The purpose of this guidance is to
provide further clarification and updated information on the use of International Standard ISO
10993-1, “Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process” to support applications to FDA. This guidance replaces Office of Device
Evaluation (ODE) Blue Book Memorandum #G95-1 (1995), entitled “Use of International
Standard ISO-10993, &#39;Biological Evaluation of Medical Devices — Part 1: Evaluation and Testing.” This guidance document also incorporates several new considerations, including the
use of risk-based approaches to determine if biocompatibility testing is needed, chemical
assessment recommendations, and recommendations for biocompatibility test article preparation
for devices with submicron or nanotechnology components and for devices made from in situ polymerizing and/or absorbable materials, which were not previously discussed in G95-1.&lt;/p&gt;
&lt;p&gt;FDA 制定了本指南文件，以协助行业准备前市场申请（PMA）、人道设备例外（HDE）、调查性设备豁免（IDE）申请、预市通知（510(k)）和 De Novo 请求，这些申请涉及直接或间接与人体&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn1&quot; id=&quot;fnref1:1&quot;&gt;[1:1]&lt;/a&gt;&lt;/sup&gt;接触的医疗器械，以确定器械的组分材料与人体接触可能导致不可接受的不良生物反应的潜在风险。本指南的目的是进一步明确和更新有关使用国际标准 ISO 10993-1《医疗器械的生物学评价 — 第 1 部分：在风险管理过程中的评估和测试》以支持向 FDA 提交申请的信息。本指南取代了 1995 年 FDA 器械评估办公室（ODE）的蓝皮书备忘录 #G95-1，题为《国际标准 ISO-10993 的使用，&#39;医疗器械的生物学评价 — 第 1 部分：评估和测试》。本指南文件还融入了几个新的考虑因素，包括使用基于风险的方法确定是否需要生物相容性测试、化学评估建议以及对具有亚微米或纳米技术组分以及由原位聚合和/或可吸收材料制成的器械的生物相容性试验物品准备的建议，这些在 G95-1 中以前没有讨论过。在评估新设备时，赞助商应明确说明设备是否没有直接或间接组织接触，并且不需要进一步的生物相容性信息。&lt;/p&gt;
&lt;p&gt;When assessing new devices, the sponsor should specifically state if the device does not have
any direct or indirect tissue contact&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn2&quot; id=&quot;fnref2&quot;&gt;[2]&lt;/a&gt;&lt;/sup&gt;, and no further biocompatibility information would be
needed.&lt;/p&gt;
&lt;p&gt;在评估新设备时，赞助商应明确说明设备是否没有直接或间接组织接触&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn2&quot; id=&quot;fnref2:1&quot;&gt;[2:1]&lt;/a&gt;&lt;/sup&gt;，并且不需要进一步的生物相容性信息。&lt;/p&gt;
&lt;p&gt;When assessing device modifications, the sponsor should specifically state if the modification
does not result in a change to any direct or indirect tissue-contacting components, and no further
biocompatibility information would typically be needed. However, if the change could affect
other parts of the device with direct or indirect contact that were not changed, a biocompatibility
evaluation should be conducted to assess the potential impact of the change. For example, if a
new non-contact internal component is added, but it requires the application of heat in order to
join to another component that has patient contact, the patient-contacting component may be
impacted by the application of heat such that biocompatibility could be impacted, and should be
assessed.&lt;/p&gt;
&lt;p&gt;在评估设备修改时，赞助商应明确说明修改是否不会导致任何直接或间接与组织接触的组分发生变化，并且通常不需要进一步的生物相容性信息。然而，如果变更可能影响未更改的设备的其他部分，这些部分与直接或间接接触有关，则应进行生物相容性评估以评估变更的潜在影响。例如，如果添加了一个新的非接触式内部组件，但它需要应用热量与另一个与患者接触的组件连接，那么受热应用可能影响与患者接触的组件，从而需要进行生物相容性评估。&lt;/p&gt;
&lt;p&gt;For the current edition of the FDA-recognized consensus standard(s) referenced in this
document, see the FDA Recognized Consensus Standards Database#footnote&lt;sup class=&quot;footnote-ref&quot;&gt;&lt;a href=&quot;#fn3&quot; id=&quot;fnref3&quot;&gt;[3]&lt;/a&gt;&lt;/sup&gt;.&lt;/p&gt;</summary>
    
    
    
    
    <category term="KDL" scheme="https://blog.kamasylvia.com/tags/KDL/"/>
    
    <category term="QMS" scheme="https://blog.kamasylvia.com/tags/QMS/"/>
    
    <category term="FDA" scheme="https://blog.kamasylvia.com/tags/FDA/"/>
    
  </entry>
  
  <entry>
    <title>【玩转docker】反向代理神器：Nginx Proxy Manager</title>
    <link href="https://blog.kamasylvia.com/p/1ff9cff3/"/>
    <id>https://blog.kamasylvia.com/p/1ff9cff3/</id>
    <published>2023-09-05T00:56:38.000Z</published>
    <updated>2023-10-30T00:50:05.717Z</updated>
    
    <content type="html"><![CDATA[<blockquote><p><a href="https://zhuanlan.zhihu.com/p/536791628">原文链接</a></p></blockquote><h2 id="一、什么是反向代理？">一、什么是反向代理？</h2><p>众所周知，浏览器访问网页需要<code>域名:端口号</code> 或者<code>ip:端口号</code> 这种形式，而当你访问页面时不输入端口号时，浏览器会根据<code>http</code>协议或者<code>https</code>协议，自动在后面加上默认端口号<code>80</code>或者<code>443</code> 。</p><p>但是我这种小白使用服务器搭建服务时，一个服务器上往往有多种 web 服务。端口又不能复用，所以其他服务都是需要<code>域名:端口号</code> 或者<code>ip:端口号</code> 这种形式来访问。于是，我就有一个疑问了，能不能用不同的域名来对应不同的服务呢。</p><p>那这就是反向代理的作用了。</p><p>反向代理类似于一个菜鸟驿站。邮局（互联网）对于地址（域名）是每个咱们小区（服务器）的包裹（数据报文）都直接发给咱们小区的菜鸟驿站（反向代理服务器），然后菜鸟驿站根据每个包裹地址（域名）然后交付给咱们小区的具体家庭（服务器中的每一个服务）。</p><p><img src="https://pic3.zhimg.com/v2-8b188ded15d0ead47d5734d8f424bb22_b.jpg" alt="" loading="lazy"></p><p>反向代理作用</p><p>而 Nginx 则作为非常有名的反向代理 web 服务器，被广大站长采用。Nginx 功能十分强大，但是配置对于小白来说，还是有一些门槛。那么有没有一款基于 Nginx 的 web 管理界面，来设置 Nginx 的反向代理呢？</p><p>这就是此篇博客要写的神器：Nginx Proxy Manager。</p><h3 id="二、Nginx-Proxy-Manager-有什么功能？">二、Nginx Proxy Manager 有什么功能？</h3><p>以下是 Nginx Proxy Manager 的官网介绍</p><blockquote><p>This project comes as a pre-built docker image that enables you to easily forward to your websites running at home or otherwise, including free SSL, without having to know too much about Nginx or Letsencrypt.<br>该项目作为一个预构建的 docker 镜像提供，使您能够轻松地转发到在家里或其他地方运行的网站，包括免费的 SSL，而无需对 Nginx 或 Letsencrypt 有太多了解。</p></blockquote><p>它的功能总结起来就是以下几点：</p><ul><li>轻松的反向代理设置</li><li>轻松配置 HTTPS</li><li>提供简单的访问权限设置</li></ul><p>好了，talk is cheap。接下来进入 Nginx Proxy Manager 一系列实战操作，让我们玩转 Nginx Proxy Manager！</p><h3 id="三、Nginx-Proxy-Manager-的安装">三、Nginx Proxy Manager 的安装</h3><h3 id="1-前提">1. 前提</h3><ul><li><a href="https://link.zhihu.com/?target=https%3A//blog.cyicz123.top/docker%25E5%25AE%2589%25E8%25A3%2585/">安装 docker 和 docker-compose</a></li></ul><h3 id="2-安装">2. 安装</h3><p>ssh 连接上服务器后，新建一个名为 ngingx_proxy_manager 的文件夹用来存放文件和数据（最好建一个统一存放各种 docker 容器应用的目录，例如本人命名为 docker 文件夹）</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br></pre></td><td class="code"><pre><span class="line"><span class="built_in">cd</span> ~/docker/</span><br><span class="line"><span class="built_in">mkdir</span> ngingx_proxy_manager &amp;&amp; <span class="built_in">cd</span> ngingx_proxy_manager</span><br></pre></td></tr></table></figure><p>新建 docker-compose.yml 文件并复制以下内容</p><figure class="highlight yml"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br><span class="line">5</span><br><span class="line">6</span><br><span class="line">7</span><br><span class="line">8</span><br><span class="line">9</span><br><span class="line">10</span><br><span class="line">11</span><br><span class="line">12</span><br><span class="line">13</span><br><span class="line">14</span><br><span class="line">15</span><br><span class="line">16</span><br><span class="line">17</span><br><span class="line">18</span><br><span class="line">19</span><br><span class="line">20</span><br><span class="line">21</span><br><span class="line">22</span><br><span class="line">23</span><br><span class="line">24</span><br><span class="line">25</span><br><span class="line">26</span><br><span class="line">27</span><br><span class="line">28</span><br><span class="line">29</span><br><span class="line">30</span><br><span class="line">31</span><br><span class="line">32</span><br><span class="line">33</span><br><span class="line">34</span><br><span class="line">35</span><br><span class="line">36</span><br><span class="line">37</span><br><span class="line">38</span><br><span class="line">39</span><br><span class="line">40</span><br></pre></td><td class="code"><pre><span class="line"><span class="comment"># 编辑文件</span></span><br><span class="line"><span class="string">vim</span> <span class="string">docker-compose.yml</span></span><br><span class="line"></span><br><span class="line"><span class="comment"># 复制以下内容</span></span><br><span class="line"><span class="attr">version:</span> <span class="string">&quot;3&quot;</span></span><br><span class="line"><span class="attr">services:</span></span><br><span class="line">  <span class="attr">app:</span></span><br><span class="line">    <span class="attr">image:</span> <span class="string">&#x27;jc21/nginx-proxy-manager:latest&#x27;</span></span><br><span class="line">    <span class="attr">restart:</span> <span class="string">unless-stopped</span></span><br><span class="line">    <span class="attr">ports:</span></span><br><span class="line">      <span class="comment"># These ports are in format &lt;host-port&gt;:&lt;container-port&gt;</span></span><br><span class="line">      <span class="bullet">-</span> <span class="string">&#x27;80:80&#x27;</span> <span class="comment"># Public HTTP Port</span></span><br><span class="line">      <span class="bullet">-</span> <span class="string">&#x27;443:443&#x27;</span> <span class="comment"># Public HTTPS Port</span></span><br><span class="line">      <span class="bullet">-</span> <span class="string">&#x27;81:81&#x27;</span> <span class="comment"># Admin Web Port</span></span><br><span class="line">      <span class="comment"># Add any other Stream port you want to expose</span></span><br><span class="line">      <span class="comment"># - &#x27;21:21&#x27; # FTP</span></span><br><span class="line">    <span class="attr">environment:</span></span><br><span class="line">      <span class="attr">DB_MYSQL_HOST:</span> <span class="string">&quot;db&quot;</span></span><br><span class="line">      <span class="attr">DB_MYSQL_PORT:</span> <span class="number">3306</span></span><br><span class="line">      <span class="attr">DB_MYSQL_USER:</span> <span class="string">&quot;npm&quot;</span></span><br><span class="line">      <span class="attr">DB_MYSQL_PASSWORD:</span> <span class="string">&quot;npm&quot;</span></span><br><span class="line">      <span class="attr">DB_MYSQL_NAME:</span> <span class="string">&quot;npm&quot;</span></span><br><span class="line">      <span class="comment"># Uncomment this if IPv6 is not enabled on your host</span></span><br><span class="line">      <span class="comment"># DISABLE_IPV6: &#x27;true&#x27;</span></span><br><span class="line">    <span class="attr">volumes:</span></span><br><span class="line">      <span class="bullet">-</span> <span class="string">./data:/data</span></span><br><span class="line">      <span class="bullet">-</span> <span class="string">./letsencrypt:/etc/letsencrypt</span></span><br><span class="line">    <span class="attr">depends_on:</span></span><br><span class="line">      <span class="bullet">-</span> <span class="string">db</span></span><br><span class="line"></span><br><span class="line">  <span class="attr">db:</span></span><br><span class="line">    <span class="attr">image:</span> <span class="string">&#x27;jc21/mariadb-aria:latest&#x27;</span></span><br><span class="line">    <span class="attr">restart:</span> <span class="string">unless-stopped</span></span><br><span class="line">    <span class="attr">environment:</span></span><br><span class="line">      <span class="attr">MYSQL_ROOT_PASSWORD:</span> <span class="string">&#x27;npm&#x27;</span></span><br><span class="line">      <span class="attr">MYSQL_DATABASE:</span> <span class="string">&#x27;npm&#x27;</span></span><br><span class="line">      <span class="attr">MYSQL_USER:</span> <span class="string">&#x27;npm&#x27;</span></span><br><span class="line">      <span class="attr">MYSQL_PASSWORD:</span> <span class="string">&#x27;npm&#x27;</span></span><br><span class="line">    <span class="attr">volumes:</span></span><br><span class="line">      <span class="bullet">-</span> <span class="string">./data/mysql:/var/lib/mysql</span></span><br></pre></td></tr></table></figure><p>启动服务</p><p>在确保云服务器防火墙已经放行 80、81 和 443 端口后即可访问服务器<code>ip:81</code> 进入 ngingx_proxy_manager 的 web 管理界面。默认密码为：</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br></pre></td><td class="code"><pre><span class="line">Email:    admin@example.com</span><br><span class="line">Password: changeme</span><br></pre></td></tr></table></figure><p>输入密码，进入后台后会强制要求更改用户名和密码。</p><h2 id="实战一、设置后台管理界面的反向代理">实战一、设置后台管理界面的反向代理</h2><p>在前文中，已介绍了反向代理的作用，即常见的需求是输入<code>ip:port</code> 形式访问界面太不优雅，并且无法设置 https，因此需要用一个域名与此绑定。用户浏览器输入域名，服务器会根据此域名自动转发请求报文到对应绑定的<code>ip:port</code> 服务，然后将响应报文回复给用户。</p><p>这里，我们就用<a href="https://link.zhihu.com/?target=http%3A//a.test.com">http://a.test.com</a>来绑定我们的端口号为 81 的后台管理界面，实现浏览器输入<a href="https://link.zhihu.com/?target=http%3A//a.test.com">http://a.test.com</a>即可访问后台管理界面，并且设置 HTTPS。</p><h3 id="1-前提-2">1. 前提</h3><ul><li>安装好 Nginx Proxy Manager</li><li>拥有一个域名</li><li>将<a href="https://link.zhihu.com/?target=http%3A//a.test.com">http://a.test.com</a>解析到安装 Nginx Proxy Manager 的服务器 ip 地址上</li></ul><h3 id="2-反向代理操作">2. 反向代理操作</h3><p>先用<code>ip:81</code> 访问后台管理界面，然后输入账号密码进入后台。</p><p>点击绿色图标的选项</p><p><img src="https://pic4.zhimg.com/v2-c8df921d677de6c33da6caf7d5a4dacb_r.jpg" alt="" loading="lazy"></p><p>设置反向代理</p><p>点击右边<code>Add Proxy Host</code> ，在弹出的界面<code>Details</code>选项中填写相应的字段。</p><blockquote><p><strong>Domain Names</strong>: 填写要反向代理的域名，这里就是<a href="https://link.zhihu.com/?target=http%3A//a.test.com">http://a.test.com</a><br><strong>Forward Hostname / IP</strong>: 填写的 ip 值见下文解释<br><strong>Forward Port</strong>: 反向代理的端口，这里就是 81<br><strong>Block Common Exploits</strong>: 开启后阻止一些常见漏洞<br>其余两个暂不知作用</p></blockquote><p><strong>Forward Hostname / IP 填写说明</strong></p><p>如果搭建的服务和 nginx proxy manager 服务所在不是一个服务器，则填写能访问对应服务的 IP。<br>如果都在同一台服务器上，则填写在服务器中输入`ip addr show docker0` 命令获取得到的 ip。</p><p><img src="https://pic4.zhimg.com/v2-94623083cac7f7a9b75aa91fdea92c1f_r.jpg" alt="" loading="lazy"></p><p>查看宿主机 ip</p><p>这里不填<code>127.0.0.1</code>的原因是使用的是 docker 容器搭建 web 应用，docker 容器和宿主机即服务器不在同一个网络下，所以<code>127.0.0.1</code>并不能访问到宿主机，而<code>ip addr show docker0</code>获得的 ip 地址就是宿主机地址。</p><p><img src="https://pic1.zhimg.com/v2-219fbd783a111b457a08d49f690aa0f8_r.jpg" alt="" loading="lazy"></p><p>反代设置细节</p><p>接下来即可用<code>a.test.com</code> 访问后台管理界面，此时还只是 http 协议，没有 https。不过此时就可以把之前的 81 端口关闭了，输入<code>a.test.com</code> 访问的是服务器<code>80</code>端口，然后在转发给内部的 81 端口。</p><h3 id="3-申请泛域名-ssl-证书">3. 申请泛域名 ssl 证书</h3><p>就是申请一个<code>*.test.com</code> 证书，这样二级域名无论是什么都可以用这个证书，不需要一个二级域名申请一个。</p><p>在 Nginx Proxy Manager 管理后台，选择<code>Access Lists</code>-&gt;<code>Add SSL Certificate</code>-&gt;<code>Let's Encrypt</code>选项。</p><p><img src="https://pic1.zhimg.com/v2-d1542934c6c2fa2f6ea2b1765610ed24_r.jpg" alt="" loading="lazy"></p><p>SSL 管理</p><p>Domain Names 中填写<code>*.test.com</code> <code>test.com</code> ，打开<code>Use a DNS Challenge</code> 选项，并选择个人域名的 DNS 解析服务商（本人就是腾讯的 DNSPod），最后填入服务商提供的 api key 或者 token。</p><p><strong>DNSPod 的 id，key 获取教程</strong></p><p>1. 进入<a href="https://link.zhihu.com/?target=https%3A//console.dnspod.cn/">DNSPod 控制台</a></p><p>2. 步骤直接看图</p><p><img src="https://pic2.zhimg.com/v2-8c49adc9edf0251117422d18ce325349_r.jpg" alt="" loading="lazy"></p><p>DNSPod 密钥管理</p><p>3. 随便取一个名字后，复制 ID 和 Token 到对应位置。</p><p><img src="https://pic3.zhimg.com/v2-5ab0833986e608bea3e03d5c3cd622e2_r.jpg" alt="" loading="lazy"></p><p>获取密钥</p><p><img src="https://pic1.zhimg.com/v2-470f7ec822321a7f21860e3bfb570f88_r.jpg" alt="" loading="lazy"></p><p>SSL 全部设置</p><h3 id="4-设置-HTTPS">4. 设置 HTTPS</h3><p>进入反向代理设置界面，编辑上文创建的反代服务，选择 SSL 选项，下拉菜单中选择我们申请的证书，然后可以勾选<code>Force SSL</code>即强制 HTTPS。</p><p><img src="https://pic4.zhimg.com/v2-73688ba2f9c4da2dd53997adafaeed53_r.jpg" alt="" loading="lazy"></p><p>选择相应的证书</p><p>同理以后新创建的反向代理可以直接在 SSL 选项中选择我们刚刚申请的泛域名证书。</p><h2 id="实战二、搭建服务器监控并用-NPM-设置密码访问">实战二、搭建服务器监控并用 NPM 设置密码访问</h2><p>下面再通过用 docker 搭建的小而美的服务器监控，来介绍 Nginx Proxy Manager 添加权限访问的操作。</p><p><img src="https://pic2.zhimg.com/v2-e4351b5a0bdee790d06a5d54d1046b7d_r.jpg" alt="" loading="lazy"></p><p>ward 服务器状态监控界面</p><h3 id="1-小而美的服务器状态监控：ward">1. 小而美的服务器状态监控：ward</h3><blockquote><p>Ward is a simple and and minimalistic server monitoring tool. Ward supports adaptive design system. Also it supports dark theme. It shows only principal information and can be used, if you want to see nice looking dashboard instead looking on bunch of numbers and graphs. Ward works nice on all popular operating systems, because it uses OSHI.<br>Ward 是一个简单且最低限度的服务器监控工具。Ward 支持自适应设计系统。它还支持黑暗主题。如果您想看到漂亮的仪表板，而不是查看一堆数字和图形，那么它只显示主要信息，并且可以使用。Ward 在所有流行的操作系统上都运行良好，因为它使用<a href="https://link.zhihu.com/?target=https%3A//github.com/oshi/oshi">OSHI</a>。</p></blockquote><h3 id="2-前提">2. 前提</h3><ul><li>安装好 Nginx Proxy Manager</li><li>拥有一个域名</li><li>将<a href="https://link.zhihu.com/?target=http%3A//b.test.com">http://b.test.com</a>解析到安装 Nginx Proxy Manager 的服务器 ip 地址上</li></ul><h3 id="3-安装">3. 安装</h3><p>ssh 连接上服务器后，新建一个名为 ward 的文件夹用来存放文件和数据（最好建一个统一存放各种 docker 容器应用的目录，例如本人命名为 docker 文件夹）</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br></pre></td><td class="code"><pre><span class="line">cd ~/docker/</span><br><span class="line">mkdir ward &amp;&amp; cd ward</span><br></pre></td></tr></table></figure><p>新建 docker-compose.yml 文件并复制以下内容</p><figure class="highlight yml"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br><span class="line">5</span><br><span class="line">6</span><br><span class="line">7</span><br><span class="line">8</span><br><span class="line">9</span><br><span class="line">10</span><br><span class="line">11</span><br><span class="line">12</span><br><span class="line">13</span><br><span class="line">14</span><br><span class="line">15</span><br><span class="line">16</span><br><span class="line">17</span><br></pre></td><td class="code"><pre><span class="line"><span class="comment"># 编辑文件</span></span><br><span class="line"><span class="string">vim</span> <span class="string">docker-compose.yml</span></span><br><span class="line"></span><br><span class="line"><span class="comment"># 复制以下内容</span></span><br><span class="line"><span class="attr">version:</span> <span class="string">&#x27;3.3&#x27;</span></span><br><span class="line"><span class="attr">services:</span></span><br><span class="line">    <span class="attr">run:</span></span><br><span class="line">        <span class="attr">restart:</span> <span class="string">unless-stopped</span></span><br><span class="line">        <span class="attr">container_name:</span> <span class="string">ward</span></span><br><span class="line">        <span class="attr">ports:</span></span><br><span class="line">            <span class="bullet">-</span> <span class="string">&#x27;4000:4000&#x27;</span> <span class="comment"># 第一个4000表示外部可访问的端口，可修改</span></span><br><span class="line">        <span class="attr">environment:</span></span><br><span class="line">            <span class="bullet">-</span> <span class="string">WARD_PORT=4000</span> <span class="comment"># 和上面后一个端口号相同</span></span><br><span class="line">            <span class="bullet">-</span> <span class="string">WARD_THEME=dark</span> <span class="comment"># 可选light或者dark</span></span><br><span class="line">            <span class="bullet">-</span> <span class="string">WARD_NAME=leons-server</span> <span class="comment"># 网站名称，可修改</span></span><br><span class="line">        <span class="attr">privileged:</span> <span class="literal">true</span></span><br><span class="line">        <span class="attr">image:</span> <span class="string">antonyleons/ward</span></span><br></pre></td></tr></table></figure><p>启动服务</p><h3 id="4-设置反向代理和-ssl">4. 设置反向代理和 ssl</h3><p>打开 Nginx Proxy Manager 的管理页面。 新建反向代理，<code>Detail</code>填写如上文。</p><p><img src="https://pic2.zhimg.com/v2-cd190cf209a0bef12dc637315645f6bd_r.jpg" alt="" loading="lazy"></p><p>detail 设置</p><p><code>SSL</code>选项选择自己申请的泛域名证书。</p><p><img src="https://pic4.zhimg.com/v2-2524925865066e9b0e49dc4545b6045b_r.jpg" alt="" loading="lazy"></p><p>ssl 设置</p><h3 id="5-权限设置">5. 权限设置</h3><p>在 Nginx Proxy Manager 管理首页，选<code>Access Lists</code>页面-&gt;点击<code>Add Access List</code>。</p><p><strong><code>Detail</code>页面</strong></p><blockquote><p><strong>Name</strong>: 这个权限设置的名称<br><strong>Satisfy Any</strong>: <code>Access</code>选项条件满足任意即可访问<br><strong>Pass Auth to Host</strong>: 暂不知作用</p></blockquote><p><img src="https://pic4.zhimg.com/v2-927cc07886b4ecebd123679fef2754cf_r.jpg" alt="" loading="lazy"></p><p>detail 设置</p><p><code>**Authorization**</code></p><p>可设置多个账户密码</p><p><strong><code>Access</code></strong></p><p>可设置 ip 白、黑名单。</p><p>最后保存即可，然后在设置反向代理界面<code>Details</code>-&gt;<code>Access List</code>选择刚刚设置的权限选项。</p><p><img src="https://pic1.zhimg.com/v2-bbf578269057dd05f92313b59dc15828_r.jpg" alt="" loading="lazy"></p><p>权限设置</p><p>以后想设置权限的都可以选择该权限选项。</p><p>最后效果如下</p><p><img src="https://pic4.zhimg.com/v2-6dcddcb47c6cbd6e4eb9e9118cad26d7_r.jpg" alt="" loading="lazy"></p><p>权限登陆</p><h2 id="参考链接">参考链接</h2><p>[1] <a href="https://link.zhihu.com/?target=https%3A//nginxproxymanager.com/">Nginx Proxy Manager 官网</a></p><p>[2] <a href="https://link.zhihu.com/?target=https%3A//github.com/Rudolf-Barbu/Ward">Ward github</a></p><h2 id="欢迎访问个人博客查看原文">欢迎访问个人博客查看原文</h2>]]></content>
    
    
    <summary type="html">&lt;blockquote&gt;
&lt;p&gt;&lt;a href=&quot;https://zhuanlan.zhihu.com/p/536791628&quot;&gt;原文链接&lt;/a&gt;&lt;/p&gt;
&lt;/blockquote&gt;
&lt;h2 id=&quot;一、什么是反向代理？&quot;&gt;一、什么是反向代理？&lt;/h2&gt;
&lt;p&gt;众所周知，浏览器访问网页需要&lt;code&gt;域名:端口号&lt;/code&gt; 或者&lt;code&gt;ip:端口号&lt;/code&gt; 这种形式，而当你访问页面时不输入端口号时，浏览器会根据&lt;code&gt;http&lt;/code&gt;协议或者&lt;code&gt;https&lt;/code&gt;协议，自动在后面加上默认端口号&lt;code&gt;80&lt;/code&gt;或者&lt;code&gt;443&lt;/code&gt; 。&lt;/p&gt;
&lt;p&gt;但是我这种小白使用服务器搭建服务时，一个服务器上往往有多种 web 服务。端口又不能复用，所以其他服务都是需要&lt;code&gt;域名:端口号&lt;/code&gt; 或者&lt;code&gt;ip:端口号&lt;/code&gt; 这种形式来访问。于是，我就有一个疑问了，能不能用不同的域名来对应不同的服务呢。&lt;/p&gt;
&lt;p&gt;那这就是反向代理的作用了。&lt;/p&gt;
&lt;p&gt;反向代理类似于一个菜鸟驿站。邮局（互联网）对于地址（域名）是每个咱们小区（服务器）的包裹（数据报文）都直接发给咱们小区的菜鸟驿站（反向代理服务器），然后菜鸟驿站根据每个包裹地址（域名）然后交付给咱们小区的具体家庭（服务器中的每一个服务）。&lt;/p&gt;
&lt;p&gt;&lt;img src=&quot;https://pic3.zhimg.com/v2-8b188ded15d0ead47d5734d8f424bb22_b.jpg&quot; alt loading=&quot;lazy&quot;&gt;&lt;/p&gt;
&lt;p&gt;反向代理作用&lt;/p&gt;
&lt;p&gt;而 Nginx 则作为非常有名的反向代理 web 服务器，被广大站长采用。Nginx 功能十分强大，但是配置对于小白来说，还是有一些门槛。那么有没有一款基于 Nginx 的 web 管理界面，来设置 Nginx 的反向代理呢？&lt;/p&gt;
&lt;p&gt;这就是此篇博客要写的神器：Nginx Proxy Manager。&lt;/p&gt;</summary>
    
    
    
    
    <category term="知乎" scheme="https://blog.kamasylvia.com/tags/%E7%9F%A5%E4%B9%8E/"/>
    
    <category term="Nginx" scheme="https://blog.kamasylvia.com/tags/Nginx/"/>
    
    <category term="DevOps" scheme="https://blog.kamasylvia.com/tags/DevOps/"/>
    
  </entry>
  
  <entry>
    <title>有人能解释一下官僚资本主义和社会资本主义的区别吗? - 知乎</title>
    <link href="https://blog.kamasylvia.com/p/6725b532/"/>
    <id>https://blog.kamasylvia.com/p/6725b532/</id>
    <published>2023-09-04T23:59:36.000Z</published>
    <updated>2023-10-30T00:50:06.489Z</updated>
    
    <content type="html"><![CDATA[<blockquote><p><a href="https://www.zhihu.com/question/620085969/answer/3195959707">原文链接</a></p></blockquote><p>准确说叫官僚垄断资本主义。</p><p>官垄，不是资本主义，是封建主义嫁接了资本主义的生产力。</p><p>资本主义是用货币调动生产资料。</p><p>例如，你干活，我给你钱。</p><p>官垄不是，他用手中的权力，垄断生产要素，例如土地。再通过行政命令，扭曲整个市场，谋取巨额收益。例如各种红头文件。</p><p>这样，市场就无法形成真正充分的竞争，货币的真实价值就无法形成，永远是一张象征意义的纸。</p><p>这么做，隐藏了劳动的真正价值，最终的结果就是，你干活，它给你 q 币。</p><p>例如，很少有人思考，为银行劳动三十年，换 60 平钢筋混凝土。对等吗？为什么会这样？</p><p>官僚再把人民财富换得真金白银，通过援助的方式合法运至海外。</p><p>官垄是为极少数官僚服务的，资本是为全人类服务的。</p><p>如果说资本主义是人类社会发展的必然阶段，也必然走向社会主义，例如北欧已经出现了社会主义的雏形。</p><p>那么官垄的结局必然是法西斯主义，军国主义二选一。二战前的德国，日本已经做出了榜样。</p>]]></content>
    
    
    <summary type="html">硅基网友​注册监理，注册造价，副高，周易研究会会员​ 关注</summary>
    
    
    
    
    <category term="知乎" scheme="https://blog.kamasylvia.com/tags/%E7%9F%A5%E4%B9%8E/"/>
    
  </entry>
  
  <entry>
    <title>Standard: how to cite with APA? – Grafiati</title>
    <link href="https://blog.kamasylvia.com/p/c69f6a8e/"/>
    <id>https://blog.kamasylvia.com/p/c69f6a8e/</id>
    <published>2023-08-31T02:03:40.000Z</published>
    <updated>2023-10-30T00:50:05.709Z</updated>
    
    <content type="html"><![CDATA[<blockquote><p><a href="https://www.grafiati.com/en/info/apa-7/standard/#:~:text=A%20standard%20%28such%20as%20an%20ISO%20standard%29%20should,accessed%20online.%20How%20to%20cite%20in%20a%20bibliography">Source</a></p></blockquote><h2 id="Create-a-spot-on-reference-in-APA-7-and-6">Create a spot-on reference in APA 7 and 6</h2><p>Select a source type:</p><h2 id="Basic-rules">Basic rules</h2><p>A standard (such as an ISO standard) should be cited in a list of references in APA (7th ed.) by giving the following data: title of the institution that developed the standard, title of the standard, standard code and number, and publisher. Indicate the URL, if the standard was accessed online.</p><h2 id="How-to-cite-in-a-bibliography">How to cite in a bibliography</h2><p>Basic reference template:</p><p>Institution. (Year). <em>Standard Title</em> (Standard Code and Number). Publisher. URL</p><p>Note: if the institution that developed the standard is the same as the publisher, the name of the publisher is not given in the reference.</p><h2 id="Examples-of-references">Examples of references</h2><p>Standards Australia &amp; Standards New Zealand. (2014). <em>Safety in laboratories — Part 8: Fume cupboards</em> (AS/NZS 2243.8:2014).</p><p>International Organization for Standardization. (2019). <em>Date and time — Representations for information interchange — Part 1: Basic rules</em> (ISO Standard No. 8601-1:2019).</p>]]></content>
    
    
    <summary type="html">&lt;blockquote&gt;
&lt;p&gt;&lt;a href=&quot;https://www.grafiati.com/en/info/apa-7/standard/#:~:text=A%20standard%20%28such%20as%20an%20ISO%20standard%29%20should,accessed%20online.%20How%20to%20cite%20in%20a%20bibliography&quot;&gt;Source&lt;/a&gt;&lt;/p&gt;
&lt;/blockquote&gt;
&lt;h2 id=&quot;Create-a-spot-on-reference-in-APA-7-and-6&quot;&gt;Create a spot-on reference in APA 7 and 6&lt;/h2&gt;
&lt;p&gt;Select a source type:&lt;/p&gt;
&lt;h2 id=&quot;Basic-rules&quot;&gt;Basic rules&lt;/h2&gt;
&lt;p&gt;A standard (such as an ISO standard) should be cited in a list of references in APA (7th ed.) by giving the following data: title of the institution that developed the standard, title of the standard, standard code and number, and publisher. Indicate the URL, if the standard was accessed online.&lt;/p&gt;
&lt;h2 id=&quot;How-to-cite-in-a-bibliography&quot;&gt;How to cite in a bibliography&lt;/h2&gt;
&lt;p&gt;Basic reference template:&lt;/p&gt;
&lt;p&gt;Institution. (Year). &lt;em&gt;Standard Title&lt;/em&gt; (Standard Code and Number). Publisher. URL&lt;/p&gt;
&lt;p&gt;Note: if the institution that developed the standard is the same as the publisher, the name of the publisher is not given in the reference.&lt;/p&gt;
&lt;h2 id=&quot;Examples-of-references&quot;&gt;Examples of references&lt;/h2&gt;</summary>
    
    
    
    
    <category term="LaTeX" scheme="https://blog.kamasylvia.com/tags/LaTeX/"/>
    
    <category term="Typst" scheme="https://blog.kamasylvia.com/tags/Typst/"/>
    
  </entry>
  
  <entry>
    <title>Bold the heading numbering but unbold the heading content</title>
    <link href="https://blog.kamasylvia.com/p/7b577545/"/>
    <id>https://blog.kamasylvia.com/p/7b577545/</id>
    <published>2023-08-25T01:38:39.000Z</published>
    <updated>2023-10-30T00:50:05.705Z</updated>
    
    <content type="html"><![CDATA[<h1 id="Problem">Problem</h1><p>I want to style the heading with bold numbers and unbolded content.</p><p>![[bcc1040d05ba76428e482cc8780fce03_MD5.png]]</p><h1 id="Solution">Solution</h1><h2 id="Code">Code</h2><p>Please add the given code above the target heading.</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br></pre></td><td class="code"><pre><span class="line">#show heading.where(level: 2): it =&gt; [</span><br><span class="line">  #counter(heading).display()</span><br><span class="line">  #text(weight: &quot;regular&quot;)[#it.body] // The font size is not fixed.</span><br><span class="line">]</span><br></pre></td></tr></table></figure><p>Full example code:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br><span class="line">5</span><br><span class="line">6</span><br><span class="line">7</span><br><span class="line">8</span><br><span class="line">9</span><br><span class="line">10</span><br><span class="line">11</span><br><span class="line">12</span><br><span class="line">13</span><br><span class="line">14</span><br><span class="line">15</span><br><span class="line">16</span><br></pre></td><td class="code"><pre><span class="line">#set heading(numbering: &quot;1.1&quot;)</span><br><span class="line"></span><br><span class="line">#show heading.where(level: 2): it =&gt; [</span><br><span class="line">  #counter(heading).display()</span><br><span class="line">  #text(28pt, weight: &quot;regular&quot;)[#it.body]</span><br><span class="line">]</span><br><span class="line"></span><br><span class="line">#counter(heading).update(4)</span><br><span class="line"></span><br><span class="line">#heading(level:1)[Shape and dimensions]</span><br><span class="line"></span><br><span class="line">#heading(level: 2, outlined: false)[The shapes and dimensions of plunger stoppers as shown in Figure 1 are as given in Table tab:1.] &lt;sec:5.1&gt;</span><br><span class="line"></span><br><span class="line">The dimension d#sub[1] shall be specified by using the selected cartridges according to ISO 13926-1 and the selected seal as per ISO 13926-3. The system can then be validated as described in ISO 11608-3.</span><br><span class="line"></span><br><span class="line">The dimensions that refer to the plunger stopper diameters (d#sub[1], d#sub[2]. d#sub[3]) are informative.</span><br></pre></td></tr></table></figure><h2 id="Output">Output</h2><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br><span class="line">5</span><br><span class="line">6</span><br><span class="line">7</span><br><span class="line">8</span><br><span class="line">9</span><br><span class="line">10</span><br><span class="line">11</span><br><span class="line">12</span><br><span class="line">13</span><br><span class="line">14</span><br><span class="line">15</span><br><span class="line">16</span><br></pre></td><td class="code"><pre><span class="line">#set heading(numbering: &quot;1.1&quot;)</span><br><span class="line"></span><br><span class="line">#show heading.where(level: 2): it =&gt; [</span><br><span class="line">  #counter(heading).display()</span><br><span class="line">  #text(28pt, weight: &quot;regular&quot;)[#it.body]</span><br><span class="line">]</span><br><span class="line"></span><br><span class="line">#counter(heading).update(4)</span><br><span class="line"></span><br><span class="line">#heading(level:1)[Shape and dimensions]</span><br><span class="line"></span><br><span class="line">#heading(level: 2, outlined: false)[The shapes and dimensions of plunger stoppers as shown in Figure 1 are as given in Table tab:1.] &lt;sec:5.1&gt;</span><br><span class="line"></span><br><span class="line">The dimension d#sub[1] shall be specified by using the selected cartridges according to ISO 13926-1 and the selected seal as per ISO 13926-3. The system can then be validated as described in ISO 11608-3.</span><br><span class="line"></span><br><span class="line">The dimensions that refer to the plunger stopper diameters (d#sub[1], d#sub[2]. d#sub[3]) are informative.</span><br></pre></td></tr></table></figure>]]></content>
    
    
    <summary type="html">&lt;h1 id=&quot;Problem&quot;&gt;Problem&lt;/h1&gt;
&lt;p&gt;I want to style the heading with bold numbers and unbolded content.&lt;/p&gt;
&lt;p&gt;![[bcc1040d05ba76428e482cc8780fce03_MD5.png]]&lt;/p&gt;
&lt;h1 id=&quot;Solution&quot;&gt;Solution&lt;/h1&gt;
&lt;h2 id=&quot;Code&quot;&gt;Code&lt;/h2&gt;
&lt;p&gt;Please add the given code above the target heading.&lt;/p&gt;
&lt;figure class=&quot;highlight plaintext&quot;&gt;&lt;table&gt;&lt;tr&gt;&lt;td class=&quot;gutter&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;1&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;2&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;3&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;4&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;td class=&quot;code&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;#show heading.where(level: 2): it =&amp;gt; [&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;  #counter(heading).display()&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;  #text(weight: &amp;quot;regular&amp;quot;)[#it.body] // The font size is not fixed.&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;]&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/figure&gt;
&lt;p&gt;Full example code:&lt;/p&gt;
&lt;figure class=&quot;highlight plaintext&quot;&gt;&lt;table&gt;&lt;tr&gt;&lt;td class=&quot;gutter&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;1&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;2&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;3&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;4&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;5&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;6&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;7&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;8&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;9&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;10&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;11&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;12&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;13&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;14&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;15&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;16&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;td class=&quot;code&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;#set heading(numbering: &amp;quot;1.1&amp;quot;)&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;#show heading.where(level: 2): it =&amp;gt; [&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;  #counter(heading).display()&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;  #text(28pt, weight: &amp;quot;regular&amp;quot;)[#it.body]&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;]&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;#counter(heading).update(4)&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;#heading(level:1)[Shape and dimensions]&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;#heading(level: 2, outlined: false)[The shapes and dimensions of plunger stoppers as shown in Figure 1 are as given in Table tab:1.] &amp;lt;sec:5.1&amp;gt;&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;The dimension d#sub[1] shall be specified by using the selected cartridges according to ISO 13926-1 and the selected seal as per ISO 13926-3. The system can then be validated as described in ISO 11608-3.&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;The dimensions that refer to the plunger stopper diameters (d#sub[1], d#sub[2]. d#sub[3]) are informative.&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/figure&gt;
&lt;h2 id=&quot;Output&quot;&gt;Output&lt;/h2&gt;</summary>
    
    
    
    
    <category term="Typst" scheme="https://blog.kamasylvia.com/tags/Typst/"/>
    
  </entry>
  
  <entry>
    <title>Podman</title>
    <link href="https://blog.kamasylvia.com/p/84896756/"/>
    <id>https://blog.kamasylvia.com/p/84896756/</id>
    <published>2023-08-23T00:05:24.000Z</published>
    <updated>2023-10-30T00:50:05.713Z</updated>
    
    <content type="html"><![CDATA[<h1 id="What-is-Podman">What is Podman?</h1><blockquote><p><a href="https://www.redhat.com/en/topics/containers/what-is-podman">What is Podman?</a></p></blockquote><h1 id="Why-use-Podman-instead-of-Docker">Why use Podman instead of Docker?</h1><ol><li>Firewalld cannot block ports opened by docker containers.</li><li>Podman can be managed by Cockpit.</li><li>RedHat distros support Podman natively.</li></ol><h1 id="Post-installation-steps-for-Podman">Post-installation steps for Podman</h1><h2 id="Rootless-user">Rootless user</h2><p>Podman supports rootless user natively, but the default settings are not appropriate for all applications. Some extra jobs are required.</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br></pre></td><td class="code"><pre><span class="line">sudo sysctl net.ipv4.ip_unprivileged_port_start=80</span><br><span class="line">sudo loginctl enable-linger <span class="variable">$USER</span></span><br></pre></td></tr></table></figure><h2 id="Communication-between-containers-and-host">Communication between containers and host.</h2><ul><li>Docker containers use <code>172.17.0.1</code> to connect to host.</li><li>Podman containers use <code>10.0.2.2</code> to connect to host.</li></ul>]]></content>
    
    
    <summary type="html">&lt;h1 id=&quot;What-is-Podman&quot;&gt;What is Podman?&lt;/h1&gt;
&lt;blockquote&gt;
&lt;p&gt;&lt;a href=&quot;https://www.redhat.com/en/topics/containers/what-is-podman&quot;&gt;What is Podman?&lt;/a&gt;&lt;/p&gt;
&lt;/blockquote&gt;
&lt;h1 id=&quot;Why-use-Podman-instead-of-Docker&quot;&gt;Why use Podman instead of Docker?&lt;/h1&gt;
&lt;ol&gt;
&lt;li&gt;Firewalld cannot block ports opened by docker containers.&lt;/li&gt;
&lt;li&gt;Podman can be managed by Cockpit.&lt;/li&gt;
&lt;li&gt;RedHat distros support Podman natively.&lt;/li&gt;
&lt;/ol&gt;
&lt;h1 id=&quot;Post-installation-steps-for-Podman&quot;&gt;Post-installation steps for Podman&lt;/h1&gt;
&lt;h2 id=&quot;Rootless-user&quot;&gt;Rootless user&lt;/h2&gt;
&lt;p&gt;Podman supports rootless user natively, but the default settings are not appropriate for all applications. Some extra jobs are required.&lt;/p&gt;
&lt;figure class=&quot;highlight sh&quot;&gt;&lt;table&gt;&lt;tr&gt;&lt;td class=&quot;gutter&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;1&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;2&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;td class=&quot;code&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;sudo sysctl net.ipv4.ip_unprivileged_port_start=80&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;sudo loginctl enable-linger &lt;span class=&quot;variable&quot;&gt;$USER&lt;/span&gt;&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/figure&gt;
&lt;h2 id=&quot;Communication-between-containers-and-host&quot;&gt;Communication between containers and host.&lt;/h2&gt;
&lt;ul&gt;
&lt;li&gt;Docker containers use &lt;code&gt;172.17.0.1&lt;/code&gt; to connect to host.&lt;/li&gt;
&lt;li&gt;Podman containers use &lt;code&gt;10.0.2.2&lt;/code&gt; to connect to host.&lt;/li&gt;
&lt;/ul&gt;</summary>
    
    
    
    
    <category term="Docker" scheme="https://blog.kamasylvia.com/tags/Docker/"/>
    
  </entry>
  
  <entry>
    <title>How To Configure SSH Key-Based Authentication on a Linux Server</title>
    <link href="https://blog.kamasylvia.com/p/81ba3a94/"/>
    <id>https://blog.kamasylvia.com/p/81ba3a94/</id>
    <published>2023-08-18T00:31:50.000Z</published>
    <updated>2023-10-30T00:50:05.713Z</updated>
    
    <content type="html"><![CDATA[<h3 id="Introduction"><a href="https://www.digitalocean.com/community/tutorials/how-to-configure-ssh-key-based-authentication-on-a-linux-server#introduction">Introduction</a></h3><p>SSH, or secure shell, is an encrypted protocol used to administer and communicate with servers. When working with a Linux server you may often spend much of your time in a terminal session connected to your server through SSH.</p><p>While there are a few different ways of logging into an SSH server, in this guide, we’ll focus on setting up SSH keys. SSH keys provide an extremely secure way of logging into your server. For this reason, this is the method we recommend for all users.</p><p>Simplify deploying applications to servers with <a href="https://www.digitalocean.com/products/app-platform">DigitalOcean App Platform</a>. Deploy directly from GitHub in minutes.</p><h2 id="How-Do-SSH-Keys-Work"><a href="https://www.digitalocean.com/community/tutorials/how-to-configure-ssh-key-based-authentication-on-a-linux-server#how-do-ssh-keys-work">How Do SSH Keys Work?</a></h2><p>An SSH server can authenticate clients using a variety of different methods. The most basic of these is password authentication, which is easy to use, but not the most secure.</p><p>Although passwords are sent to the server in a secure manner, they are generally not complex or long enough to be resistant to repeated, persistent attackers. Modern processing power combined with automated scripts make brute-forcing a password-protected account very possible. Although there are other methods of adding additional security (<a href="https://www.digitalocean.com/community/tutorials/how-fail2ban-works-to-protect-services-on-a-linux-server"><code>fail2ban</code></a>, etc.), SSH keys prove to be a reliable and secure alternative.</p><p>SSH key pairs are two cryptographically secure keys that can be used to authenticate a client to an SSH server. Each key pair consists of a public key and a private key.</p><p>The private key is retained by the client and should be kept absolutely secret. Any compromise of the private key will allow the attacker to log into servers that are configured with the associated public key without additional authentication. As an additional precaution, the key can be encrypted on disk with a passphrase.</p><p>The associated public key can be shared freely without any negative consequences. The public key can be used to encrypt messages that <strong>only</strong> the private key can decrypt. This property is employed as a way of authenticating using the key pair.</p><p>The public key is uploaded to a remote server that you want to be able to log into with SSH. The key is added to a special file within the user account you will be logging into called <code>~/.ssh/authorized_keys</code>.</p><p>When a client attempts to authenticate using SSH keys, the server can test the client on whether they are in possession of the private key. If the client can prove that it owns the private key, a shell session is spawned or the requested command is executed.</p><h2 id="Step-1-—-Creating-SSH-Keys"><a href="https://www.digitalocean.com/community/tutorials/how-to-configure-ssh-key-based-authentication-on-a-linux-server#step-1-creating-ssh-keys">Step 1 — Creating SSH Keys</a></h2><p>The first step to configure SSH key authentication to your server is to generate an SSH key pair on your local computer.</p><p>To do this, we can use a special utility called <code>ssh-keygen</code>, which is included with the standard OpenSSH suite of tools. By default, this will create a 3072 bit RSA key pair.</p><p>On your local computer, generate a SSH key pair by typing:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br></pre></td><td class="code"><pre><span class="line">ssh-keygen</span><br><span class="line"></span><br></pre></td></tr></table></figure><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br></pre></td><td class="code"><pre><span class="line">OutputGenerating public/private rsa key pair.</span><br><span class="line">Enter file in which to save the key (/home/username/.ssh/id_rsa):</span><br></pre></td></tr></table></figure><p>The utility will prompt you to select a location for the keys that will be generated. By default, the keys will be stored in the <code>~/.ssh</code> directory within your user’s home directory. The private key will be called <code>id_rsa</code> and the associated public key will be called <code>id_rsa.pub</code>.</p><p>Usually, it is best to stick with the default location at this stage. Doing so will allow your SSH client to automatically find your SSH keys when attempting to authenticate. If you would like to choose a non-standard path, type that in now, otherwise, press <code>ENTER</code> to accept the default.</p><p>If you had previously generated an SSH key pair, you may see a prompt that looks like this:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br></pre></td><td class="code"><pre><span class="line">Output/home/username/.ssh/id_rsa already exists.</span><br><span class="line">Overwrite (y/n)?</span><br></pre></td></tr></table></figure><p>If you choose to overwrite the key on disk, you will <strong>not</strong> be able to authenticate using the previous key anymore. Be very careful when selecting yes, as this is a destructive process that cannot be reversed.</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br></pre></td><td class="code"><pre><span class="line">OutputCreated directory &#x27;/home/username/.ssh&#x27;.</span><br><span class="line">Enter passphrase (empty for no passphrase):</span><br><span class="line">Enter same passphrase again:</span><br></pre></td></tr></table></figure><p>Next, you will be prompted to enter a passphrase for the key. This is an optional passphrase that can be used to encrypt the private key file on disk.</p><p>You may be wondering what advantages an SSH key provides if you still need to enter a passphrase. Some of the advantages are:</p><ul><li>The private SSH key (the part that can be passphrase protected), is never exposed on the network. The passphrase is only used to decrypt the key on the local machine. This means that network-based brute forcing will not be possible against the passphrase.</li><li>The private key is kept within a restricted directory. The SSH client will not recognize private keys that are not kept in restricted directories. The key itself must also have restricted permissions (read and write only available for the owner). This means that other users on the system cannot snoop.</li><li>Any attacker hoping to crack the private SSH key passphrase must already have access to the system. This means that they will already have access to your user account or the root account. If you are in this position, the passphrase can prevent the attacker from immediately logging into your other servers. This will hopefully give you time to create and implement a new SSH key pair and remove access from the compromised key.</li></ul><p>Since the private key is never exposed to the network and is protected through file permissions, this file should never be accessible to anyone other than you (and the <strong>root</strong> user). The passphrase serves as an additional layer of protection in case these conditions are compromised.</p><p>A passphrase is an optional addition. If you enter one, you will have to provide it every time you use this key (unless you are running SSH agent software that stores the decrypted key). We recommend using a passphrase, but if you do not want to set a passphrase, you can press <code>ENTER</code> to bypass this prompt.</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br><span class="line">5</span><br><span class="line">6</span><br><span class="line">7</span><br><span class="line">8</span><br><span class="line">9</span><br><span class="line">10</span><br><span class="line">11</span><br><span class="line">12</span><br><span class="line">13</span><br><span class="line">14</span><br><span class="line">15</span><br><span class="line">16</span><br></pre></td><td class="code"><pre><span class="line">OutputYour identification has been saved in /home/username/.ssh/id_rsa.</span><br><span class="line">Your public key has been saved in /home/username/.ssh/id_rsa.pub.</span><br><span class="line">The key fingerprint is:</span><br><span class="line">SHA256:CAjsV9M/tt5skazroTc1ZRGCBz+kGtYUIPhRvvZJYBs username@hostname</span><br><span class="line">The key&#x27;s randomart image is:</span><br><span class="line">+---[RSA 3072]----+</span><br><span class="line">|o   ..oo.++o ..  |</span><br><span class="line">| o o +o.o.+...   |</span><br><span class="line">|. . + oE.o.o  .  |</span><br><span class="line">| . . oo.B+  .o   |</span><br><span class="line">|  .   .=S.+ +    |</span><br><span class="line">|      . o..*     |</span><br><span class="line">|        .+= o    |</span><br><span class="line">|        .=.+     |</span><br><span class="line">|       .oo+      |</span><br><span class="line">+----[SHA256]-----+</span><br></pre></td></tr></table></figure><p>You now have a public and private key that you can use to authenticate. The next step is to place the public key on your server so that you can use SSH key authentication to log in.</p><h2 id="Step-2-—-Copying-an-SSH-Public-Key-to-Your-Server"><a href="https://www.digitalocean.com/community/tutorials/how-to-configure-ssh-key-based-authentication-on-a-linux-server#step-2-copying-an-ssh-public-key-to-your-server">Step 2 — Copying an SSH Public Key to Your Server</a></h2><p>There are multiple ways to upload your public key to your remote SSH server. The method you use depends largely on the tools you have available and the details of your current configuration.</p><p>The following methods all yield the same end result. The simplest, most automated method is described first, and the ones that follow it each require additional manual steps. You should follow these only if you are unable to use the preceding methods.</p><h3 id="Copying-Your-Public-Key-Using-ssh-copy-id"><a href="https://www.digitalocean.com/community/tutorials/how-to-configure-ssh-key-based-authentication-on-a-linux-server#copying-your-public-key-using-ssh-copy-id">Copying Your Public Key Using <code>ssh-copy-id</code></a></h3><p>The simplest way to copy your public key to an existing server is to use a utility called <code>ssh-copy-id</code>. Because of its simplicity, this method is recommended if available.</p><p>The <code>ssh-copy-id</code> tool is included in the OpenSSH packages in many distributions, so you may already have it available on your local system. For this method to work, you must currently have password-based SSH access to your server.</p><p>To use the utility, you need to specify the remote host that you would like to connect to, and the user account that you have password-based SSH access to. This is the account where your public SSH key will be copied.</p><p>The syntax is:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">ssh-copy-id username@remote_host</span><br></pre></td></tr></table></figure><p>You may see a message like this:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br></pre></td><td class="code"><pre><span class="line">OutputThe authenticity of host &#x27;203.0.113.1 (203.0.113.1)&#x27; can&#x27;t be established.</span><br><span class="line">ECDSA key fingerprint is fd:fd:d4:f9:77:fe:73:84:e1:55:00:ad:d6:6d:22:fe.</span><br><span class="line">Are you sure you want to continue connecting (yes/no)? yes</span><br></pre></td></tr></table></figure><p>This means that your local computer does not recognize the remote host. This will happen the first time you connect to a new host. Type <code>yes</code> and press <code>ENTER</code> to continue.</p><p>Next, the utility will scan your local account for the <code>id_rsa.pub</code> key that we created earlier. When it finds the key, it will prompt you for the password of the remote user’s account:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br></pre></td><td class="code"><pre><span class="line">Output/usr/bin/ssh-copy-id: INFO: attempting to log in with the new key(s), to filter out any that are already installed</span><br><span class="line">/usr/bin/ssh-copy-id: INFO: 1 key(s) remain to be installed -- if you are prompted now it is to install the new keys</span><br><span class="line">username@203.0.113.1&#x27;s password:</span><br></pre></td></tr></table></figure><p>Type in the password (your typing will not be displayed for security purposes) and press <code>ENTER</code>. The utility will connect to the account on the remote host using the password you provided. It will then copy the contents of your <code>~/.ssh/id_rsa.pub</code> key into a file in the remote account’s home <code>~/.ssh</code> directory called <code>authorized_keys</code>.</p><p>You will see output that looks like this:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br></pre></td><td class="code"><pre><span class="line">OutputNumber of key(s) added: 1</span><br><span class="line"></span><br><span class="line">Now try logging into the machine, with:   &quot;ssh &#x27;username@203.0.113.1&#x27;&quot;</span><br><span class="line">and check to make sure that only the key(s) you wanted were added.</span><br></pre></td></tr></table></figure><p>At this point, your <code>id_rsa.pub</code> key has been uploaded to the remote account. You can continue onto the next section.</p><h3 id="Copying-Your-Public-Key-Using-SSH"><a href="https://www.digitalocean.com/community/tutorials/how-to-configure-ssh-key-based-authentication-on-a-linux-server#copying-your-public-key-using-ssh">Copying Your Public Key Using SSH</a></h3><p>If you do not have <code>ssh-copy-id</code> available, but you have password-based SSH access to an account on your server, you can upload your keys using a conventional SSH method.</p><p>We can do this by outputting the content of our public SSH key on our local computer and piping it through an SSH connection to the remote server. On the other side, we can make sure that the <code>~/.ssh</code> directory exists under the account we are using and then output the content we piped over into a file called <code>authorized_keys</code> within this directory.</p><p>We will use the <code>&gt;&gt;</code> redirect symbol to append the content instead of overwriting it. This will let us add keys without destroying previously added keys.</p><p>The full command will look like this:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line"><span class="built_in">cat</span> ~/.ssh/id_rsa.pub | ssh username@remote_host <span class="string">&quot;mkdir -p ~/.ssh &amp;&amp; cat &gt;&gt; ~/.ssh/authorized_keys&quot;</span></span><br></pre></td></tr></table></figure><p>You may see a message like this:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br></pre></td><td class="code"><pre><span class="line">OutputThe authenticity of host &#x27;203.0.113.1 (203.0.113.1)&#x27; can&#x27;t be established.</span><br><span class="line">ECDSA key fingerprint is fd:fd:d4:f9:77:fe:73:84:e1:55:00:ad:d6:6d:22:fe.</span><br><span class="line">Are you sure you want to continue connecting (yes/no)? yes</span><br></pre></td></tr></table></figure><p>This means that your local computer does not recognize the remote host. This will happen the first time you connect to a new host. Type <code>yes</code> and press <code>ENTER</code> to continue.</p><p>Afterwards, you will be prompted with the password of the account you are attempting to connect to:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">Outputusername@203.0.113.1&#x27;s password:</span><br></pre></td></tr></table></figure><p>After entering your password, the content of your <code>id_rsa.pub</code> key will be copied to the end of the <code>authorized_keys</code> file of the remote user’s account. Continue to the next section if this was successful.</p><h3 id="Copying-Your-Public-Key-Manually"><a href="https://www.digitalocean.com/community/tutorials/how-to-configure-ssh-key-based-authentication-on-a-linux-server#copying-your-public-key-manually">Copying Your Public Key Manually</a></h3><p>If you do not have password-based SSH access to your server available, you will have to do the above process manually.</p><p>The content of your <code>id_rsa.pub</code> file will have to be added to a file at <code>~/.ssh/authorized_keys</code> on your remote machine somehow.</p><p>To display the content of your <code>id_rsa.pub</code> key, type this into your local computer:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line"><span class="built_in">cat</span> ~/.ssh/id_rsa.pub</span><br></pre></td></tr></table></figure><p>You will see the key’s content, which may look something like this:</p><p>~/.ssh/id_rsa.pub</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">ssh-rsa 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 username@hostname</span><br></pre></td></tr></table></figure><p>Access your remote host using whatever method you have available. This may be a web-based console provided by your infrastructure provider.</p><p>Once you have access to your account on the remote server, you should make sure the <code>~/.ssh</code> directory is created. This command will create the directory if necessary, or do nothing if it already exists:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line"><span class="built_in">mkdir</span> -p ~/.ssh</span><br></pre></td></tr></table></figure><p>Now, you can create or modify the <code>authorized_keys</code> file within this directory. You can add the contents of your <code>id_rsa.pub</code> file to the end of the <code>authorized_keys</code> file, creating it if necessary, using this:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line"><span class="built_in">echo</span> public_key_string &gt;&gt; ~/.ssh/authorized_keys</span><br></pre></td></tr></table></figure><p>In the above command, substitute the <code>public_key_string</code> with the output from the <code>cat ~/.ssh/id_rsa.pub</code> command that you executed on your local system. It should start with <code>ssh-rsa AAAA...</code> or similar.</p><p>Set the permissions on the <code>authorized_keys</code> file such that it is only readable and writable by you, the owner.</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br></pre></td><td class="code"><pre><span class="line"><span class="built_in">chmod</span> 600 authorized_keys</span><br><span class="line"><span class="built_in">chmod</span> 700 ~/.ssh</span><br></pre></td></tr></table></figure><p>If this works, you can move on to test your new key-based SSH authentication.</p><h2 id="Step-3-—-Authenticating-to-Your-Server-Using-SSH-Keys"><a href="https://www.digitalocean.com/community/tutorials/how-to-configure-ssh-key-based-authentication-on-a-linux-server#step-3-authenticating-to-your-server-using-ssh-keys">Step 3 — Authenticating to Your Server Using SSH Keys</a></h2><p>If you have successfully completed one of the procedures above, you should be able to log into the remote host <em>without</em> the remote account’s password.</p><p>The process is mostly the same:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">ssh username@remote_host</span><br></pre></td></tr></table></figure><p>If this is your first time connecting to this host (if you used the last method above), you may see something like this:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br></pre></td><td class="code"><pre><span class="line">OutputThe authenticity of host &#x27;203.0.113.1 (203.0.113.1)&#x27; can&#x27;t be established.</span><br><span class="line">ECDSA key fingerprint is fd:fd:d4:f9:77:fe:73:84:e1:55:00:ad:d6:6d:22:fe.</span><br><span class="line">Are you sure you want to continue connecting (yes/no)? yes</span><br></pre></td></tr></table></figure><p>This means that your local computer does not recognize the remote host. Type <code>yes</code> and then press <code>ENTER</code> to continue.</p><p>If you did not supply a passphrase for your private key, you will be logged in immediately. If you supplied a passphrase for the private key when you created the key, you will be required to enter it now. Afterwards, a new shell session will be created for you with the account on the remote system.</p><p>If successful, continue on to find out how to lock down the server.</p><h2 id="Step-4-—-Disabling-Password-Authentication-on-your-Server"><a href="https://www.digitalocean.com/community/tutorials/how-to-configure-ssh-key-based-authentication-on-a-linux-server#step-4-disabling-password-authentication-on-your-server">Step 4 — Disabling Password Authentication on your Server</a></h2><p>If you were able to login to your account using SSH without a password, you have successfully configured SSH key-based authentication to your account. However, your password-based authentication mechanism is still active, meaning that your server is still exposed to brute-force attacks.</p><p>Before completing the steps in this section, make sure that you either have SSH key-based authentication configured for the <strong>root</strong> account on this server, or preferably, that you have SSH key-based authentication configured for an account on this server with <code>sudo</code> access. This step will lock down password-based logins, so ensuring that you will still be able to get administrative access is essential.</p><p>Once the above conditions are true, log into your remote server with SSH keys, either as <strong>root</strong> or with an account with <code>sudo</code> privileges. Open the SSH daemon’s configuration file:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">sudo nano /etc/ssh/sshd_config</span><br></pre></td></tr></table></figure><p>Inside the file, search for a directive called <code>PasswordAuthentication</code>. This may be commented out. Uncomment the line by removing any <code>#</code> at the beginning of the line, and set the value to <code>no</code>. This will disable your ability to log in through SSH using account passwords:</p><p>Edit <code>/etc/ssh/sshd_config</code></p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">PasswordAuthentication no</span><br></pre></td></tr></table></figure><p>Save and close the file when you are finished. To actually implement the changes we just made, you must restart the service.</p><p>On most Linux distributions, you can issue the following command to do that:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">sudo systemctl restart ssh</span><br></pre></td></tr></table></figure><p>After completing this step, you’ve successfully transitioned your SSH daemon to only respond to SSH keys.</p><h2 id="Conclusion"><a href="https://www.digitalocean.com/community/tutorials/how-to-configure-ssh-key-based-authentication-on-a-linux-server#conclusion">Conclusion</a></h2><p>You should now have SSH key-based authentication configured and running on your server, allowing you to sign in without providing an account password. From here, there are many directions you can head. If you’d like to learn more about working with SSH, take a look at our <a href="https://www.digitalocean.com/community/tutorials/ssh-essentials-working-with-ssh-servers-clients-and-keys">SSH essentials guide</a>.</p><h1 id="Reference">Reference</h1><ul><li><a href="https://www.digitalocean.com/community/tutorials/how-to-configure-ssh-key-based-authentication-on-a-linux-server#step-4-disabling-password-authentication-on-your-server">Source</a></li><li><a href="https://wiki.archlinux.org/title/SSH_keys">SSH keys - ArchWiki</a></li></ul>]]></content>
    
    
    <summary type="html">Justin Ellingwood, Brian Boucheron</summary>
    
    
    
    
    <category term="Linux" scheme="https://blog.kamasylvia.com/tags/Linux/"/>
    
  </entry>
  
  <entry>
    <title>Docker - openSUSE Wiki</title>
    <link href="https://blog.kamasylvia.com/p/d7aa0931/"/>
    <id>https://blog.kamasylvia.com/p/d7aa0931/</id>
    <published>2023-08-18T00:15:26.000Z</published>
    <updated>2023-10-30T00:50:05.713Z</updated>
    
    <content type="html"><![CDATA[<p>Jump to: <a href="https://en.opensuse.org/Docker#mw-head">navigation</a>, <a href="https://en.opensuse.org/Docker#p-search">search</a></p><h2 id="Installation">Installation</h2><p>Tumbleweed packages: <code>docker docker-compose docker-compose-switch</code></p><p>Leap packages: <code>docker python3-docker-compose</code></p><h3 id="with-YaST2">with YaST2</h3><p>To install the docker and docker-compose packages start YaST2, select “Software” and start the module “Software Management”. Search for docker and choose to install the Packages appropriate for the openSUSE flavor you’re running. Then click “Accept”, and if the installation was successful, “Finish”.</p><p>To start the docker daemon during boot start YaST2, select “System” and start the module “Services Manager”. Select the “docker” service and click “Enable/Disable” and “Start/Stop”. To apply your changes click “OK”.</p><p>To join the docker group that is allowed to use the docker daemon start YaST2, select “Security and Users” and start the module “User and Group Management”. Select your user and click “Edit”. On the “Details” tab select “docker” in the list of “Additional Groups”. Then click “OK” twice.</p><p>Now you have to “Log out” of your session and “Log in” again for the changes to take effect.</p><h3 id="with-Command-line">with Command line</h3><h4 id="Install-packages">Install packages</h4><p>To install the <code>docker</code> and <code>docker-compose</code> packages:</p><h5 id="For-Tumbleweed">For Tumbleweed:</h5><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">zypper install docker docker-compose docker-compose-switch</span><br></pre></td></tr></table></figure><h5 id="For-Leap">For Leap:</h5><p>1. Add the Python devel repository (for the purposes of obtaining <code>python3-docker-compose</code>):</p><p>2. Install the packages</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">zypper install docker python3-docker-compose</span><br></pre></td></tr></table></figure><h4 id="Enable-start-run-Docker">Enable, start, run Docker</h4><p>To start the docker daemon during boot:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">sudo systemctl <span class="built_in">enable</span> docker</span><br></pre></td></tr></table></figure><p>To join the docker group that is allowed to use the docker daemon:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">sudo usermod -G docker -a <span class="variable">$USER</span></span><br></pre></td></tr></table></figure><p>Restart the docker daemon:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">sudo systemctl restart docker</span><br></pre></td></tr></table></figure><p>Verify docker is running:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">docker version</span><br></pre></td></tr></table></figure><p>This will pull down and run the, “Hello World” docker container from dockerhub:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">docker run --<span class="built_in">rm</span> hello-world</span><br></pre></td></tr></table></figure><p>Clean up and remove docker image we pulled down:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br></pre></td><td class="code"><pre><span class="line">docker images</span><br><span class="line">docker rmi -f IMAGE_ID</span><br></pre></td></tr></table></figure><p>Where “IMAGE_ID” is the Id value of the “Hello World” container.</p><h3 id="Adding-buildx-Support-As-Plugin-Where-It-Is-Not-Included-By-Default">Adding <code>buildx</code> Support As Plugin Where It Is Not Included By Default</h3><p>This concerns (e.g.) <code>s390x</code>. The following commands can all be executed in your home directory on your LinuxONE instance/machine. The steps outlined here can be used analogously for other docker plugins (provided that a binary for the architecture in question is actually available).</p><p>Perform the following steps (<code>v0.6.1</code> should be treated like a placeholder, it just happened to be the current version at the time of this writing. An overview of all available releases can always be obtained by just browsing <code>releases</code> w/o any additional URL components; command output for .eg. <code>wget</code> has deliberately been omitted for the sake of brevity):</p><h3 id="Use-Docker">Use Docker</h3><p>If you followed the instructions your openSUSE is ready to make use of docker containers. Dive into the great <a href="https://docs.docker.com/">docker documentation</a> and have a lot of fun…</p><h1 id="Reference">Reference</h1><blockquote><p><a href="https://en.opensuse.org/Docker">Source</a></p></blockquote>]]></content>
    
    
    <summary type="html">&lt;p&gt;Jump to: &lt;a href=&quot;https://en.opensuse.org/Docker#mw-head&quot;&gt;navigation&lt;/a&gt;, &lt;a href=&quot;https://en.opensuse.org/Docker#p-search&quot;&gt;search&lt;/a&gt;&lt;/p&gt;
&lt;h2 id=&quot;Installation&quot;&gt;Installation&lt;/h2&gt;
&lt;p&gt;Tumbleweed packages: &lt;code&gt;docker docker-compose docker-compose-switch&lt;/code&gt;&lt;/p&gt;
&lt;p&gt;Leap packages: &lt;code&gt;docker python3-docker-compose&lt;/code&gt;&lt;/p&gt;
&lt;h3 id=&quot;with-YaST2&quot;&gt;with YaST2&lt;/h3&gt;
&lt;p&gt;To install the docker and docker-compose packages start YaST2, select “Software” and start the module “Software Management”. Search for docker and choose to install the Packages appropriate for the openSUSE flavor you’re running. Then click “Accept”, and if the installation was successful, “Finish”.&lt;/p&gt;
&lt;p&gt;To start the docker daemon during boot start YaST2, select “System” and start the module “Services Manager”. Select the “docker” service and click “Enable/Disable” and “Start/Stop”. To apply your changes click “OK”.&lt;/p&gt;
&lt;p&gt;To join the docker group that is allowed to use the docker daemon start YaST2, select “Security and Users” and start the module “User and Group Management”. Select your user and click “Edit”. On the “Details” tab select “docker” in the list of “Additional Groups”. Then click “OK” twice.&lt;/p&gt;
&lt;p&gt;Now you have to “Log out” of your session and “Log in” again for the changes to take effect.&lt;/p&gt;
&lt;h3 id=&quot;with-Command-line&quot;&gt;with Command line&lt;/h3&gt;</summary>
    
    
    
    
    <category term="Linux" scheme="https://blog.kamasylvia.com/tags/Linux/"/>
    
  </entry>
  
  <entry>
    <title>Setup openSUSE VPS - openSUSE Wiki</title>
    <link href="https://blog.kamasylvia.com/p/61cd5fd5/"/>
    <id>https://blog.kamasylvia.com/p/61cd5fd5/</id>
    <published>2023-08-18T00:08:55.000Z</published>
    <updated>2023-10-30T00:50:05.713Z</updated>
    
    <content type="html"><![CDATA[<p>Jump to: <a href="https://en.opensuse.org/Setup_openSUSE_VPS#mw-head">navigation</a>, <a href="https://en.opensuse.org/Setup_openSUSE_VPS#p-search">search</a></p><h2 id="Connect-to-your-VPS">Connect to your VPS</h2><p>When you purchase a VPS running openSUSE, you usually get:</p><ol><li>an IP address like <code>111.111.111.111</code></li><li>the root password</li></ol><p>With them, you can use SSH to access your VPS:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">ssh root@111.111.111.111</span><br></pre></td></tr></table></figure><p>Then, you can run commands to setup your server.</p><h2 id="System-update">System update</h2><p>VPS are usually created with the original release image. This means your VPS may miss some important security patches. So the first thing you should do is to update the system and reboot:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br></pre></td><td class="code"><pre><span class="line">zypper up</span><br><span class="line">reboot</span><br></pre></td></tr></table></figure><p>After reboot, you can connect to your VPS via SSH again.</p><h2 id="Create-a-normal-user">Create a normal user</h2><p>Using root is dangerous. You better create a normal user with sudo permission. Don’t use <em>admin</em>, <em>shop</em>, a nick name or a real name. It should only be known by the person actually use it.</p><p>The following command will create a user named <em>zmvxr</em> and create its home directory:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">useradd -m zmvxr</span><br></pre></td></tr></table></figure><p>Set a passowrd for <em>zmvxr</em>:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">passwd zmvxr</span><br></pre></td></tr></table></figure><p>Give <em>zmvxr</em> sudo power:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">visudo</span><br></pre></td></tr></table></figure><p>You need basic vi knowledge here. Check <a href="https://wiki.gentoo.org/wiki/Vim/Learning">this tutorial</a>.</p><p>Change the following:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">root ALL=(ALL) ALL</span><br></pre></td></tr></table></figure><p>To:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br></pre></td><td class="code"><pre><span class="line">root ALL=(ALL) ALL</span><br><span class="line">zmvxr ALL=(ALL) ALL</span><br></pre></td></tr></table></figure><p>Now you can exit root and ssh with new user:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">ssh zmvxr@111.111.111.111</span><br></pre></td></tr></table></figure><h2 id="SSH-configuration">SSH configuration</h2><p>Here are millions of evil bots are trying to hack your server, 24/7. Usually they will guess your SSH password. If your root’s password is your date of birth, your server will be easily hacked. To protect your server, you need to do the following to harden SSH access.</p><p>First, exit SSH connection and return to your local shell environment.</p><p>Generate yourself a SSH key if you don’t already have one:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">ssh-keygen -b 4096</span><br></pre></td></tr></table></figure><p>Copy the public key to your user on VPS</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">ssh-copy-id zmxvr@111.111.111.111</span><br></pre></td></tr></table></figure><p>Next time when you SSH, you won’t need to type the password because your local PC will authenticate with SSH keys. It is a much more secure way than using a password.</p><p>However, hackers still access your machine if they got the password. Now, let’s disable SSH access with password.</p><p>SSH to your server again. Run the following command to edit your server’s SSH configuration:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">sudo vi /etc/ssh/sshd_config</span><br></pre></td></tr></table></figure><p>Change the following line to disable password login:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">PasswordAuthentication no</span><br></pre></td></tr></table></figure><p>Also, we would like to forbid SSH connection as root user:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">PermitRootLogin no</span><br></pre></td></tr></table></figure><p>Save the file and restart SSH service:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">sudo systemctl restart sshd</span><br></pre></td></tr></table></figure><p>The SSH connection will be closed and you need to connect again.</p><h2 id="Firewalld-configuration">Firewalld configuration</h2><p>Install firewalld:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">sudo zypper install firewalld</span><br></pre></td></tr></table></figure><p>Then start firewalld’s systemd service:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br></pre></td><td class="code"><pre><span class="line">sudo systemctl <span class="built_in">enable</span> firewalld</span><br><span class="line">sudo systemctl start firewalld</span><br></pre></td></tr></table></figure><p>Firewalld has several different firewall zones/areas, to be used in different network environment. Usually <strong>public</strong> is chosen by default, which means that the server is in public network and is visible to unknown people and devices. Run <code>firewall-cmd --list-all</code> to check which zone is active and what services are enabled.</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br><span class="line">5</span><br><span class="line">6</span><br><span class="line">7</span><br><span class="line">8</span><br><span class="line">9</span><br><span class="line">10</span><br><span class="line">11</span><br><span class="line">12</span><br><span class="line">13</span><br><span class="line">14</span><br><span class="line">15</span><br></pre></td><td class="code"><pre><span class="line">localhost:~ <span class="comment"># firewall-cmd --list-all</span></span><br><span class="line">public (active)</span><br><span class="line">target: default</span><br><span class="line">icmp-block-inversion: no</span><br><span class="line">interfaces: eth0</span><br><span class="line">sources:</span><br><span class="line">services: dhcpv6-client ssh</span><br><span class="line">ports:</span><br><span class="line">protocols:</span><br><span class="line">forward: no</span><br><span class="line">masquerade: no</span><br><span class="line">forward-ports:</span><br><span class="line">source-ports:</span><br><span class="line">icmp-blocks:</span><br><span class="line">rich rules:</span><br></pre></td></tr></table></figure><p>In a zone, you can add services or ports to allow certain connections. For a common web server, we need SSH, HTTP and HTTPS access. To enable these services:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br></pre></td><td class="code"><pre><span class="line">sudo firewall-cmd --permanent --zone=public --add-service=http</span><br><span class="line">sudo firewall-cmd --permanent --zone=public --add-service=https</span><br><span class="line">sudo firewall-cmd --permanent --zone=public --add-service=ssh</span><br></pre></td></tr></table></figure><p>Reload firewalld to take effects:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">sudo firewall-cmd --reload</span><br></pre></td></tr></table></figure><h2 id="MariaDB-configuration">MariaDB configuration</h2><p>MariaDB is a compatible implementation of MySQL.</p><p>Install:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">sudo zypper <span class="keyword">in</span> mariadb</span><br></pre></td></tr></table></figure><p>Start service:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br></pre></td><td class="code"><pre><span class="line">sudo systemctl <span class="built_in">enable</span> mariadb</span><br><span class="line">sudo systemctl start mariadb</span><br></pre></td></tr></table></figure><p>Run security setup:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">sudo mysql_secure_installation</span><br></pre></td></tr></table></figure><p>Choose Y for all y/n questions. And type a strong password when asked.</p><p>Create a new user and a database for it:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">mysql -u root</span><br></pre></td></tr></table></figure><figure class="highlight sql"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br></pre></td><td class="code"><pre><span class="line"><span class="operator">&gt;</span> <span class="keyword">CREATE</span> <span class="keyword">USER</span> <span class="string">&#x27;mydbuser&#x27;</span>@<span class="string">&#x27;localhost&#x27;</span> IDENTIFIED <span class="keyword">BY</span> <span class="string">&#x27;xxxxxx&#x27;</span>;</span><br><span class="line"><span class="operator">&gt;</span> <span class="keyword">CREATE</span> DATABASE mydb;</span><br><span class="line"><span class="operator">&gt;</span> <span class="keyword">GRANT</span> <span class="keyword">ALL</span> PRIVILEGES <span class="keyword">ON</span> mydb.\<span class="operator">*</span> <span class="keyword">TO</span> <span class="string">&#x27;mydbuser&#x27;</span>@<span class="string">&#x27;localhost&#x27;</span>;</span><br><span class="line"><span class="operator">&gt;</span> exit</span><br></pre></td></tr></table></figure><h1 id="Reference">Reference</h1><blockquote><p><a href="https://en.opensuse.org/Setup_openSUSE_VPS">Source</a></p></blockquote><h2 id="NGINX-configuration">NGINX configuration</h2><p>See <a href="https://en.opensuse.org/NGINX" title="NGINX">NGINX</a></p><h2 id="Get-SSL-certificates-with-Certbot">Get SSL certificates with Certbot</h2><p>See <a href="https://en.opensuse.org/Certbot" title="Certbot">Certbot</a></p><h2 id="External-links">External links</h2><p>1. <a href="https://www.linode.com/docs/guides/securing-your-server/">How to Secure Your Server</a></p>]]></content>
    
    
    <summary type="html">&lt;p&gt;Jump to: &lt;a href=&quot;https://en.opensuse.org/Setup_openSUSE_VPS#mw-head&quot;&gt;navigation&lt;/a&gt;, &lt;a href=&quot;https://en.opensuse.org/Setup_openSUSE_VPS#p-search&quot;&gt;search&lt;/a&gt;&lt;/p&gt;
&lt;h2 id=&quot;Connect-to-your-VPS&quot;&gt;Connect to your VPS&lt;/h2&gt;
&lt;p&gt;When you purchase a VPS running openSUSE, you usually get:&lt;/p&gt;
&lt;ol&gt;
&lt;li&gt;an IP address like &lt;code&gt;111.111.111.111&lt;/code&gt;&lt;/li&gt;
&lt;li&gt;the root password&lt;/li&gt;
&lt;/ol&gt;
&lt;p&gt;With them, you can use SSH to access your VPS:&lt;/p&gt;
&lt;figure class=&quot;highlight sh&quot;&gt;&lt;table&gt;&lt;tr&gt;&lt;td class=&quot;gutter&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;1&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;td class=&quot;code&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;ssh root@111.111.111.111&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/figure&gt;
&lt;p&gt;Then, you can run commands to setup your server.&lt;/p&gt;
&lt;h2 id=&quot;System-update&quot;&gt;System update&lt;/h2&gt;
&lt;p&gt;VPS are usually created with the original release image. This means your VPS may miss some important security patches. So the first thing you should do is to update the system and reboot:&lt;/p&gt;
&lt;figure class=&quot;highlight sh&quot;&gt;&lt;table&gt;&lt;tr&gt;&lt;td class=&quot;gutter&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;1&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;2&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;td class=&quot;code&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;zypper up&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;line&quot;&gt;reboot&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/figure&gt;</summary>
    
    
    
    
    <category term="Linux" scheme="https://blog.kamasylvia.com/tags/Linux/"/>
    
  </entry>
  
  <entry>
    <title>How to change hostname on Linux</title>
    <link href="https://blog.kamasylvia.com/p/9b37ae35/"/>
    <id>https://blog.kamasylvia.com/p/9b37ae35/</id>
    <published>2023-08-18T00:00:35.000Z</published>
    <updated>2023-10-30T00:50:05.713Z</updated>
    
    <content type="html"><![CDATA[<p>The hostname of a <a href="https://linuxconfig.org/linux-download">Linux system</a> is important because it’s used to identify the device on a network. The hostname is also shown in other prominent places, such as in the terminal prompt. This gives you a constant reminder of which system you’re working with. It’s a real life saver when you’re managing multiple systems through <a href="https://linuxconfig.org/how-to-make-the-most-of-openssh">SSH</a> and those <a href="https://linuxconfig.org/linux-command-line-tutorial">command line</a> terminals start to blend together in your mind.</p><p>Of course, <a href="https://linuxconfig.org/check-your-local-and-public-ip-address">IP addresses</a> are used when devices need to communicate with each other, but those can change frequently. Hostnames give us a way to know which device we’re interacting with either on the network or physically, without remembering a bunch of numbers that are subject to change. Thus, it’s important that your system bears a hostname which helps you to identify it quickly. For example, “backup-server” is much more informative than “server2.”</p><p>In this guide, we’ll show you how to change the hostname on Linux. This can be done via command line or from GUI, and we’ll be showing the methods for both. If you can’t easily identify a system’s purpose from the hostname, it’s time to change it.</p><p><strong>In this tutorial you will learn:</strong></p><ul><li>How to change hostname from command line</li><li>How to change hostname from GNOME GUI</li></ul><p><a href="https://linuxconfig.org/wp-content/uploads/2020/08/05-how-to-change-hostname-on-linux.png" title="Changing hostname on Linux"><img src="https://linuxconfig.org/wp-content/uploads/2020/08/05-how-to-change-hostname-on-linux.png" alt="" loading="lazy"></a></p><p>Changing hostname on Linux</p><p>Software Requirements and Linux Command Line Conventions</p><table><thead><tr><th>Category</th><th>Requirements, Conventions or Software Version Used</th></tr></thead><tbody><tr><td>System</td><td>Any <a href="https://linuxconfig.org/linux-download">Linux distro</a></td></tr><tr><td>Software</td><td>N/A</td></tr><tr><td>Other</td><td>Privileged access to your Linux system as root or via the <code>sudo</code> command.</td></tr><tr><td rowspan="2">Conventions</td><td><strong>#</strong> – requires given <a href="https://linuxconfig.org/linux-commands">linux commands</a> to be executed with root privileges either directly as a root user or by use of <code>sudo</code> command</td></tr><tr><td><strong>$</strong> – requires given <a href="https://linuxconfig.org/linux-commands">linux commands</a> to be executed as a regular non-privileged user</td></tr></tbody></table><h2 id="Change-hostname-from-command-line">Change hostname from command line</h2><p>The following method will work on systems that use systemd (most of the <a href="https://linuxconfig.org/how-to-choose-the-best-linux-distro">popular Linux distros</a> today). If your system uses init, we cover a separate method in the next section.</p><hr><hr><ol><li>First, let’s check the current hostname by using either the <code>hostname</code> or <code>hostnamectl</code> command.</li></ol><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br><span class="line">3</span><br><span class="line">4</span><br><span class="line">5</span><br><span class="line">6</span><br><span class="line">7</span><br><span class="line">8</span><br><span class="line">9</span><br><span class="line">10</span><br><span class="line">11</span><br><span class="line">12</span><br><span class="line">13</span><br></pre></td><td class="code"><pre><span class="line">$ hostname</span><br><span class="line">linux-server</span><br><span class="line"></span><br><span class="line">$ hostnamectl</span><br><span class="line">Static hostname: linux-server</span><br><span class="line">Icon name: computer-vm</span><br><span class="line">Chassis: vm</span><br><span class="line">Machine ID: e94c741849c848f8baca2ec406f88c41</span><br><span class="line">Boot ID: 55f7533a0cb6448ba677ef30b2104481</span><br><span class="line">Virtualization: oracle</span><br><span class="line">Operating System: Ubuntu 20.04.1 LTS</span><br><span class="line">Kernel: Linux 5.4.0-42-generic</span><br><span class="line">Architecture: x86-64</span><br></pre></td></tr></table></figure><p>Both commands indicate that our hostname is <code>linux-server</code>.</p><ol start="2"><li>Next, change the hostname with the following command. In this example, we’ll change our hostname to <code>linuxconfig</code>.</li></ol><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">$ sudo hostnamectl set-hostname linuxconfig</span><br></pre></td></tr></table></figure><p>Run the commands from Step 1 again to confirm the new change.</p><ol start="3"><li><p>Lastly, edit the <code>/etc/hosts</code> file to reflect the change. For example:</p><p>Change this:</p></li></ol><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br></pre></td><td class="code"><pre><span class="line">127.0.0.1 localhost</span><br><span class="line">127.0.1.1 linux-server</span><br></pre></td></tr></table></figure><p>To this:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br><span class="line">2</span><br></pre></td><td class="code"><pre><span class="line">127.0.0.1 localhost</span><br><span class="line">127.0.1.1 linuxconfig</span><br></pre></td></tr></table></figure><p><a href="https://linuxconfig.org/wp-content/uploads/2020/08/01-how-to-change-hostname-on-linux.png" title="Editing the hosts file"><img src="https://linuxconfig.org/wp-content/uploads/2020/08/01-how-to-change-hostname-on-linux.png" alt="" loading="lazy"></a></p><p>Editing the hosts file</p><p>That’s all there is to it. But there are more command line methods to change the hostname than just this one. We cover more below.</p><h3 id="Change-hostname-from-command-line-init-systems">Change hostname from command line (init systems)</h3><p>An alternative method to the above instructions is to edit the following two files.</p><ol><li>Open <code>/etc/hostname</code> with nano or your preferred text editor and change the name inside of it.</li></ol><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">$ sudo nano /etc/hostname</span><br></pre></td></tr></table></figure><p><a href="https://linuxconfig.org/wp-content/uploads/2020/08/06-how-to-change-hostname-on-linux.png" title="Editing the /etc/hostname file"><img src="https://linuxconfig.org/wp-content/uploads/2020/08/06-how-to-change-hostname-on-linux.png" alt="" loading="lazy"></a></p><p>Editing the /etc/hostname file</p><ol start="2"><li>Next, open the <code>/etc/hosts</code> file and change the name there as well.</li></ol><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">$ sudo nano /etc/hosts</span><br></pre></td></tr></table></figure><h3 id="Change-hostname-from-command-line-hostname-command">Change hostname from command line (hostname command)</h3><p>The last method for changing the hostname from command line is with the <code>hostname</code> command. In most environments, this only temporarily changes the name and it will revert once the system is rebooted. For example, to change the hostname to <code>linuxconfig</code>:</p><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">$ hostname linuxconfig</span><br></pre></td></tr></table></figure><p>Check the changes by just typing <code>hostname</code>:</p><figure class="highlight plaintext"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">$ hostname</span><br></pre></td></tr></table></figure><h2 id="Change-hostname-from-GNOME-GUI">Change hostname from GNOME GUI</h2><p>If you’re running the GNOME desktop environment and don’t wish to use the command line method, follow along with the steps below.</p><ol><li><p>Start by opening the Settings menu from GNOME’s application launcher.</p><p><a href="https://linuxconfig.org/wp-content/uploads/2020/08/02-how-to-change-hostname-on-linux.png" title="Open the Settings menu"><img src="https://linuxconfig.org/wp-content/uploads/2020/08/02-how-to-change-hostname-on-linux.png" alt="" loading="lazy"></a></p><p>Open the Settings menu</p></li><li><p>Click on the About tab at the bottom and then click on Device Name.</p><p><a href="https://linuxconfig.org/wp-content/uploads/2020/08/03-how-to-change-hostname-on-linux.png" title="Change the device name (hostname) inside the About tab"><img src="https://linuxconfig.org/wp-content/uploads/2020/08/03-how-to-change-hostname-on-linux.png" alt="" loading="lazy"></a></p><p>Change the device name (hostname) inside the About tab</p></li><li><p>Type your new desired hostname and click Rename to finalize the changes.</p><p><a href="https://linuxconfig.org/wp-content/uploads/2020/08/04-how-to-change-hostname-on-linux.png" title="Rename the device"><img src="https://linuxconfig.org/wp-content/uploads/2020/08/04-how-to-change-hostname-on-linux.png" alt="" loading="lazy"></a></p><p>Rename the device</p></li></ol><h2 id="Conclusion">Conclusion</h2><p>In this guide, we saw various methods for changing the hostname of a Linux system via command line and GUI. We also learned about the importance of picking an applicable hostname to assist in the easy identification of a system. Administrators can use these methods to ensure that they have a network of appropriately named devices.</p><h1 id="Reference">Reference</h1><blockquote><p><a href="https://linuxconfig.org/how-to-change-hostname-on-linux">Source</a></p></blockquote>]]></content>
    
    
    <summary type="html">Korbin Brown</summary>
    
    
    
    
    <category term="Linux" scheme="https://blog.kamasylvia.com/tags/Linux/"/>
    
  </entry>
  
  <entry>
    <title>Cheap VPS provider</title>
    <link href="https://blog.kamasylvia.com/p/cfe57d20/"/>
    <id>https://blog.kamasylvia.com/p/cfe57d20/</id>
    <published>2023-08-17T00:04:21.000Z</published>
    <updated>2023-10-30T00:50:05.713Z</updated>
    
    <content type="html"><![CDATA[<h1 id="Cheap-VPS-provider">Cheap VPS provider</h1><table><thead><tr><th>Name</th><th>Price ($)</th><th>RAM (GB)</th><th>CPU</th><th>Storage (GB)</th><th>Transfer (TB)</th><th>Speed (Gbit/s)</th><th>Zone</th></tr></thead><tbody><tr><td><a href="https://www.linode.com">Linode</a></td><td>5</td><td>1</td><td>1</td><td>25</td><td>1</td><td></td><td></td></tr><tr><td><a href="https://contabo.com">Contabo</a></td><td>€ 5.99</td><td>8</td><td>4</td><td>50</td><td>32</td><td></td><td>Singapore, Japan, US West</td></tr><tr><td><a href="https://www.hostens.com/">Hostens</a></td><td>3.75 ( $ 135 for 3 years)</td><td>2</td><td>1</td><td>20</td><td>4</td><td></td><td></td></tr><tr><td><a href="https://www.ionos.com">IONOS</a></td><td>2</td><td>1</td><td>1</td><td>10</td><td>∞</td><td>1</td><td>US</td></tr><tr><td><a href="https://www.hostinger.com">Hostinger</a></td><td>5.99 first year, 7.99 later</td><td>4</td><td>1</td><td>50</td><td>1</td><td>0.3</td><td></td></tr><tr><td rowspan="2"><a href="https://www.kamatera.com">Kamatera</a></td><td>4</td><td>1</td><td>1</td><td>20</td><td>5</td><td></td><td></td></tr><tr><td>6</td><td>2</td><td>1</td><td>20</td><td>5</td><td></td><td></td></tr></tbody></table>]]></content>
    
    
    <summary type="html">&lt;h1 id=&quot;Cheap-VPS-provider&quot;&gt;Cheap VPS provider&lt;/h1&gt;
&lt;table&gt;
&lt;thead&gt;
&lt;tr&gt;
&lt;th&gt;Name&lt;/th&gt;
&lt;th&gt;Price ($)&lt;/th&gt;
&lt;th&gt;RAM (GB)&lt;/th&gt;
&lt;th&gt;CPU&lt;/th&gt;
&lt;th&gt;Storage (GB)&lt;/th&gt;
&lt;th&gt;Transfer (TB)&lt;/th&gt;
&lt;th&gt;Speed (Gbit/s)&lt;/th&gt;
&lt;th&gt;Zone&lt;/th&gt;
&lt;/tr&gt;
&lt;/thead&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td&gt;&lt;a href=&quot;https://www.linode.com&quot;&gt;Linode&lt;/a&gt;&lt;/td&gt;
&lt;td&gt;5&lt;/td&gt;
&lt;td&gt;1&lt;/td&gt;
&lt;td&gt;1&lt;/td&gt;
&lt;td&gt;25&lt;/td&gt;
&lt;td&gt;1&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;a href=&quot;https://contabo.com&quot;&gt;Contabo&lt;/a&gt;&lt;/td&gt;
&lt;td&gt;€ 5.99&lt;/td&gt;
&lt;td&gt;8&lt;/td&gt;
&lt;td&gt;4&lt;/td&gt;
&lt;td&gt;50&lt;/td&gt;
&lt;td&gt;32&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;Singapore, Japan, US West&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;a href=&quot;https://www.hostens.com/&quot;&gt;Hostens&lt;/a&gt;&lt;/td&gt;
&lt;td&gt;3.75 ( $ 135 for 3 years)&lt;/td&gt;
&lt;td&gt;2&lt;/td&gt;
&lt;td&gt;1&lt;/td&gt;
&lt;td&gt;20&lt;/td&gt;
&lt;td&gt;4&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;a href=&quot;https://www.ionos.com&quot;&gt;IONOS&lt;/a&gt;&lt;/td&gt;
&lt;td&gt;2&lt;/td&gt;
&lt;td&gt;1&lt;/td&gt;
&lt;td&gt;1&lt;/td&gt;
&lt;td&gt;10&lt;/td&gt;
&lt;td&gt;∞&lt;/td&gt;
&lt;td&gt;1&lt;/td&gt;
&lt;td&gt;US&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;a href=&quot;https://www.hostinger.com&quot;&gt;Hostinger&lt;/a&gt;&lt;/td&gt;
&lt;td&gt;5.99 first year, 7.99 later&lt;/td&gt;
&lt;td&gt;4&lt;/td&gt;
&lt;td&gt;1&lt;/td&gt;
&lt;td&gt;50&lt;/td&gt;
&lt;td&gt;1&lt;/td&gt;
&lt;td&gt;0.3&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td rowspan=&quot;2&quot;&gt;&lt;a href=&quot;https://www.kamatera.com&quot;&gt;Kamatera&lt;/a&gt;&lt;/td&gt;
&lt;td&gt;4&lt;/td&gt;
&lt;td&gt;1&lt;/td&gt;
&lt;td&gt;1&lt;/td&gt;
&lt;td&gt;20&lt;/td&gt;
&lt;td&gt;5&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;6&lt;/td&gt;
&lt;td&gt;2&lt;/td&gt;
&lt;td&gt;1&lt;/td&gt;
&lt;td&gt;20&lt;/td&gt;
&lt;td&gt;5&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
</summary>
    
    
    
    
    <category term="VPS" scheme="https://blog.kamasylvia.com/tags/VPS/"/>
    
  </entry>
  
  <entry>
    <title>How to remove docker container, images, and volumes with docker-compose</title>
    <link href="https://blog.kamasylvia.com/p/188c0dd4/"/>
    <id>https://blog.kamasylvia.com/p/188c0dd4/</id>
    <published>2023-08-16T00:37:22.000Z</published>
    <updated>2023-10-30T00:50:05.713Z</updated>
    
    <content type="html"><![CDATA[<h1 id="Stop-services-only">Stop services only</h1><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">docker-compose stop</span><br></pre></td></tr></table></figure><h1 id="Stop-and-remove-containers-networks…">Stop and remove containers, networks…</h1><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">docker-compose down</span><br></pre></td></tr></table></figure><h1 id="Down-and-remove-volumes">Down and remove volumes</h1><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">docker-compose down --volumes</span><br></pre></td></tr></table></figure><h1 id="Down-and-remove-images">Down and remove images</h1><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">docker-compose down --rmi &lt;all|<span class="built_in">local</span>&gt;</span><br></pre></td></tr></table></figure><h1 id="Down-and-remove-images-and-volumes">Down and remove images and volumes</h1><figure class="highlight sh"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">docker-compose down -v --rmi &lt;all|<span class="built_in">local</span>&gt;</span><br></pre></td></tr></table></figure><h1 id="References">References</h1><ul><li><a href="https://docs.docker.com/engine/reference/commandline/compose_down/">docker compose down | Docker Documentation</a></li></ul>]]></content>
    
    
    <summary type="html">&lt;h1 id=&quot;Stop-services-only&quot;&gt;Stop services only&lt;/h1&gt;
&lt;figure class=&quot;highlight sh&quot;&gt;&lt;table&gt;&lt;tr&gt;&lt;td class=&quot;gutter&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;1&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;td class=&quot;code&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;docker-compose stop&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/figure&gt;
&lt;h1 id=&quot;Stop-and-remove-containers-networks…&quot;&gt;Stop and remove containers, networks…&lt;/h1&gt;
&lt;figure class=&quot;highlight sh&quot;&gt;&lt;table&gt;&lt;tr&gt;&lt;td class=&quot;gutter&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;1&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;td class=&quot;code&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;docker-compose down&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/figure&gt;
&lt;h1 id=&quot;Down-and-remove-volumes&quot;&gt;Down and remove volumes&lt;/h1&gt;
&lt;figure class=&quot;highlight sh&quot;&gt;&lt;table&gt;&lt;tr&gt;&lt;td class=&quot;gutter&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;1&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;td class=&quot;code&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;docker-compose down --volumes&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/figure&gt;
&lt;h1 id=&quot;Down-and-remove-images&quot;&gt;Down and remove images&lt;/h1&gt;
&lt;figure class=&quot;highlight sh&quot;&gt;&lt;table&gt;&lt;tr&gt;&lt;td class=&quot;gutter&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;1&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;td class=&quot;code&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;docker-compose down --rmi &amp;lt;all|&lt;span class=&quot;built_in&quot;&gt;local&lt;/span&gt;&amp;gt;&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/figure&gt;
&lt;h1 id=&quot;Down-and-remove-images-and-volumes&quot;&gt;Down and remove images and volumes&lt;/h1&gt;
&lt;figure class=&quot;highlight sh&quot;&gt;&lt;table&gt;&lt;tr&gt;&lt;td class=&quot;gutter&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;1&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;td class=&quot;code&quot;&gt;&lt;pre&gt;&lt;span class=&quot;line&quot;&gt;docker-compose down -v --rmi &amp;lt;all|&lt;span class=&quot;built_in&quot;&gt;local&lt;/span&gt;&amp;gt;&lt;/span&gt;&lt;br&gt;&lt;/pre&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/figure&gt;</summary>
    
    
    
    
    <category term="Docker" scheme="https://blog.kamasylvia.com/tags/Docker/"/>
    
  </entry>
  
  <entry>
    <title>AiLake 在线绘画</title>
    <link href="https://blog.kamasylvia.com/p/a0ee51bc/"/>
    <id>https://blog.kamasylvia.com/p/a0ee51bc/</id>
    <published>2023-08-14T09:20:22.000Z</published>
    <updated>2023-10-30T00:50:05.709Z</updated>
    
    <content type="html"><![CDATA[<p>[[2e772ed12147f5125b9e5089f51e4016_MD5.png|Open: Pasted image 20230814172112.png]]![[2e772ed12147f5125b9e5089f51e4016_MD5.png]]</p><p>[[b4bef795cd41c30e0f2f7e20d0b74ed8_MD5.png|Open: Pasted image 20230815101134.png]]![[b4bef795cd41c30e0f2f7e20d0b74ed8_MD5.png]]</p><p>[[66e3b7954ee8085737233ce4821a8d4e_MD5.png|Open: Pasted image 20230815101237.png]]![[66e3b7954ee8085737233ce4821a8d4e_MD5.png]]</p>]]></content>
    
    
    <summary type="html">&lt;p&gt;[[2e772ed12147f5125b9e5089f51e4016_MD5.png|Open: Pasted image 20230814172112.png]]
![[2e772ed12147f5125b9e5089f51e4016_MD5.png]]&lt;/p&gt;
&lt;p&gt;[[b4bef795cd41c30e0f2f7e20d0b74ed8_MD5.png|Open: Pasted image 20230815101134.png]]
![[b4bef795cd41c30e0f2f7e20d0b74ed8_MD5.png]]&lt;/p&gt;
&lt;p&gt;[[66e3b7954ee8085737233ce4821a8d4e_MD5.png|Open: Pasted image 20230815101237.png]]
![[66e3b7954ee8085737233ce4821a8d4e_MD5.png]]&lt;/p&gt;
</summary>
    
    
    
    
    <category term="AI" scheme="https://blog.kamasylvia.com/tags/AI/"/>
    
  </entry>
  
</feed>
